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Background: Dissemination of clinical guidelines is necessary but seldom sufficient by itself to ensure the
reliable uptake of evidence-based practice. There are further challenges in implementing multiple clinical
guidelines and clinical practice recommendations in the pressurised environment of general practice.
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Objectives: We aimed to develop and evaluate an implementation package that could be adapted to
support the uptake of a range of clinical guideline recommendations and be sustainably integrated
within general practice systems and resources. Over five linked work packages, we developed ‘high-
impact’ quality indicators to show where a measurable change in clinical practice can improve patient
outcomes (work package 1), analysed adherence to selected indicators (work package 2), developed
an adaptable implementation package (work package 3), evaluated the effects and cost-effectiveness
of adapted implementation packages targeting four indicators (work package 4) and examined
intervention fidelity and mechanisms of action (work package 5).
Setting and participants: Health-care professionals and patients from general practices in West
Yorkshire, UK.
Design: We reviewed recommendations from existing National Institute for Health and Care Excellence
clinical guidance and used a multistage consensus process, including 11 professionals and patients, to
derive a set of ‘high-impact’ evidence-based indicators that could be measured using routinely collected
data (work package 1). In 89 general practices that shared data, we found marked variations and scope
for improvement in adherence to several indicators (work package 2). Interviews with 60 general
practitioners, practice nurses and practice managers explored perceived determinants of adherence to
selected indicators and suggested the feasibility of adapting an implementation package to target different
indicators (work package 3). We worked with professional and patient panels to develop four adapted
implementation packages. These targeted risky prescribing involving non-steroidal anti-inflammatory and
antiplatelet drugs, type 2 diabetes control, blood pressure control and anticoagulation for atrial fibrillation.
The implementation packages embedded behaviour change techniques within audit and feedback,
educational outreach and (for risky prescribing) computerised prompts.We randomised 178 practices to
implementation packages targeting either diabetes control or risky prescribing (trial 1), or blood pressure
control or anticoagulation (trial 2), or to a further control (non-intervention) group, and undertook economic
modelling (work package 4). In trials 1 and 2, practices randomised to the implementation package for one
indicator acted as control practices for the other package, and vice versa. A parallel process evaluation
included a further eight practices (work package 5).
Main outcome measures: Trial primary end points at 11 months comprised achievement of all
recommended levels of glycated haemoglobin, blood pressure and cholesterol; risky prescribing levels;
achievement of recommended blood pressure; and anticoagulation prescribing.
Results: We recruited 178 (73%) out of 243 eligible general practices. We randomised 80 practices to trial
1 (40 per arm) and 64 to trial 2 (32 per arm), with 34 non-intervention controls. The risky prescribing
implementation package reduced risky prescribing (odds ratio 0.82, 97.5% confidence interval 0.67 to 0.99;
p = 0.017) with an incremental cost-effectiveness ratio of £2337 per quality-adjusted life-year. The other
three packages had no effect on primary end points. The process evaluation suggested that trial outcomes
were influenced by losses in fidelity throughout intervention delivery and enactment, and by the nature of
the targeted clinical and patient behaviours.
Limitations: Our programme was conducted in one geographical area; however, practice and patient
population characteristics are otherwise likely to be sufficiently diverse and typical to enhance
generalisability to the UK. We used an ‘opt-out’ approach to recruit general practices to the randomised
trials. Subsequently, our trial practices may have engaged with the implementation package less than if
they had actively volunteered. However, this approach increases confidence in the wider applicability of
trial findings as it replicates guideline implementation activities under standard conditions.
Conclusions: This pragmatic, rigorous evaluation indicates the value of an implementation package
targeting risky prescribing. In broad terms, an adapted ‘one-size-fits-all’ approach did not consistently
work, with no improvement for other targeted indicators.
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Future work: There are challenges in designing ‘one-size-fits-all’ implementation strategies that are
sufficiently robust to bring about change in the face of difficult clinical contexts and fidelity losses.
We recommend maximising feasibility and ‘stress testing’ prior to rolling out interventions within a
definitive evaluation. Our programme has led on to other work, adapting audit and feedback for other
priorities and evaluating different ways of delivering feedback to improve patient care.
Trial registration: Current Controlled Trials ISRCTN91989345.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 8, No. 4. See the NIHR Journals Library website for further project information.
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Plain English summary
C linical research identifies ways to improve patient care that can help people live longer and better.However, recommendations from research do not always become part of everyday patient care.
Providing health-care staff and services with recommendations from clinical guidelines to inform clinical
decision-making is often not enough by itself to change how care is delivered. Furthermore, general
practice, where 9 out of 10 NHS patient contacts occur, struggles to apply many different guidelines
within limited time and resources.
We developed and tested an improvement package to help general practices adapt their care according
to one of four guideline recommendations.
We identified recommendations that were most likely to make a real difference to patient care.Wemeasured
how closely practices followed these recommendations and found that practices varied a lot.We adapted the
package for use in one of four topics: diabetes control, blood pressure control, stroke prevention and ‘risky
prescribing’ (to reduce particular combinations of medicines that may cause harm). We used the play of
chance to assign general practices to one package for each topic. We found that only the risky prescribing
package improved patient care and provided good value for money. We also found that the improvement
packages were often not delivered or used as we had intended, and that professionals found it easier to
change some types of clinical practice (e.g. prescribing) than others.
Our findings will inform practical guidance to help general practices improve patient care.
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Scientific summary
Background
Clinical evidence that can improve patient outcomes does not reliably find its way into everyday care.
The gap between evidence and practice limits the health, social and economic impacts of clinical research.
Dissemination of evidence-based practice via clinical guidelines is necessary but seldom sufficient by itself
to ensure implementation. The general practice context presents particular challenges – especially given
limited practice organisational capacity, increasing workload and complexity of care, and competing
priorities. Furthermore, many implementation studies focus on one condition. This limits confidence in
applying research findings; it is uncertain how an intervention developed for one clinical condition will
work for another. It is also impracticable and inefficient to invent and evaluate an implementation
strategy for every new guideline.
Aim and objectives
We aimed to develop and evaluate an implementation package that could be adapted to support the
uptake of a range of guideline recommendations and sustainably integrate within general practice
systems and resources. We undertook this through five linked work packages, which are also
summarised in Figure a.
Work package 1 identified and developed ‘high-impact’ quality indicators where a measurable change
in clinical practice can lead to significant patient benefit.
Work package 2 measured and analysed levels of adherence to high-impact indicators.
Work package 3 developed an implementation package that is adaptable to target different indicators.
This included theory-guided interviews to understand adherence to multiple indicators in primary care
(work package 3a) and systematic, stakeholder-guided intervention development (work package 3b).
Work package 4 evaluated the effects and cost-effectiveness of the adapted implementation package
in targeting the implementation of high-impact indicators. This included a cluster-randomised evaluation
(work package 4a) and economic modelling (work package 4b).
Work package 5 comprised an in-depth process evaluation examining implementation package delivery
and mechanisms of action.
Work package 1: identifying and developing ‘high-impact’ quality indicators
We reviewed existing national clinical guidelines and quality indicators and used a four-stage consensus
development process to derive a set of ‘high-impact’ indicators relevant to primary care. Prioritisation
criteria included burden of illness, potential for significant patient benefit, scope for improvement on
current levels of achievement, the extent to which following a recommendation is directly within the
control of individual practice teams, and the feasibility of measurement using routinely collected data.We
screened 2365 recommendations to produce a shortlist of 102. These were considered by a consensus
panel of 11 members, including primary care professionals, commissioners and patient representatives.
We derived a set of 18 indicators (five single, 13 composites – comprising 2–9 individual recommendations)
for field testing.
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Work package 2: analysing adherence to ‘high-impact’ indicators
We undertook a cross-sectional analysis of adherence to seven indicators using routinely collected
electronic data from a sample of 89 general practices in West Yorkshire. The indicators spanned
processes and intermediate clinical outcomes of care related to diabetes, hypertension, atrial fibrillation,
myocardial infarction, chronic kidney disease and ‘risky prescribing’ combinations. Regression modelling
explored the impact of practice and patient characteristics on indicator achievement.
Median practice achievement of indicators ranged from 43.2% (diabetes control) to 72.2% (blood pressure
control in chronic kidney disease). Considerable between-practice variation existed for all indicators: the
absolute difference between the highest and lowest performing practices was 26.3% for risky prescribing
and 100% for anticoagulation in atrial fibrillation. Odds ratios associated with the random effects for
practices emphasised this; there was a greater than 10-fold difference in the likelihood of achieving
the hypertension indicator between the lowest and highest performing practices (odds ratio range
0.50–5.24). Patient but not practice characteristics were modestly and consistently associated with
indicator achievement, particularly age, gender and comorbidity.
Practice and patient characteristics partly accounted for marked inappropriate variations in practice.
This may, in part, reflect the limitations of using routinely collected data but it is also likely that much
of the remaining variation is attributable to differences in clinical and organisational behaviour.
Work package 3: developing an implementation package
We initially explored health professionals’ perceived determinants of adherence to four indicators:
achievement of recommended treatment targets for all of glycated haemoglobin, blood pressure and
cholesterol in type 2 diabetes; avoidance of risky prescribing involving non-steroidal anti-inflammatory
and anti-platelet drugs; achievement of anticoagulant prescribing for stroke prevention in atrial
fibrillation; and achievement of recommended blood pressure levels in hypertension. We interviewed
60 general practitioners, practice nurses and practice managers in West Yorkshire, drawing on the
theoretical domains framework. Data were analysed using framework analysis. We examined the
degree to which determinants were indicator specific or potentially generalisable across indicators.
Professional role and identity and environmental context and resources featured prominently across
all indicators, whereas the importance of other domains, for example beliefs about consequences,
social influences and knowledge, varied across indicators. We identified five meta-themes that broadly
underlined the need to align the design of interventions targeting general practices with higher-level
supports and broader contextual considerations. These included the perceived nature of the job and
norms of practice; internal and external sources of support; communication pathways and interaction;
meeting the needs of patients; and perceptions of indicators. Our findings suggested that it was
feasible to develop interventions to promote the uptake of different evidence-based indicators that
share common features while also including content-specific adaptations.
We next used a staged process to develop an implementation package adaptable to the four indicators.
We identified evidence-based delivery mechanisms: mainly audit and feedback, educational outreach,
and prompts and reminders. Research team members independently mapped determinants of adherence
(from the above interviews) to candidate behaviour change techniques, resolving discrepancies by
discussion.We discussed key interview findings during a series of multidisciplinary panel meetings, each
involving 5 to 10 primary care professionals, quality improvement specialists and service commissioners,
and prioritised likely determinants and intervention content.We piloted and refined components of the
implementation packages with five general practices.We downgraded our original plan for more extensive
piloting of the whole implementation package because we prioritised starting the trials 3 months earlier to
coincide with data collection for the 2015–16 Quality and Outcomes Framework year.
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Work package 4: evaluating effectiveness and cost-effectiveness
We undertook two parallel, pragmatic cluster-randomised trials with balanced incomplete block
designs. We recruited general practices in West Yorkshire using an ‘opt-out’ process. We randomised
practices to an implementation package targeting either diabetes control or risky prescribing (trial 1),
or blood pressure control or anticoagulation in atrial fibrillation (trial 2). In trials 1 and 2, practices
randomised to the implementation package for one indicator acted as control practices for the other
implementation package, and vice versa. The implementation package was tailored to each indicator
and included behaviour change techniques embedded within audit and feedback, educational outreach
and computerised support. Respective primary end points assessed after 11 months comprised
achievement of all recommended levels of glycated haemoglobin, blood pressure and cholesterol; risky
prescribing levels; achievement of recommended blood pressure levels in people with hypertension or
at increased risk of cardiovascular events related to other conditions (e.g. chronic kidney disease); and
anticoagulation prescribing. An intention-to-treat analysis using two-level binary logistic regression
models with patients nested within registered practices adjusted for both patient- and practice-level
covariates. We completed a within-trial cost-effectiveness analysis for all targeted indicators except
anticoagulation in atrial fibrillation.
We approached 243 eligible general practices and recruited 178. We randomised 80 practices to trial 1
(40 per arm) and 64 to trial 2 (32 per arm), with 34 no-intervention controls. The implementation
package reduced risky prescribing (odds ratio 0.82, 97.5% confidence interval 0.67 to 0.99); the
estimated number needed to treat to prevent one case of risky prescribing was 95. The package had
no effect on other primary end points; the odds ratio for diabetes control compared with controls was
1.03 (97.5% confidence interval 0.89 to 1.18), for blood pressure control was 1.05 (97.5% confidence
interval 0.96 to 1.16) and for anticoagulation in atrial fibrillation was 0.90 (97.5% confidence interval
0.75 to 1.09).
The risky prescribing implementation package was more expensive and on average more effective
than usual practice. This yielded an incremental cost-effectiveness ratio of £2337 per incremental
quality-adjusted life-year, falling below the National Institute for Health and Care Excellence preferred
threshold of £20,000–30,000 per quality-adjusted life-year. Over 75% of simulations conducted for
the probabilistic sensitivity analysis fell below this threshold. The blood pressure implementation
package was also more expensive and non-significantly more effective than usual practice, yielding
an incremental cost-effectiveness ratio of £3954. However, the uncertainty around this result was
considerable and the intervention incremental cost-effectiveness ratio had just over a 50% chance of
falling below the £20,000 per quality-adjusted life-year threshold in the sensitivity analysis. Modelling
indicated that the diabetes implementation package was unlikely to have favourable cost per quality-
adjusted life-year estimates.
Work package 5: process evaluation
We conducted an in-depth process evaluation in eight practices recruited in addition to those in the
trial and randomised to receive one of the implementation packages (two practices per package).
Guided by the theoretical domains framework and normalisation process theory, we interviewed
individual staff and practice teams, inspected relevant practice documents (e.g. meeting notes and
policies) and observed team meetings. We also collected administrative data from and surveyed all trial
practices to further assess fidelity. We analysed interview and observational data using a framework
approach; this included constructs from the theoretical domains framework to compare planned versus
actual intervention content and normalisation process theory to understand individual and group
implementation processes. We compared trial fidelity data with in-depth practice case narratives to
help to explain trial findings.
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We had set out to devise an implementation package that could be adapted to target a range of
high-impact indicators and that could also be delivered within existing resources and ways of working
in general practice. Our process evaluation offers three main explanations for its limited impact. First,
we observed losses in fidelity from delivery through to enrolment and enactment by practice teams;
for example, although all practices received feedback reports, under half (67; 46.5%) accepted outreach
visits. Second, the type and scale of targeted behaviour changes varied by indicator, such that practice
teams may have perceived and exerted greater control over goal-setting and action-planning for
risky prescribing. In some cases, receiving quarterly feedback reports that drew attention to perceived
insufficient progress towards achieving targets (particularly in the diabetes and blood pressure control
practices) seemed to activate a negative feedback loop and demotivate staff. Third, we had sought to
ensure that targeted indicators were well aligned with existing clinical priorities; this inadvertently resulted
in the implementation package being insufficiently differentiated from other improvement initiatives.
Patient and public involvement
Our patient and public involvement panel comprised nine people from diverse ethnic, occupational and
social backgrounds and with considerable collective lay experience in commissioning and governance
of health care, national clinical audits, patient advocacy and community development. The panel met
quarterly and contributed to all work packages and wider stakeholder events. In addition, we undertook
further work on the role of patient and public involvement in implementation research.
Patient and public involvement contributions to Action to Support Practices Implementing
Research Evidence
The panel played an integral role in the development conduct of the Action to Support Practices Implementing
Research Evidence (ASPIRE) programme. Specific contributions included patient representation in consensus
processes (e.g. the selection of research areas; work package 1), endorsement of an opt-out recruitment
process (work package 2 and work package 4), feedback on the interpretation of emerging data (all) and
assistance with relationship-building and dissemination.
The role of patient and public involvement in implementation research
Patient and public involvement is generally an essential requirement for research funding. As an implementation
research programme, ASPIRE generally focused on health professionals’ behaviour. This is in contrast to clinical
research, which generally focuses on patients. Discussions with our panel identified uncertainty about the
role of patient and public involvement in implementation research and we decided to explore this issue further
to inform relevant good practice guidance. Via a structured consensus process, our panel considered and rated
21 potential patient and public involvement roles in research. There were more disagreements relating to
patient and public involvement roles in implementation research than in clinical research. The work informed a
framework to guide the planning, conduct and reporting of patient and public involvement in implementation
research.
Conclusions
Our highly pragmatic and rigorous evaluation indicates the value of an implementation package
targeting risky prescribing, given predictable population reductions in avoidable morbidity, deaths and
hospital admissions. However, in broad terms, an adapted ‘one-size-fits-all’ approach did not work, with
no improvement for other targeted indicators.
Our programme had several limitations. It was set in one geographical area; however, practice and
patient population characteristics are otherwise likely to be sufficiently diverse and typical to enhance
generalisability. We used an ‘opt-out’ approach to recruit general practices to the randomised trials.
Subsequently, our trial practices may not have engaged with the implementation package as much as if
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they had actively volunteered. However, this approach may also have ensured the applicability of our
findings to ‘real-world’ quality improvement initiatives targeting all practices in a given locality.
There are challenges in designing implementation strategies that are sufficiently robust to bring about
change in the face of difficult clinical contexts and likely losses to fidelity. Despite our systematic
intervention development, we now believe that we could have conducted more feasibility and ‘stress-
testing’ work prior to rolling out interventions within a definitive evaluation – and recommend this to
others. Our programme has led onto other work, adapting our audit and feedback approach for other
priorities and evaluating different ways of delivering feedback to improve patient care. We are also
producing practical, evidence-based guidance and supporting materials to promote the implementation
of National Institute for Health and Care Excellence guidance in general practice.
Implications for practice
Selecting priorities for implementation may be facilitated by a realistic appraisal of the likelihood of being
able to bring about change for the targeted clinical practice, ideally ensuring that any goals for change
are within the control of the professionals and patients who need to change behaviour. Specifically, we
demonstrated a reduction in risky prescribing by a strategy exploiting routinely available data and
involving repeated audit and feedback accompanied by persuasive messages, realistic goal-setting and
action-planning. Implementation strategies may have small to modest effects but such effects can
translate into worthwhile population health gains.
Recommendations for research
We recommend maximising feasibility and ‘stress-testing’ work prior to rolling out interventions within
a definitive, pragmatic trial. We specifically recommend further implementation research addressing
type 2 diabetes control, blood pressure control and anticoagulation for atrial fibrillation that builds on
our experience and the wider body of research literature. Concerted strategies that target system,
organisational and patient levels as well as general practices may be required to bring about significant
change.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN91989345.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 8, No. 4. See the NIHR Journals Library website for further project information.
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SYNOPSIS
Work package 1: developing ‘high-impact’ quality indicators for
primary care
Parts of this section are reproduced from Rushforth et al.1 This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Background
Clinical evidence that can cut avoidable deaths and enhance quality of life does not reliably find its
way into everyday patient care. The translation of evidence into practice is unpredictable and can be
a slow and haphazard process.2 This gap between evidence and practice is a strategically important
problem for policy-makers, health-care systems and research funders because it limits the health, social
and economic impacts of clinical research.3
The primary care context presents particular implementation challenges – given growing demand,
increasing complexity of care and limited workforce capacity, and against a background of continual
organisational reconfigurations and the dispersed and independent nature of practices.4–7 An
international review of quality-of-care studies from primary care concluded ‘In almost all studies
reviewed the quality of care did not attain acceptable standards of practice’.8 A number of initiatives
in the UK have aimed to increase implementation of effective practice in primary care. These include
the development and dissemination of evidence-based clinical guidelines by the National Institute for
Health and Care Excellence (NICE)9 and financial incentives to reward adherence to performance
indicators set out in the Quality and Outcomes Framework (QOF).10
Measuring adherence to recommended practice is a cornerstone of any strategy to improve quality of
care. Measurement is required to identify inappropriate variations in practice, target improvement
efforts and monitor their impact. The development of quality indicators (QIs) from clinical guidelines
offers a way to assess adherence to recommended practice.11–13 Formal consensus methods are generally
used both to prioritise clinical guideline recommendations suitable for indicator development and to
develop valid and reliable indicators.13–15
Several challenges and considerations need to be balanced in developing indicators:
l Indicators developed solely by expert panels may be ‘unoperationalisable, unreliable, too rare to be
useful, or too hard to extract reliably’.16
l Methods requiring manual data extraction are resource intensive.
l The utility of routinely collected data drawn from existing schemes, such as QOF, is limited by
incomplete coverage of health care.17
l Health-care process indicators need a strong evidence base showing that the care process leads to
improved outcomes.18
l Indicators focusing on processes of care rather than health outcomes may not help overcome
therapeutic inertia (i.e. the failure to intensify treatment in patients with an abnormal
clinical measurement).19
l Health outcome indicators are subject to higher ‘noise-to-signal’ ratios, whereby a range of factors
beyond professional practice influence outcomes.20–22
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Improvement strategies in primary care also need to take account of efficiency. Implementation studies
generally focus on one clinical condition. This has advantages, for example so that an intervention to
promote better detection of hypertension can complement another to improve the treatment of detected
hypertension. However, the impact and generalisability of such studies is limited in a number of ways:
l Only a minority of single-issue guideline recommendations are relevant to primary care and
sufficiently clinically important to justify concerted implementation and provide an acceptable
return on investment.
l Many important clinical practice recommendations are not directly amenable to measurement.
l There are risks of encountering ‘ceiling effects’ when adherence to a given recommendation has
reached a point beyond which it is difficult to improve practice further.
General practitioners (GPs) need to contend with a large number of implicitly competing indicators.
We used a structured multistage consensus process and field testing to prioritise clinical practice
recommendations and develop a set of ‘high-impact’ indicators that could be measured using routinely
recorded data and, if implemented, yield significant patient and population benefits.
Methods and results
Stage 1: initial screening of candidate recommendations
We identified candidate recommendations and indicators from 147 NICE clinical guidelines (published
December 2002–June 2012), 19 NICE quality standards (June 2010–June 2012) and 95 QOF clinical
indicators (extracted June 2012). One researcher (BR) screened titles and summaries of NICE guidelines
and quality standards for relevance to primary care; 20 were excluded as they were exclusively related
to secondary care.We excluded a further 20 that had been superseded by a more recent update. We
excluded four QOF indicators mainly related to secondary care. Together, these sources yielded a total
of 2365 candidate recommendations.
Two clinical researchers (BR and RF) then independently screened candidate recommendations, discarding
those judged irrelevant to primary care or not measurable using routine data.We grouped clearly linked
sets of recommendations to form ‘composite’ recommendations (e.g. the nine recommended processes of
care for patients with type 2 diabetes).23 We resolved disagreements through discussion. The final ‘longlist’
of 102 candidate recommendations comprised 56 single and 46 composite recommendations (additional
files published with Rushforth et al.1).
Stage 2: online shortlisting by consensus panel
We used a modified RAND consensus process.14 We convened an 11-member multidisciplinary consensus
panel, which comprised five GPs (including two with responsibilities for commissioning services), a practice
nurse, a practice manager, a consultant clinical advisor from NICE, a health informatics specialist and two
patient representatives.We deliberately weighted the panel towards professionals who would typically act
on clinical practice recommendations, recognising that a number of judgements required an in-depth, tacit
understanding of the day-to-day realities of clinical practice. The panel was limited to 11 members as there
are only marginal gains in reliability beyond this number.14
Each panellist independently rated all 102 recommendations via an online survey according to three criteria:
burden of illness (e.g. prevalence, severity, costs), potential for significant patient benefit (e.g. longevity,
quality of life, safety of care) and scope for improvement on current levels of adherence (e.g. from perceived
current low levels or large variations). All ratings were completed on a 9-point Likert scale (where 1 is low
and 9 is high according to their perceptions of current practice) with ‘don’t know’ options available.
Panel ratings of recommendations were generally high for patient burden [mean ‘median’ score of 7.6;
standard deviation (SD) 0.68] and potential for patient benefit (7.8; SD 0.81), with lower scores for scope
for improvement (5.00; SD 0.88). We excluded 18 recommendations from further review at this stage
because they scored ≤ 4 on scope for improvement (indicating that the panel perceived adherence to
these recommendations to be relatively good).
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A second online survey contained the top 62 recommendations (31 single and 31 composites) based on
the highest aggregate rankings. Panellists rated shortlisted recommendations using three further criteria:
the feasibility of measuring adherence (e.g. from routinely collected clinical data); the extent to which
following a recommendation is directly within the control of practice teams or individual professionals;
and the likelihood of cost savings without patient harm (all assessed on 1–9 Likert scales). Thresholds for
disagreement were defined in advance as at least three panellists scoring a recommendation 1–3 on a
particular criterion, and at least three scoring it 7–9. The panel disagreed on a total of 22 (11.8%) ratings;
20 disagreements concerned the feasibility of measuring adherence and two concerned the extent to
which following a recommendation was directly within the control of practice teams or professionals.
Stage 3: face-to-face consensus panel meeting
The panel met for a facilitated, structured discussion, led by an experienced researcher.We presented
summaries of the evidence for each recommendation, clarified any aspects of recommendations and
discussed reasons for low or high rankings with a view to reaching, but not forcing, consensus. Panellists
independently re-rated each recommendation immediately after discussing each recommendation.
Following the panel meeting, there were disagreements for 12 (6.4%) ratings. Across the 62 shortlisted
recommendations, the mean ‘median’ ratings were 6.8 (SD 1.57) for the feasibility of measuring adherence,
7.2 (SD 0.76) for the extent to which following a recommendation is directly within the control of individual
practice teams or professionals and 7.3 (SD 0.73) for the likelihood of cost savings without patient harm.
This process produced a ranked list of 50 recommendations for which consensus was achieved.
Stage 4: informal sense-checking
We added a sense-checking exercise to guide the final selection of recommendations, aiming for a list of
around 20 that could be taken forward to the next stage of the programme. During the consensus and
ranking exercise, we were struck by some unexpected anomalous rankings that appeared to lack face
validity when considered against our rating criteria. For example, we doubted the feasibility of using
routinely available data to measure adherence on recommended secondary prevention following
myocardial infarction (MI), which had made the top 20 list after the panel rating. Current and past activity
levels and preferences should be considered when advising on physical activity. An appropriately qualified
health professional can help tailor advice on the benefits of exercise.24 We also wanted to ensure that
identified recommendations would be consistent with local priorities although their measurement was
unlikely to face ceiling effects given known national and local initiatives.
We therefore identified a convenience sample of four GP commissioning leads and six academic GPs that
we had existing working relationships with and who had practical experience of measuring primary care
outcomes.We e-mailed and asked them to review the full ranked list of recommendations from the
consensus panel.We invited them to select between 5 and 10 recommendations that they considered would
best meet our aims and highlight any that they considered problematic to target.We then collated their
selections and written comments. During this process, we amalgamated two similar recommendations
(concerning initiation of insulin in type 2 diabetes) and replaced one recommendation concerning prescribing
non-steroid anti-inflammatory drugs (NSAIDs) with a composite recommendation on risky prescribing.25
Comments from this sense-checking exercise centred on concerns regarding perceived likelihoods of ceiling
effects, difficulties in measurement or recommendations being outside the immediate control of the primary
care team.This process produced 18 recommendations (Box 1), 11 of which had been ranked in the top 20
by our panel. These mainly covered chronic disease management and cardiovascular disease.
Stage 5: field testing of indicators
We assessed the extent to which it was feasible to operationalise the QIs in a sample of general
practices [sampling described under work package (WP) 2]. Search algorithms were generated by a
clinical researcher (BR) and a primary care data analyst. We applied and iteratively refined the
algorithms with input from two external GP advisors. Appendix 1, Box 2, illustrates two examples.
The full set of SystmOne (The Phoenix Partnership, Leeds, UK) searches for each of the 18
recommendations is available in Rushforth et al.1
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Discussion
We developed high-impact indicators that can be measured using routinely collected data in primary
care. Our development process required considerable filtering of existing guidelines and depends on
the availability of routinely recorded data. Our 18 indicators were drawn from 2365 recommendations
and indicators; earlier research attempting similar work also found this to be a labour-intensive
process with a limited ‘yield’.26 Our indicators overlapped substantially with existing primary care QI
sets17,27,28 that largely focus on long-term conditions, such as diabetes and cardiovascular disease.
BOX 1 Summary of ‘high-impact’ QIs agreed following consensus process (work package 1)
1. Smoking: the percentage of patients in high-risk groups whose notes record smoking status and the
offer of support and treatment within the preceding 15 months (composite).
2. COPD: diagnosis of COPD through use of spirometry and chest radiograph (composite).
3. CKD: the percentage of patients on the CKD register with hypertension and proteinuria who are
treated with an angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker.
4. CKD: measurement of blood pressure, urinary protein excretion and lifestyle advice (composite).
5. CKD: blood pressure and urinary protein excretion targets, and appropriate drug therapy (composite).
6. MI: all patients who have had an acute MI should be offered specific combination drug treatment.
7. Chronic heart failure: measurement of serum natriuretic peptides and referral where
appropriate (composite).
8. AF: recommendations concerning use of anticoagulants in AF (composite).
9. Hypertension: blood pressure targets in those aged under/over 80 years (composite).
10. Hypertension: lifestyle advice and monitoring of cholesterol and urinary protein excretion (composite).
11. Type 2 diabetes: nine annual processes of care (i.e. measurement of blood pressure, lipids, renal
function, urine ACR, glycaemic control, BMI, smoking status, plus foot and eye checks) (composite).
12. Type 2 diabetes: integrate dietary advice with a personalised diabetes management plan.
13. Type 2 diabetes: cardiovascular risk assessment and subsequent statin therapy when indicated.
14. Type 2 diabetes: achievement of target levels for blood pressure, cholesterol and glycaemic
control (composite).
15. Type 2 diabetes: for a person on dual therapy who is markedly hyperglycaemic, consider starting
insulin therapy in preference to adding other drugs to control blood glucose.
16. Diabetes mellitus: the percentage of patients with diabetes in whom the last blood pressure is
≤ 140/80 mmHg.
17. Risky prescribing: indicators focusing on avoiding adverse gastrointestinal, renal and cardiac effects
of NSAIDs and anti-platelet drugs (composite).
18. Depression in adults: recommendations concerning severity-appropriate treatment of
depression (composite).
ACR, albumin–creatinine ratio; AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease;
COPD, chronic obstructive pulmonary disease. Reproduced from Rushforth et al.1 This article is distributed
under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
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We highlight five limitations. First, our process lost a degree of transparency through the addition of a
less formal ‘sense-checking’ stage. The need to add this stage somewhat highlights a relative failure of
our preceding consensus process to scrutinise the candidate indicators. Panels developing indicators
may tend to overestimate the feasibility of data collection.29 Second, our indicator set is skewed
towards biomarkers (e.g. glycaemic control in diabetes) that are used for chronic disease monitoring.
We recognise the risk of marginalising holistic medical care through focusing attention on what is
measurable and what is not necessarily important to patients or physicians.30 However, as well as
including patient representatives in our consensus process, we also sought to maintain a focus on
recommendations supported by evidence of benefits for patient and population outcomes (e.g. smoking
cessation). Third, our approach to indicator development prioritised those associated with higher
population burdens of illness; this discounts rare diseases for which appropriate care could make a
major difference to individual outcomes.31 We recognise that we made a trade-off. Fourth, we did not
directly assess the reliability of data recording. However, our measures were mostly derived from data
that either had been through reliability checks during piloting or were QOF indicators.32 Fifth, the
detailed operationalisation of our indicators is only relevant to UK primary care. Nevertheless, their
evidence base and basic structures may be transferable to similar primary care settings.
Conclusion
We developed 18 high-impact QIs that can be measured using routinely collected data. Our methods
were more iterative and required more judgement than originally planned, especially considering our
additional sense-checking stage and refinements following field testing.
Work package 2: variations in achievement of evidence-based, high-impact
quality indicators in general practice
Parts of this section are reproduced from Willis et al.33 This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
Background
There is well-documented variation in the delivery of primary care in the UK and internationally.8,34–39
‘Big data’ offer considerable promise in assessing population health-care and researching variations.40,41
For example, the NHS Atlas of Variation in Healthcare42 illustrates large geographical variations in care
across England for several clinical conditions, including diabetes, stroke and cancer. The magnitude of
these differences cannot be easily explained by population and case mix factors; much variation is
likely to be attributable to ‘idiosyncratic practices of clinicians and of healthcare organisations.’
(Reproduced from NHS Right Care.42 Contains public sector information licensed under the Open
Government Licence v3.0). Such variations can, therefore, be considered to be inappropriate if patients
are not receiving recommended care.
Gaps between recommended and actual care can have substantial implications; for example, in England
an estimated 7000 strokes per year could be prevented and 2100 lives saved from increased adherence
to guidelines on the management of atrial fibrillation (AF).43 Clearly, quality improvement initiatives
cannot focus on all clinical practice recommendations at once; there is a need to identify and prioritise
those with the potential for the most patient and population benefit. We examined levels of adherence
to selected high-impact QIs, developed in WP1, and assessed the extent to which variations in
achievement could be explained by practice and patient characteristics using routinely collected data.
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Methods
Study design and setting
We conducted a cross-sectional analysis of achievement against QIs using routinely collected,
electronic data from randomly sampled general practices in West Yorkshire.
Participants
Of 334 general practices in West Yorkshire at the time of the study, 272 used the SystmOne clinical
information system which permitted centralised data extraction. We sampled randomly from this group
and stratified them by the then configured five NHS primary care trusts. We assumed a 30% decline
rate based on earlier work44 and initially asked 78 practices to ‘opt in’ to the sharing of anonymised
data to achieve a sample of 60 (see Sample size). After receiving several declines and a small number of
acceptances, we approached and sampled an additional 36 practices, making 114 in total. At the same
time, the local NHS Research Ethics Committee granted permission to change to ‘opt-out’ recruitment
to reduce selection bias by facilitating general practices’ agreement to share anonymised patient data.
Variables
We selected seven of the QIs developed in WP1 based on likely scope for improvement and amenability
to change (see table 1 of Willis et al.33). Four indicators focused on processes of care (e.g. prescribing) and
three focused on clinical outcomes (achievement of treatment goals).
We examined patient-level demographic variables (age, gender and ethnicity) and comorbidities as
recorded for QOF disease registers. Practice-level variables comprised the number of GP partners
(a proxy for practice size), the number of salaried GPs and training status. We used practice-level Index
of Multiple Deprivation (IMD) scores. We used overall QOF clinical domain (2012–13) achievement as
a proxy measure for overall quality of care. Patient data were remotely extracted and anonymised
before transfer. We obtained data from National General Practice Profiles45 for two further practice-level
variables: patient satisfaction (the proportion recommending the practice to others) and accessibility
(the proportion reporting being able to speak with a GP or nurse within 48 hours of approach).
Data analysis
For each QI, we assessed the proportion of cases with documented receipt of appropriate care or
attainment of treatment goals. Denominators were eligible patients, identified by diagnostic codes and
prescribing records. Numerators were patients with evidence of a clinical intervention offered or received,
or meeting defined treatment goals. In assessing the impact of practice and patient characteristics, we
initially calculated unadjusted odds ratios (ORs) before adjusting for other variables associated with
outcomes.
Data for almost all patients were complete. Data on age were missing from a small proportion (< 1%)
of patients and excluded from analysis.
Sample size
Effect size calculations informed a recruitment target of 60 practices. With seven covariates, and a
large effect size (defined by a difference of at least 0.8 SDs),46 60 practices would provide 94% power.
Results
Participants
Eighty-nine practices (78.1% of those approached) shared patient data. Practices declining participation
only differed from participating practices in having a smaller mean number of GPs (5 vs. 3.6; p = 0.05).
The total number of patients for each indicator denominator ranged from 4773 (anticoagulation in AF)
to 77,587 [blood pressure (BP) control]. Willis et al.33 summarises patient demography (see table 2 of
Willis et al.33). Practice size was indicated by the number of practice partners (mean 3.7, SD 2.3) and
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salaried GPs (mean 1.3, SD 1.8). Mean practice-aggregated IMD score was 31.2 (SD 11.9, approximating
to the highest quarter of deprivation). Mean QOF 2012–13 performance for clinical domains across
practices was 637.4 (SD 27.6; approximating to the national mean47) and 20.2% were training practices.
Achievement of indicators
Median practice achievement of the indicators ranged from 43.2% (range 20.8–66.2%) for diabetes
outcomes to 74.2% (range 50.7–100%) for BP control in chronic kidney disease (CKD) (see tables 3 and 4
in Willis et al.).33 Median achievement of the risky prescribing indicator was 8.7%, although lower scores
were indicative of fewer instances of risky prescribing and were, therefore, desirable. Considerable
between-practice variation in achievement existed for all indicators: the difference between the highest
and the lowest achievers was 26.3% for risky prescribing and 100% for anticoagulation in AF and BP
control in CKD.33
Associations with achievement
The range of ORs associated with the random effects for practices demonstrate that the likelihood of
achieving a specific indicator varied substantially as a consequence of the practice at which a patient was
registered (see tables 3 and 4 in Willis et al.).33 These ORs were typically of a much greater magnitude
than those for other variables, demonstrating strong practice effects. For process indicators, the impact
of the practice attended was most pronounced for risky prescribing, with a sevenfold difference between
the lowest and highest performing practices (OR range 0.40–3.51). Practice effects were least apparent
for secondary prevention of MI (OR range 0.70–1.42). There were also sizeable practice effects for
outcome indicators. For the achievement of target BP values in hypertension there was a greater than
10-fold difference between the highest and lowest performing practices (OR range 0.50–5.24) and a
fourfold difference for diabetes control (OR range 0.51–2.05). Practice effects were less marked for
the achievement of BP targets in CKD (OR range 0.54–1.60). Across the seven indicators, statistically
significant associations were identified more frequently with patient than with practice characteristics
(see tables 3 and 4 in Willis et al.).33 The amount of variance explained by these variables, however,
was relatively low; practice characteristics explained less than 8% of variance across all seven models.
Variance due to patient ethnicity typically explained a small amount of variance in achievement
(< 10% of the variation due to practices).
Process indicators
Diabetes processes of care
Males were more likely to receive all nine of the recommended processes of care in diabetes than
females [adjusted OR 1.24, 95% confidence interval (CI) 1.17 to 1.30]. Relative to younger patients,
receipt was more likely in each of the age groups > 40 years old: 40–59 years (adjusted OR 1.52,
95% CI 1.33 to 1.73), 60–79 years (adjusted OR 2.07, 95% CI 1.81 to 2.36) and ≥ 80 years (adjusted
OR 1.51, 95% CI 1.30 to 1.76). Indicator achievement was more likely in those with a greater number
of comorbidities: compared with patients appearing on 0–3 QOF registers, the odds were higher for
those on 4–5 QOF registers (adjusted OR 1.24, 95% CI 1.17 to 1.32) and on 6–13 QOF registers
(adjusted OR 1.33, 95% CI 1.23 to 1.45).
Risky prescribing
Males were more likely to be prescribed at least one risky prescribing combination than females
(adjusted OR 1.11, 95% CI 1.02 to 1.19). Risky prescribing was more likely in patients aged 40–59 years
(adjusted OR 1.71, 95% CI 1.12 to 2.60) and 60–79 years (adjusted OR 1.95, 95% CI 1.26 to 2.96),
but not in those aged ≥ 80 years, relative to patients < 40 years. Compared with patients with 0–3
comorbidities, risky prescribing was less likely in those on 4–5 (adjusted OR 0.81, 95% CI 0.74 to 0.88)
and 6–11 (adjusted OR 0.56, 95% CI 0.51 to 0.62) QOF registers. Registration at a practice with a
greater proportion of salaried GPs was associated with lower likelihood of risky prescribing (adjusted
OR 0.76, 95% CI 0.61 to 0.94).
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Anticoagulation in atrial fibrillation
Males were more likely than females to be prescribed anticoagulants (adjusted OR 1.27, 95% CI
1.12 to 1.44). Patients aged ≥ 80 years were less likely to be treated than those aged < 60 years
(adjusted OR 0.62, 95% CI 0.43 to 0.89).
Secondary prevention of myocardial infarction
Males were more likely than females to be prescribed the four recommended medications (adjusted
OR 1.12, 95% CI 1.02 to 1.23). Patients aged ≥ 80 years were less likely to be treated (adjusted OR
0.38, 95% CI 0.22 to 0.65) than those in the youngest quartile. Patients with higher levels of comorbidity,
featuring on 6 or more QOF registers, were more likely to be treated than those on 0–3 registers
(adjusted OR 0.83, 95% CI 0.73 to 0.94).
Outcome indicators
Diabetes control
Achievement of all three target values for (glycated haemoglobin) HbA1c, cholesterol and BP in diabetes
was slightly higher in males than in females (adjusted OR 1.09, 95% CI 1.03 to 1.14). This likelihood
increased with age, with all three age groups significantly more likely than patients aged < 40 years to
achieve treatment goals (40–59 years: adjusted OR 1.28, 95% CI 1.10 to 1.47; 60–79 years: adjusted
OR 2.55, 95% CI 2.21 to 2.94; ≥ 80 years: adjusted OR 2.91, 95% CI 2.48 to 3.40). Comorbidity levels
were associated with indicator achievement: patients on 4–5 (adjusted OR 1.10, 95% CI 1.04 to 1.17)
and 6–13 QOF registers (adjusted OR 1.31, 95% CI 1.21 to 1.42) were more likely to achieve treatment
goals than those on 0–3 registers. Practices with better than average QOF performance (adjusted OR
1.19, 95% CI 1.02 to 1.39) and better reported accessibility (adjusted OR 1.18, 95% CI 1.02 to 1.38)
were more likely to achieve this indicator.
Blood pressure control in hypertension
Males were less likely to achieve target BP values than females (adjusted OR 0.86, 95% CI 0.84 to 0.89).
Achievement likelihood increased with age, with patients aged 60–79 years (adjusted OR 1.19, 95% CI
1.07 to 1.31) and particularly those aged ≥ 80 years (adjusted OR 3.34, 95% CI 2.99 to 3.74) more likely
to achieve treatment goals than patients aged < 40 years. Patients with greater levels of comorbidity
were more likely to achieve control than patients on 0–3 registers (3–4 QOF registers: adjusted OR
1.54, 95% CI 1.48 to 1.60; 5–13 registers: adjusted OR 2.32, 95% CI 2.20 to 2.44). Achievement was
more likely in practices with better QOF performance (adjusted OR 1.24, 95% CI 1.06 to 1.46).
Blood pressure control in chronic kidney disease
Target achievement was less likely as the level of comorbidity increased, through 4–5 QOF registers
(adjusted OR 0.88, 95% CI 0.81 to 0.95) and 6–13 QOF registers (adjusted OR 0.86, 95% CI 0.79 to 0.95).
Discussion
We found marked variations between general practices in the achievement of clinically important
indicators. The odds of patients receiving recommended care or achieving recommended treatment
targets varied between two- and over 10-fold by indicator according to the practice attended. These
variations were partly explained by a range of routinely available practice and patient variables; it is
likely that much remaining variation is related to clinical and organisational behaviours as well as
unmeasured characteristics.
We highlight four study limitations. First, we considered quality of care from a single, technical perspective
(i.e. achievement against selected clinical indicators). Nevertheless, the indicators were derived from a
rigorous consensus process and we are confident of their importance to both clinicians and patients. Second,
the study was limited to one geographical area and practices using one computerised patient record system.
West Yorkshire has practice characteristics broadly similar to English averages and regional SystmOne
coverage was high (> 80% of practices during the study). Furthermore, opt-out recruitment efficiently
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enabled practice participation while avoiding biases associated with opt-in recruitment,44,48 strengthening
generalisability. Third, combined indicators can mask varying performance between individual component
indicators. Giving equal weighting to indicators can be contentious;49 however, there is no single agreed
method of combining indicators and our methods were similar to those used elsewhere (e.g. Steel et al.38 and
Levine et al.50). Fourth, our rather crude measure of deprivation (practice-averaged IMD) did not consider
deprivation at the individual patient level and may have masked differences in variation within practice
populations.We had been unable to use patient-level data because of the risk of breaching confidentiality.
We highlight three implications for practice. First, the consistent, substantial variations between the
practices that we observed are at similar levels to those identified almost two decades ago.8 Patients and,
perhaps, clinicians and policy-makers might be surprised, if not concerned, to learn of such variations in
the receipt of recommended care and achievement of treatment goals. Our findings suggest the continuing
salience of inappropriate variations to policy and research agendas. Second, the associations between
patient and practice variables and indicator achievement suggests the importance of clinical and
organisational behaviours. There is some evidence to suggest that health-care professionals may
believe that practice performance is predominantly influenced by local case mix and demography.51
Our findings suggest an interpretation that highlights the role of clinical and organisational
behaviours. Third, the modest but significant associations between achievement and specific patient
characteristics have implications for improvement strategies. Better performance on the diabetes,
hypertension and risky prescribing indicators was associated with comorbidity. This suggests scope for
focusing greater attention on patients who are (relatively) healthier and perhaps less likely to attend
practices. Our analysis also identified associations between achievement and a range of further
patient characteristics, which can guide targeting of improvement strategies.
Work package 3a: using the theoretical domains framework to understand
adherence to multiple quality indicators in primary care
Parts of this section are reproduced from Lawton et al.52 This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Background
Having demonstrated major variations in achievement of a set of high-impact QIs, we next explored
primary care professionals’ perceived determinants of adherence to these indicators. A wide variety of
theories from behavioural science, economics and social marketing are available to understand clinical
behaviour.53 The theoretical domains framework (TDF) was specifically developed to identify determinants
of professional behaviour change and includes knowledge, skills, beliefs about consequences, beliefs about
capabilities, social influences, emotion, motivation/goals, professional role/identity, memory and decision
processes, environmental context and resources, and action-planning.54
We examined which TDF determinants were specific to indicators, thereby suggesting a need for
indicator-specific tailoring of implementation strategies, and which were shared across all indicators,
thereby suggesting the potential for incorporating common elements into implementation strategies
across different indicators. In considering shared determinants that may represent wider contextual
influences, we also looked for meta-themes that emerged when synthesising data from multiple
indicators. This study is fully reported in Lawton et al.52
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Methods
Design and setting
We conducted semistructured interviews with primary care professionals in West Yorkshire, UK.
Indicator selection
We selected eight indicators from WP1 and WP2 for this interview study (one of which, advising on
smoking cessation, we did not report under WP2 given doubts about its validity). Here, we focus on
the four indicators subsequently targeted by our implementation package (Table 1):
1. risky prescribing, especially involving NSAIDs55
2. treatment targets in type 2 diabetes56
3. BP targets in treated hypertension57
4. anticoagulation in AF.58
TABLE 1 Quality indicators explored in qualitative interviews with primary care staff (WP3a)
Indicator topic Indicator details
Risky prescribing Avoidance of the following prescribing combinations:
l prescribing of a traditional oral NSAID or low-dose aspirin in patients with a history of
peptic ulceration without coprescription of a gastroprotective drug
l prescribing of a traditional oral NSAID in patients aged ≥ 75 years without coprescription
of a gastroprotective drug
l prescribing of a traditional oral NSAID and aspirin in patients aged ≥ 65 years without
coprescription of a gastroprotective drug
l prescribing of aspirin and clopidogrel in patients aged ≥ 65 years without coprescription of
a gastroprotective drug
l prescribing of warfarin and a traditional oral NSAID without coprescription of a
gastroprotective drug
l prescribing of warfarin and low-dose aspirin or clopidogrel, without coprescription of a
gastroprotective drug
l prescribing an oral NSAID in patients with heart failure
l prescribing an oral NSAID in patients prescribed both a diuretic and an angiotensin-
converting-enzyme inhibitor/angiotensin receptor blocker
l prescribing an oral NSAID in patients with CKD (stages 3, 4 and 5)
Treatment targets in
type 2 diabetes
Achievement of all three recommended levels:
l BP of < 140/80 mmHg (or 130/80 mmHg if there is kidney, eye or cerebrovascular damage)
l HbA1c value of ≤ 59 mmol/mol
l cholesterol level of ≤ 4.0 mmol/l in patients who are ≥ 40 years
BP targets in treated
hypertension
Aim for a target clinic BP of < 140/90 mmHg in people aged < 80 years with treated
hypertension
Aim for a target clinic BP of < 150/90 mmHg in people aged ≥ 80 years with treated
hypertension
Anticoagulation in AF In patients with AF who either are post stroke or have had a transient ischaemic attack:
l Warfarin should be administered as the most effective thromboprophylactic agent
l Aspirin or dipyridamole should not be administered as thromboprophylactic agents unless
indicated for the treatment of comorbidities or vascular disease
Those patients with AF in whom there is a record of a CHADS2 score of 1 should be offered
antioagulation drug therapy or antiplatelet therapy
Those patients with AF whose latest record of a CHADS2 score is > 1 should be offered
anticoagulation therapy
CHADS2, congestive heart failure, hypertension, age > 75 years, diabetes mellitus and prior stroke.
Reproduced from Lawton et al.52 This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
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Sample
To gain a range of perspectives within practice teams, we aimed for a total sample comprising 30 GPs,
15 practice nurses and 15 practice managers. We invited staff from the 89 practices that shared data
in WP2 to participate. Recruitment ran from September 2013 until June 2014.
Interview procedure
Each interview covered two indicators out of the eight under consideration. The topic guide drew on
the TDF and was refined following piloting with three academic GPs54 (see table 10 of Lawton et al.52).
Data analysis
Interviews were audio-recorded and transcribed verbatim. We used NVivo 10 (QSR International,
Warrington, UK) software to facilitate analysis. Initial coding was completed by the same three
researchers who conducted the interviews (GL, JH and EI).
Data saturation was considered at the indicator level. Interviewers held regular debriefing discussions
after interviews and reached consensus on new or redundant content across the indicators. Redundancy
typically coincided with the estimated 15 interviews per indicator, ranging approximately between
12 and 14 interviews. However, for each indicator, we also sought further interviews with any less
well-represented participant group to maximise the diversity of data.
Our framework analysis comprised familiarisation, identification of a framework, indexing, charting and
mapping, and interpretation.59 The coding framework was developed through an iterative process that
incorporated the study aims, the TDF and the detailed reading of interview transcripts. The coding
framework included code definitions to ensure consistency.
As part of familiarisation, researchers read through each transcript before coding and wrote a brief
summary outlining key themes and findings. Pieces of text were coded according to the iterative
coding framework. At this stage, TDF determinants (primary codes) were coded at a broad level.
Common additional codes and categories were organised into secondary codes for TDF determinants.
When additional codes and categories were added to the framework, we revisited coded transcripts
and applied the revised coding framework. Early-stage, face-to-face meetings ensured that there was
agreement in coding. To promote reliability, six transcripts were coded independently by each
researcher and disagreements were resolved through discussion.
We completed two stages of analysis. We first assessed determinants for individual indicators by
examining the data coded against the TDF domains. To prioritise TDF determinants for each indicator,
we focused on the key thematic content (e.g. the extent to which the TDF determinant was discussed
across participant groups) and barriers and enablers. We then identified meta-themes across multiple
indicators, including the additional codes and categories generated to produce the analytical framework.
Results
We conducted 60 face-to-face interviews, with a ratio of 2 : 1 : 1 between GPs, practice managers and
nurses, respectively, from a total of 31 general practices (Table 2). Interviews typically lasted around
30 minutes per indicator. Most participants were female (70%) and aged 40–49 years (38%). The mean
number of years of experience in general practice was 14 years (range 1 to 33 years).
Theoretical domains
Professional role and identity and environmental context and resources featured prominently across all
indicators, whereas the importance of other domains (e.g. beliefs about consequences, social influences
and knowledge) varied across indicators. Table 4 from Lawton et al.52 describes all TDF domain content
and specific barriers and enablers for each indicator and longer narrative accounts are also available in
the published paper. We next focus on the meta-themes that emerged when synthesising data from
multiple indicators.
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Meta-themes spanning multiple indicators
We identified five meta-themes that potentially represent general influences on evidence-based
practice: (1) perceived nature of the job and norms of practice, (2) internal and external sources
of support, (3) communication pathways and interaction, (4) meeting the needs of patients and
(5) perceptions of indicators. Tables 5–9 in Lawton et al.52 illustrate interview excerpts.
Perceived nature of the job and norms of practice
When discussing the indicators and associated clinical behaviours, primary care professionals generally
viewed the workload and burden associated with adherence as accepted and embedded components of
general practice. Although professionals sometimes felt that indicators were imposed on consultations
and that there was a limit as to what was achievable within a typical 10-minute consultation, they
understood their roles in meeting QOF targets and recognised standards of practice. They further
recognised that implementation could improve outcomes and reduce health-care costs in the longer
term. Awareness of the indicators encouraged familiarity with required care processes and subsequent
ingraining in everyday practice.
Although professionals described similar impacts of meeting the indicators, approaches to implementation
differed between professional groups. Although GPs acted relatively autonomously and felt able to deviate
from policies and procedures to tailor patient care, nurses preferred to follow policies and procedures,
often justifying this approach by referring to risk and the threat of litigation. Some GPs felt that system
prompts for implementing indicators disrupted consultations and sometimes directed their focus away
from issues important to patients or patients’ reasons for consulting. In contrast, many nurses said that
they relied on templates and prompts to deliver appropriate care.
Internal and external sources of support
Professionals perceived both internal and external sources of support as critical to successful
implementation. This often took the form of specific practice staff having specialised knowledge or lead
roles for a clinical area. External support was provided by colleagues in secondary care or via network
meetings with other practices. These sources provided trusted points of reference where professionals
could seek the opinion of more knowledgeable colleagues and learn from others’ experience. Other
supports assisted implementation by prompting memory and regulating clinical behaviour. These were
provided at the practice level by regular practice meetings and the development and use of internally
developed prompts and templates, and at the wider organisational level via information technology and
system infrastructure provided by Clinical Commissioning Groups (CCGs) and other bodies.
TABLE 2 Allocation of interview topics by primary care staff (WP3a)
Recommendations GP Practice manager Nurse Total
Risky prescribing 8 3 4 15
Treatment targets in type 2 diabetes 7 4 4 15
BP targets in treated hypertension 7 4 4 15
Anticoagulation in AF 7 3 5 15
Total 29 14 17 60
Reproduced from Lawton et al.52 This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
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Communication pathways and interaction
Many professionals believed that effective interaction and information sharing were key to successful
implementation. These required channels and skills to facilitate communication at three levels: between
professionals and patients; between colleagues in a practice; and between primary and secondary care.
Effective communication also depended on clear care pathways and respective professional roles;
however, some professionals felt that there was scope for improving how communication systems
provided support.
Meeting patient needs
Professionals evidently considered it important to take a holistic view of the patient when making decisions,
irrespective of whether or not this resulted in deviating from recommended practice. This individualisation
of patient care appeared to be driven by a strong sense of professional ethos and beliefs that it truly
reflected quality of care and improved patient outcomes. Interviewees, particularly GPs, also acknowledged
that patient priorities, preferences for treatment, and social and financial circumstances all influenced their
practice and hence achievement of indicators. Although the latter factors were largely captured by the
social influences TDF domain, other patient factors outside professional control influenced indicator
achievement. These included patients’ own knowledge around conditions, varying adherence to treatment
and failures to attend pre-arranged consultations. Such influences appeared particularly relevant for
indicators focused on outcomes (i.e. diabetes and BP control).
Perceptions of indicators
The content and structure of indicators and associated clinical practice recommendations were
incompletely captured by the TDF. Although some recommendations, which were regarded as relatively
clear and simple to follow, facilitated implementation, others were considered unnecessarily complex,
lacking in clarity, or too lengthy – hindering their application in a time-pressured environment. There were
also concerns about frequent revisions to recommendations and subsequent impacts on abilities to recall
required procedures and processes, as well as perceived credibility of sources and recommendations.
Discussion
We identified a wide range of factors that can determine adherence to ‘high-impact’ indicators in
primary care. Those related to social and professional roles and identity and environmental context and
resources were prominent themes across all indicators, whereas the importance of other domains, for
example beliefs about consequences, social influences and knowledge, varied across recommendations.
We further identified five more general meta-themes important to primary care professionals in the
implementation of all the indicators. Taken together, our findings suggested that it was feasible to
develop implementation strategies for different evidence-based indicators that include both common
features and content-specific adaptations.
Although some theoretical influences on adherence were shared across the four indicators, there were
important variations; for example, environmental context and resources featured in discussions of all
of the indicators. However, the specific belief contents varied considerably, with poor communication
between primary and secondary care being a problem for prescribing anticoagulation for AF, whereas
resource constraints, particularly the limited availability of ambulatory BP monitors, was identified for
hypertension management. Social and professional roles and identity was also important across all
indicators; some interviewees did not feel responsible for achieving some indicators. Other prominent
determinants included beliefs about consequences, social influences, knowledge and memory, attention
and decision processes, the latter being particularly relevant for prescribing decisions. Less evident
domains included motivation, beliefs about capabilities, skills and emotion.
We identified five meta-themes from a synthesis of data across all four indicators, which broadly
represent cultural, professional and system influences on evidence-based practice. Some of these might
be amenable to change only at higher organisational levels (i.e. beyond the practice team), such as
external sources of support and communication pathways, or even further upstream in the development
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and dissemination of guidance, particularly perceptions of indicators.60 Nevertheless, our findings
underline the value of opportunities to share knowledge, expertise and support via local information
technology systems for more efficient communication across care pathways.
Our interviewees consistently indicated the central role of patients for certain indicators, especially
where outcomes partly or largely depend on patient behaviour. Many interviewees recognised the role
of consultation and counselling skills in enabling patient behaviour change. First, patients influence
professionals’ decisions indirectly, sometimes via assumptions the latter make about the values and
preferences of their patients. Second, the patient’s own behaviour frequently featured as a barrier to
indicator achievement; for example, BP control is more difficult to achieve if a patient drinks alcohol
excessively or does not adhere to prescribed medication. Thus, the motivation and goals of both
professionals and patients may need to be addressed simultaneously to optimise outcomes.61
Interventions that target both patients and professionals appear more likely to achieve glycaemic
control in diabetes than those targeting either group in isolation.62
Professionals often discussed general perceptions of guidelines and indicators. Many participants,
particularly GPs, acknowledged that the value of guidelines was clear for the population but not
for some patients, perhaps those with comorbidities or complex needs, whose adherence to
recommendations could result in poorer outcomes. This perceived inflexibility has been reported in
other studies of guideline adherence.63,64
We highlight four limitations. First, the indicators we studied generally related to grouped behaviours
or treatment goals (e.g. BP control in hypertension); thus, responses to questions rarely related to the
enacting of a specific behaviour (e.g. taking a patient’s BP during a consultation). The TDF is more typically
proposed and used to investigate specific behaviours. Second, we actively encouraged participants to talk
about each domain and analysed the data by looking for evidence that each domain was referenced in the
language of participants. Although this may have prompted people to think about influences that might not
come to mind (e.g. emotion), it made prioritising domains for intervention development difficult. Simply
asking participants to talk about the factors that influence their behaviour may be a better technique
for identifying key domains. Third, the TDF approach is based on the assumption that explanations of
behaviour can be verbalised, that most individuals have the insight to do this and that these explanations
resemble the actual influences on behaviour. Accepting the interview findings uncritically as ‘the truth,’
free of post hoc rationalisation, self-presentation bias and so forth, would be naive. Fourth, we
acknowledge the significant influences of patients on health professionals’ behaviour, and their role as
actors in their own right. These both affect achievement of indicator targets; therefore, we may have
identified further barriers and enablers had we also interviewed patients. Our findings suggest the
potential value of interventions for selected indicators that target both patients and professionals.
Conclusion
We elicited a wide range of reported determinants of adherence to ‘high-impact’ indicators in primary
care using the TDF. It was more difficult to pinpoint which determinants, if targeted by an implementation
strategy, would maximise change. The meta-themes broadly underline the need to align the design of
interventions targeting general practices with higher-level supports and broader contextual considerations.
However, our findings suggested that it was feasible to develop interventions to promote the uptake of
different evidence-based indicators that share common features while also including content-specific
adaptations.
Work package 3b: developing an adaptable implementation package for
indicators in primary care
Background
We next aimed to develop an implementation package that could be adapted to target each of four
selected indicators. Accurate intervention descriptions can improve understanding of the effects of
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interventions to change professional behaviour and hence guide their continuing optimisation. The
Behaviour Change Taxonomy outlines 93 specific behaviour change techniques (BCTs) – observable,
replicable and irreducible ‘active ingredients’ that offer a common language with which to describe
intervention content.65,66 We planned to embed BCTs targeting determinants of adherence for each of
four indicators within the adaptable implementation package.
Methods
We built our implementation package over five overlapping stages.
Stage 1: selecting delivery mechanisms
We selected delivery mechanisms typically available within primary care and of known effectiveness:
audit and feedback (A&F),67 educational outreach68 and computerised prompts and reminders.69,70 We
aimed to embed features associated with higher effectiveness (e.g. repeated feedback of audit data,
requiring prescribers to select a reason for over-riding a computerised prompt).67,69
Stage 2: identifying candidate behaviour change techniques
Team members (LG, RL, RM and RF) independently mapped BCTs (e.g. ‘feedback on behaviour’ or
‘action-planning’)66 to theoretical domains54 and resolved discrepancies by discussion. We thereby
generated an inclusive list of ‘candidate’ change techniques.
Stage 3: prioritising determinants of behaviour
We convened a series of multidisciplinary panel meetings, one for each indicator.We invited 5–10
stakeholders with a range of perspectives and skills, including GPs, practice nurses, pharmacists,
practice managers, quality improvement specialists and service commissioners.We presented them
with emerging analyses from our earlier interviews (WP3a) with primary care professionals (frequency
data and illustrative quotes for each determinant of achievement).52 After reviewing the range of
determinants, stakeholders contextualised our findings and suggested additional professional or
organisational determinants. The panel considered the feasibility and acceptability of candidate BCTs
and intervention delivery mechanisms and their potential enhanced features, taking primary care context
and resources into account.We took field notes of discussions.We convened our patient and public
involvement (PPI) panel in parallel and followed similar methods. The research team communicated
key messages from one panel to another and reviewed suggestions from both groups. Following the
stakeholder panels, we further analysed interview findings to identify the most prominent determinants
and high-level themes.We grouped determinants into four categories: core, prominent, less evident and
not identified. Determinants considered core to all four QIs (i.e. consistently raised regardless of QI)
included ‘social and professional role’, and ‘environmental context and resources.’ Those considered
prominent (i.e. determinants that varied in importance) included ‘beliefs about consequences’, ‘social
influences’, ‘knowledge’ and ‘memory, attention and decision processes.’ ‘Skills’, ‘beliefs about capabilities’ and
‘motivation and goals’ were less evident, whereas ‘emotion’ and ‘behavioural regulation’ were not identified.
Stage 4: designing intervention content
We drew on stages 1–3 to create a prototype outline for each delivery mechanism (feedback report,
educational outreach session, and prompts and reminders).We did not develop computerised prompts
for diabetes or BP control because they were already widely used to support QOF.10 Stakeholders also
suggested patient-directed checklists to guide discussions around diabetes and BP control.We embedded
candidate BCTs to target modifiable determinants of adherence. The prototype was adapted and tailored
for each QI.We used the vocabulary and experiences expressed in interviews with health-care
professionals and stakeholder panellists to tailor BCT content within delivery mechanisms. A graphic
designer enhanced the intervention materials.
Stage 5: piloting and refining intervention content
We piloted each delivery mechanism for all QIs with five general practices involved in our earlier
interview study (WP3a).52 A researcher (EI) directly observed the delivery of each educational outreach
DOI: 10.3310/pgfar08040 Programme Grants for Applied Research 2020 Vol. 8 No. 4
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Foy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
15
session. She conducted brief, opportunistic semistructured interviews with practice staff (six GPs,
two practice managers, and three practice nurses). Participants commented on the acceptability and
feasibility of prototype feedback reports, patient-directed checklists and protocols for computerised
prompts. We reviewed field notes and iteratively refined intervention content.
Results
We developed an implementation package adapted for each QI, fully described in Glidewell et al.71
(see Appendix 1, Table 17). Behaviour change technique categories with the potential to target one
or more theoretical determinants were identified in a matrix (Tables 3 and 4). We identified 30 BCTs
with potential to target determinants from our interview study and stakeholder panels (Table 5).
We discarded those BCTs that could not be operationalised within our delivery mechanisms or existing
primary care resources (see Appendix 1, Table 18).
The implementation package adapted for four quality indicators
Audit and feedback aimed to give comparative feedback on achievement, inform and prompt recall of
clinical goals, highlight consequences of changing or not changing practice, suggest strategies for change
and encourage goal-setting and reflection on progress towards goals. Reports included remotely gathered,
individualised practice data and presented achievement for relevant trial indicators in graphical and
numerical forms. Bar charts ranked practices by achievement and allowed comparisons with other
(anonymised) trial practices in the same CCG and wider region, with accompanying text providing
positive or encouraging feedback according to whether achievement had risen or fallen since the first
report. Reports also contained brief, evidence-based clinical messages, responses to common queries
(e.g. concerning data validity) and action-planning templates. Practices received reports quarterly in
both electronic and paper form. Reports were accompanied by computerised search tools to identify
relevant patients for review and significant event audit templates to support root cause analyses (risky
prescribing; anticoagulation for AF).
Educational outreach aimed to build on feedback by facilitating individual and group reflection, discussing
barriers to action, sharing models of good practice, enhancing motivation and action-planning. We trained
pharmacists over 2 days to deliver sessions. The 30-minute sessions were designed to fit in with existing
practice meetings and were offered to but not mandatory for intervention practices. We invited all staff
involved in patient and practice management to attend.We identified a key clinical contact to support
practice engagement. We offered a follow-up session to review progress and refine action plans, as well as
2 days of pharmacist support for patient identification and review.
Prompts and reminders aimed to reinforce clinical messages and indicator adherence. Computerised
prompts for risky prescribing were triggered during consultations and repeat prescribing on the basis
of an algorithm for patient age, diagnosis, drug and duration. A one-click justification (ignore, add or
stop medication) was required before users could proceed.
The prompt for AF was not operationalised in time for trial evaluation. To avoid duplication with
existing quality improvement systems, we did not develop computerised prompts for diabetes or BP
control.72 We provided laminated reminders to convey key clinical information (e.g. management
pathways) for BP control, anticoagulation for AF and risky prescribing. We provided pens and sticky
notes containing key clinical messages to reinforce recommended practice. We developed patient-
directed checklists to facilitate shared decision-making for BP control and diabetes control practices.
However, we could not identify an efficient way to deliver these within routine consultations.
Identification of behaviour change techniques included within implementation packages
Each implementation package included at least 27 out of 30 potentially applicable BCTs (see Table 5),
representing 15 of 16 BCT categories. Each package contained multiple unique instances of the
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TABLE 3 Theoretical determinants of adherence to QIs and their prioritisation for intervention development (WP3b)
Layered
identification
of theoretical
determinants
Capability Opportunity Motivation
OtherPhysical Psychological Social Physical Reflective Automatic
Skills Knowledge Memory
Behavioural
regulation
Social
influences
Environmental
context
Beliefs about
capabilities
Beliefs about
consequences
Social
professional role Emotion
Patient
factors
1. Consensus
panel of clinical
and patient
stakeholders
DC DC
2. Extended
qualitative
analysis of
interview data
AF, RP, DC AF RP AF BP, DC All All All All
Combined
analysis
AF, BP, DC All AF, RP, DC All All All BP, RP, DC All All AF, RP, DC All
BP, blood pressure control; DC, diabetes control; RP, risky prescribing.
Reproduced from Glidewell et al.71 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data
made available in this article, unless otherwise stated.
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TABLE 4 Candidate BCTs mapped to determinants of adherence ordered by core, prominent and less evident determinants identified during interview study52 (WP3b)
Potential BCT categories66 ordered by
likelihood of targeting core, prominent
and less evident determinants
Core to all indicators Prominent across indicators Less evident
Environmental
context
Social
professional
role Knowledge Memory
Social
influences
Beliefs about
consequences Skills
Beliefs
about
capabilities
Motivation
and goals
Social support • • • •
Antecedents • •
Comparison of behaviour • • • • • •
Feedback and monitoring • • • • •
Identity •
Covert learning •
Comparison of outcomes • • • •
Natural consequences • • •
Shaping knowledge • •
Goals and planning • • •
Repetition and substitution • • •
Associations • •
Regulation •
Reward and threat • •
Self-belief •
Scheduled consequences •
Number of potentially relevant BCT
categories
2 5 4 6 4 3 3 6 8
Reproduced from Glidewell et al.71 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data
made available in this article, unless otherwise stated.
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different BCTs. Four BCTs that were intended for inclusion (‘identification of self as a role model’ and
‘verbal persuasion about capability’ in educational outreach, ‘discrepancy between current behaviour
and goal’ in feedback reports and ‘anticipated regret’ in feedback reports and educational outreach)
could not be confirmed in a subsequent content check.
Extent of shared and unique behaviour change technique content across
implementation packages
Twenty-three BCTs were shared across all QIs (see Table 5). Twenty-seven BCTs were identified in
strategies targeting risky prescribing and BP control and 30 were identified in strategies targeting
anticoagulation for AF and diabetes control. Seven BCTs were unique to implementation packages
largely focused on changing processes of care (risky prescribing and anticoagulation for AF contained
BCTs relating to ‘goal-setting for behaviour’ and ‘monitoring of behaviour’) and five BCTs were unique
to packages targeting patient outcomes (BP control and diabetes control contained BCTs relating to
‘goal-setting for outcomes’ and ‘monitoring for outcomes’). We did not operationalise ‘goal-setting
for behaviour’ or ‘monitoring of behaviours’ for BP and diabetes control that focused on outcomes
of behaviour.
Discussion
We aimed to provide a transparent account of intervention development and report sufficient detail
for adoption, adaptation or evidence synthesis. We identified a large proportion of shared BCTs
(at least 23 of 30 eligible BCTs) representing 15 of 16 BCT categories, suggesting that prioritised BCTs
can be embedded and identified across delivery mechanisms adapted for different QIs.
We had to make trade-offs between what is theoretically desirable, clinically acceptable and operationally
feasible in the context of delivery mechanisms and primary care resources. First, there were limitations in
how we assessed and prioritised determinants of behaviour and subsequently linked them to BCTs.We
used emerging and extended interview findings to inform intervention development. It was not possible
within our research timelines to use the extended findings to inform adaptation of educational outreach or
initial feedback reports. We may not have adequately operationalised BCTs to target core and prominent
determinants (‘social and professional role’ and ‘environmental context and resources’) in the following
categories: ‘social support’, ‘antecedents’, ‘identity’ and ‘covert learning’ to target the determinants. Second,
BCTs from social cognition models and the TDF more generally focus on individual cognitions and may be
insufficient to adequately target team, patient or organisational determinants. Third, although determinants
of practice may be relevant only to countries with comparable primary care systems, methods to identify
candidate BCTs and verify their presence are transferable.
We would have preferred to undertake more extensive piloting of the intervention as a whole and
across all four targeted indicators. Our time to do this was limited by our decision to bring forward the
trials’ start date by 3 months so that the intervention period would coincide with the QOF year.
Conclusion
We have demonstrated the specification of BCT content for an adaptable implementation package.
We identified variable numbers of BCTs but would not claim that ‘more is better’; the ability to
effectively target the most salient determinants is likely to be more important.
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TABLE 5 Full description of intervention content by delivery mechanism and QI
Determinants of
behaviour
BCTs verified
by independent
coder
BCT taxonomy
code reference
Implementation package (see subsequent headings for
variation in delivery mechanisms by QI) A&F
Risky
prescribing
Diabetes
control Anticoagulation
BP
control
Risky
prescribing
Diabetes
control
‘Environmental context’,
‘social and professional
role’ and ‘social
influences’
Social support Social support
unspecified (3.1)
• • • • • •
Social support
practical (3.2)
• • • • • •
‘Environmental context’
and ‘memory’
Antecedents Restructuring
the physical
environment (12.1)
•
Restructuring the
social environment
(12.2)
• •
Adding objects to
the environment
(12.5)
‘Social and professional
role’, ‘knowledge’ and
‘social influences’
Comparison of
behaviour
Social comparison
(6.2)
• • • • • •
Information about
others’ approval
(6.3)
• • • • • •
‘Social and professional
role’, ‘memory’ and
‘beliefs about
consequences’
Feedback and
monitoring
Feedback on
behaviour (2.2)
• • • • • •
Self-monitoring of
behaviour (2.3)
• • • • • •
Self-monitoring of
outcomes of
behaviour (2.4)
• • • • • •
Feedback on
outcomes of
behaviour (2.7)
• • •
‘Social and professional
role’
Identity Framing/reframing
(13.2)
•
Covert learning Vicarious
consequences
(16.3)
• • • • • •
‘Knowledge’, ‘social
influences’ and ‘beliefs
about consequences’
Comparison of
outcomes
Credible source
(9.1)
• • • • •
Pros and cons (9.2) • • • • •
‘Knowledge’ and ‘beliefs
about consequences’
Natural
consequences
Information
about health
consequences (5.1)
• • • • •
Salience of
consequences (5.2)
• • • • • •
Information
about social/
environmental
consequences (5.3)
• • • • • •
‘Knowledge’ Shaping
knowledge
Instruction on how
to perform the
behaviour (4.1)
• • • • • •
Information about
antecedents (4.2)
• • • • • •
Reattribution (4.3) • • • • • •
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Educational outreach Computerised prompts and/or paper-based reminders
Anticoagulation
BP
control
Risky
prescribing
Diabetes
control Anticoagulation
BP
control
Risky
prescribing Anticoagulation
BP
control
Diabetes control
(not developed to
prevent overlap
with other QI
initiatives)
• 1• • • • •
• • • • • •
•
• •
• • • • • •
• • • • • •
• •
• •
• •
•
•
• •
• • • • • • • •
• • • • • • •
• • • • • • • •
• •
• • • • •
• • • • • •
• •
• •
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TABLE 5 Full description of intervention content by delivery mechanism and QI (continued )
Determinants of
behaviour
BCTs verified
by independent
coder
BCT taxonomy
code reference
Implementation package (see subsequent headings for
variation in delivery mechanisms by QI) A&F
Risky
prescribing
Diabetes
control Anticoagulation
BP
control
Risky
prescribing
Diabetes
control
‘Memory’ Goals and
planning
Goal-setting
behaviour (1.1)
• • • • • •
Problem solving
(1.2)
• • • • • •
Goal-setting
outcome (1.3)
• • • •
Action-planning
(1.4)
• • • • • •
Review
behavioural goals
(1.5)
• • • • • •
Review outcome
goals (1.7)
• • • •
Behavioural
contract (1.8)
• • •
Commitment (1.9) • • •
Repetition and
substitution
Habit formation
(8.3)
• •
Graded tasks (8.7) • • • • •
Associations Prompts/cues (7.1) • • • • • •
Regulation Conserving mental
resources (11.3)
• • • • • •
‘Social influences’ Reward and
threat
Social reward
(10.4)
• • • • • •
‘Beliefs about
capabilities’
Self-belief Focus on past
success (15.3)
• • • • • •
Total number of BCTs verified by independent coder 27 30 30 27 26 29
•= present.
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Educational outreach Computerised prompts and/or paper-based reminders
Anticoagulation
BP
control
Risky
prescribing
Diabetes
control Anticoagulation
BP
control
Risky
prescribing Anticoagulation
BP
control
Diabetes control
(not developed to
prevent overlap
with other QI
initiatives)
• • • •
• • • • • •
• • • •
• • • • • •
• • • • • •
• • • • •
•
•
• • • • • •
• • • • • • • • •
• • •
• • • • • •
• •
29 28 16 16 17 17 6 6 1
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Work package 4a: a cluster-randomised evaluation of an adaptable
implementation package targeting ‘high-impact’ evidence-based indicators
in primary care
Background
Having developed an adaptable implementation package, tailored to target four high-impact indicators,
we assessed its effects and cost-effectiveness in a cluster-randomised controlled evaluation. The
published protocol is available as Willis et al.73
Methods
Study design and setting
We conducted two parallel, cluster-randomised controlled trials (cRCTs) using balanced incomplete
block designs. Cluster randomisation was essential as interventions were delivered at the general
practice level (cluster). We maximised pragmatism in trial design and execution to ensure ‘real-world’
relevance.74 Practices were recruited from West Yorkshire, England covering a socioeconomically
diverse population of 2.2 million residents75 that is broadly typical of national demographics, with
the exception of higher deprivation levels.44 Over 300 general practices are organised within
10 CCGs.
Each trial evaluated the effect of adapted implementation packages on adherence to two of four
high-impact QIs: diabetes control and risky prescribing in trial 1 and BP control and anticoagulation in
AF in trial 2. We selected the four indicators based on scope for improvement in practice (guided by
WP2 findings) and potential population benefit through the achievement of recommended treatment
goals for all of HbA1c, BP and cholesterol in type 2 diabetes, avoidance of risky prescribing of NSAIDs
and antiplatelet drugs,76 anticoagulant prescribing for stroke prevention in AF,77,78 and achievement
of recommended BP levels in patients with hypertension and others at high risk of cardiovascular
events.79 Our selection also took trial design into account. Within each trial, we assumed that any
clinical effects of either implementation package would be independent of one another; thus, practices
randomised to the implementation package for one indicator acted as control practices for the other
implementation package and vice versa (Tables 6 and 7).
TABLE 6 Overview of cluster-randomised evaluation (WP4a): trial 1
Trial 1a Practices 1–40 Practices 41–80
Adapted implementation package for diabetes control Intervention Control
Adapted implementation package for risky prescribing Control Intervention
a A further 34 general practices were randomised as non-intervention controls.
TABLE 7 Overview of cluster-randomised evaluation (WP4a): trial 2
Trial 2a Practices 81–112 Practices 113–144
Adapted implementation package for BP control Intervention Control
Adapted implementation package for anticoagulation in AF Control Intervention
a A further 34 general practices were randomised as non-intervention controls.
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General practices were eligible if they used SystmOne, the computerised clinical system used by
approximately two-thirds of West Yorkshire practices [The Phoenix Partnership, URL: www.tpp-uk.com
(accessed 16 September 2019)]. We excluded practices involved in intervention development and
piloting (i.e. WPs 2 and 3).
We used an opt-out approach to practice recruitment to facilitate participation and enhance
generalisability.80 We invited eligible practices to participate via recorded post and e-mail, with
reminders at 2 weeks to non-responding practices. We included those which had not actively declined
by 4 weeks. The use of opt-out recruitment avoided the biases associated with opt-in approaches and
enhanced sample representativeness.44,48 We obtained anonymised patient-level data81 through data
extracts from SystmOne.
Procedures
We adapted the implementation package for each QI comprising a combination of A&F reports,
educational outreach visits and computerised prompts with embedded BCTs, as detailed in WP3b.66
A dedicated administrator contacted practices to offer to co-ordinate the educational outreach visits,
which were also promoted in feedback reports and e-mail communications to all practices.
Trial end points
Table 8 lists all outcomes. In brief, primary outcomes at 11 months post randomisation were
achievement of all recommended target levels of HbA1c, BP and cholesterol in patients with type 2
diabetes; a composite indicator of risky prescribing; achievement of recommended BP targets for
specific patient groups; and anticoagulation prescribing in eligible patients with AF.
We modified three of the indicators representing the primary outcomes from those we developed and
assessed in earlier WPs:
l Risky prescribing. We modified ‘Prescribing of warfarin and a traditional oral NSAID without
coprescription of a gastroprotective drug’ to ‘Prescribing of warfarin and a traditional oral NSAID.’
Combined use of warfarin and NSAIDs is contraindicated and it would not make clinical sense to
add gastroprotection in this situation.
l BP control. We broadened the indicator that had focused on targets in treated hypertension to
encompass BP control across a range of conditions associated with higher cardiovascular risk
(e.g. CKD) as well as patients with a cardiovascular disease risk of ≥ 20%. We judged that this would
potentially permit a greater population impact and assumed that the determinants of practice were
unlikely to change markedly.
l Anticoagulation for AF. The indicator ‘Those patients with AF whose latest record of a congestive
heart failure, hypertension, age > 75 years, diabetes mellitus and prior stroke (CHADS2) score is
greater than one should be offered anti-coagulation therapy’ was superseded by one using the
congestive heart failure, hypertension, age > 75 years, diabetes mellitus, stroke and vascular disease
(CHA2DS2-VASc) score. We also dropped the specification that ‘Warfarin should be administered as
the most effective thromboprophylactic agent’ to reflect emerging guidance allowing prescribing of
non-vitamin K antagonist oral anticoagulants (NOACs) as an alternative.82
Secondary outcomes included individual indicators within the composite primary outcomes, processes
of care and continuous clinical outcomes such as HbA1c, BP and cholesterol.
Sample size
We used WP2 data to inform trial sample sizes. Mean cluster size (number of eligible patients per
practice), cluster size coefficient of variation, intracluster correlation coefficient and mean achievement
rates were calculated for each primary indicator (Table 9).
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TABLE 8 Primary and secondary outcomes in cluster-randomised evaluation of implementation package (WP4a)
Diabetes control Risky prescribing BP control Anticoagulation in AF
Primary outcomes
The proportion of patients
with type 2 diabetes
achieving all three of the
following treatment
targets:
1. BP of < 140/80 mmHg
(or 130/80 mmHg if
there is kidney, eye or
cerebrovascular
damage)
2. HbA1c value of
≤ 59mmol/mol
3. Total serum cholesterol
level of ≤ 5.0 mmol/l
The proportion of patients
achieving at least one of
the nine following
indicators of high-risk
NSAID and antiplatelet
prescribing:
1. Prescribing a
traditional oral NSAID
or low-dose aspirin in
patients with a history
of peptic ulceration
without coprescription
of gastroprotection
2. Prescribing a traditional
oral NSAID in patients
aged ≥ 75 years
without coprescription
of gastroprotection
3. Prescribing a
traditional oral NSAID
and aspirin in patients
aged ≥ 65 years
without coprescription
of gastroprotection
4. Prescribing of aspirin
and clopidogrel in
patients aged ≥ 65 years
without coprescription
of gastroprotection
5. Prescribing of warfarin
and a traditional
oral NSAID
6. Prescribing of warfarin
and low-dose aspirin or
clopidogrel without
coprescription
of gastroprotection
7. Prescribing an oral
NSAID in patients with
heart failure
8. Prescribing an oral
NSAID in patients
prescribed both a
diuretic and an
angiotensin-converting-
enzyme inhibitor
(ACE-I) or angiotensin
receptor blocker
9. Prescribing an oral
NSAID in patients
with CKD
The proportion of patients
achieving at least one of
the eight following
recommended targets for
satisfactorily controlled BP:
1. BP of < 140/90mmHg
in patients aged < 80
years with hypertension
2. BP of < 150/90mmHg
in patients aged ≥ 80
years with hypertension
3. BP of < 140/80mmHg
in patients aged < 80
years with diabetes, or
< 130/80mmHg if there
are complications
of diabetes
4. BP of < 130/80mmHg
in patients aged
< 80 years with CKD
and proteinuria
5. BP of < 140/90mmHg
in patients aged
< 80 years with
coronary heart disease
6. BP of < 140/90mmHg
in patients aged < 80
years with peripheral
arterial disease
7. BP of < 140/90mmHg
in patients aged < 80
years with a history of
stroke or transient
ischaemic attack
8. BP of < 140/90mmHg
in patients aged
< 80 years with a
cardiovascular disease
risk of ≥ 20%
Note: patients should
appear only once and,
where any appear in more
than one group with
differing BP targets, the
lower target should take
precedence
The proportion of patients
prescribed anticoagulation
therapy in the following
groups:
1. Men with AF and a
CHA2DS2-VASc score
of 1 prescribed
anticoagulation therapy
2. All people with AF and
a CHA2DS2-VASc score
of ≥ 2 prescribed
anticoagulation therapy
Secondary outcomes
1. The proportion of
patients with type 2
diabetes achieving
each of the individual
treatment targets that
make up the primary
outcome
1. The proportion of
patients achieving the
individual indicators
that make up the
primary outcome
1. The proportion of
patients achieving the
individual targets that
make up the primary
outcome
1. The proportion of
patients achieving the
indicators that make up
the primary outcome
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TABLE 8 Primary and secondary outcomes in cluster-randomised evaluation of implementation package (WP4a)
(continued )
Diabetes control Risky prescribing BP control Anticoagulation in AF
2. The proportion of
patients with type 2
diabetes receiving each
of the following nine
processes of care in the
previous 12 months:
a. BP measured
b. HbA1c levels
measured
c. Full lipid profile
performed
d. Micro-albuminuria
testing performed
e. Estimated
glomerular filtration
rate/serum
creatinine
testing performed
f. Foot care review
g. Eye screening
h. BMI recorded
i. Smoking status
recorded
3. The proportion of
patients with type 2
diabetes receiving all of
the above processes
of care
4. The proportion of
patients with type 2
diabetes receiving all of
the processes of care
as defined in above
with the exception of
(g) eye screening
5. Mean patient levels of:
a. Systolic BP
b. Diastolic BP
c. HbA1c
d. Total serum
cholesterol
2. The proportion of
patients achieving
at least one of
indicators 1–6
(gastrointestinal
composite)
3. The proportion of
patients achieving at
least one of indicators
8 and 9 (renal
composite)
2. Mean patient levels of:
a. Systolic BP
b. Diastolic BP
3. The proportion of
patients with
hypertension or at high
risk of cardiovascular
events with measured
BP in the previous
12 months
2. The proportion of
patients eligible for the
two indicators who
have contraindication
for anticoagulation, i.e.:
a. Men with AF and a
CHA2DS2-VASc
score of 1 with
contraindication
for anticoagulation
b. All people with AF
and a CHA2DS2-
VASc score of 2
or above with
contraindication for
anticoagulation
3. The combined
proportions of patients
achieving the two
indicators related to
contraindication for
anticoagulation as
defined above in 2(a)
and 2(b)
BMI, body mass index; CHA2DS2-VASc, congestive heart failure, hypertension, age > 75 years, diabetes mellitus, stroke
and vascular disease.
TABLE 9 Key sample size assumptions for cluster-randomised evaluation of implementation package (WP4a)
Diabetes
control
Risky
prescribing
BP
control
Anticoagulation
in AF
Mean cluster size (number of eligible patients per practice) 280 420 800 55
Coefficient of variation of cluster size 0.60 0.65 0.67 0.79
Intracluster correlation coefficient 0.06 0.03 0.06 0.06
Mean achievement (%) 43.0 89.0 72.0 60.0
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Median effect sizes on processes and outcomes of care for a range of guideline implementation
studies are around 4–9%.83,84 Given that we were evaluating enhanced, multifaceted interventions and
targeting indicators with scope for improvement, we judged an absolute difference of 15% for diabetes
control, BP control and AF outcomes as realistic and relevant from a population perspective. Control
group achievement rates in risky prescribing were higher and considering a potential ceiling effect, we
considered a 5% difference as realistic and clinically relevant. To achieve 90% power, and allowing for
an alpha error rate of 2.5% (to adjust for two outcome comparisons in each trial) and a 10% drop-out
rate, we required 40 practices per arm in trial 1 (diabetes and risky prescribing) and 32 practices per
arm in trial 2 (BP control and anticoagulation for AF). We therefore aimed to recruit 144 practices.
The opt-out approach resulted in 178 practices being recruited, allowing randomisation to a fifth arm:
a non-intervention control group to further assess Hawthorne effects.
Randomisation
A two-stage minimisation process (incorporating a random element) was undertaken centrally by
the trial statistician. First, practices were stratified by CCG and list size, and randomised to trial 1,
trial 2 or non-intervention group (80 : 64 : 34). Practices from one CCG involved in a concurrent
initiative targeting anticoagulation in AF were ineligible for trial 2 and allocated to either trial 1 or
non-intervention. Second, practices within each trial were randomised (1 : 1) to individual trial arms,
minimised by CCG, list size and pre-intervention adherence to the two targeted indicators relevant to
that trial. General practices and trial personnel involved in intervention delivery were, of necessity,
made aware of allocation but collection of outcomes for the primary end points was blind.
Data collection
We gathered anonymised outcome data remotely from general practices, mostly using data collected
for QOF between 1 April 2015 and 31 March 2016.
We obtained data on practice characteristics from publicly available sources (Health Education England,
Health and Social Care Information Centre)45,85,86 including practice list size (number of registered
patients); number of GP partners and salaried GPs; practice training status; practice-level IMD, ethnic
profile of practice register, achievement of QOF indicators (2014–15); patient satisfaction (proportion
who would recommend the practice to others); patient-rated practice accessibility (proportion able to
speak with GP or nurse within 48 hours of approach); and practice prescribing costs. Patient characteristics
were extracted along with QOF achievement data and included age, sex and comorbidity (number of
QOF registers on which patient appeared).
Statistical analysis
We undertook all data summaries and analyses on the intention-to-treat population, defined as all
patients registered at randomised practices, regardless of intervention uptake or loss from the trial.
Statistical testing was completed at a two-sided 2.5% significance level; effect sizes and 97.5%
confidence intervals (CIs) were reported in each case. All comparisons were conducted using the
within-trial randomised controls. Analyses utilising the non-intervention controls are reported
separately.
Data completeness for analyses depended on the completeness of SystmOne medical records and
could not be assessed within the trial data set. Missing Read codes could lead to patients being
incorrectly included in or excluded from eligible populations. Similarly, indicator achievement may have
been incorrectly specified as a result of missing data. For the primary and secondary analyses, we
assumed that data were missing at random.
We compared primary outcomes between intervention and control practices using two-level binary
logistic regression models, with patients (level 1) nested within registered practices (level 2). We
adjusted analyses for patient-level covariates (gender, baseline age) and practice-level covariates
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(baseline practice list size, CCG, pre-intervention achievement against primary outcomes, overall QOF
score 2014–15 and baseline proportion of patients with 0–3 comorbidities).
We analysed binary secondary outcomes for individual indicators within the composite primary
outcomes and recorded processes of care using similar multilevel logistic models. We analysed
continuous intermediate clinical outcomes using two-level linear models. We adjusted each model for
the same covariates specified for the primary outcome analysis. Intervention effects on related wider
practice behaviour (i.e. other indicators not targeted by the interventions) were assessed by QOF
2015–16 indicators mapped to trial outcomes. We assessed unintended effects on quality of care via
a series of non-trial related QOF indicators in coronary heart disease, mental health, smoking and
asthma (see table 1 of Willis et al.73). We used practice-level achievement of each QOF indicator as
the outcome in a linear model, adjusted for practice-level covariates (baseline practice list size, CCG,
pre-intervention achievement against primary outcomes and overall QOF score 2014–15). Age and
gender are patient-level covariates and were, therefore, not included in the analyses of QOF indicators.
We undertook appropriate regression diagnostics for binary and continuous outcomes to check the
validity of the statistical modelling. We applied log transformations to continuous outcomes in cases
where residual normality assumptions appeared to be violated.
As part of our process evaluation, we collected data to explore the fidelity of delivery, receipt, use and
sustainability in both trial and process evaluation practices (described under WP5).
All analyses were planned prior to final data extraction and no interim analyses were planned or
conducted. Statistical analyses were conducted in SAS® (SAS Institute Inc., Cary, NC, USA) software
version 9.4 (SAS and all other SAS Institute Inc. product or service names are registered trademarks
or trademarks of SAS Institute Inc. in the USA and other countries.® indicates USA registration).
Results
Screening and recruitment
Between February 2015 and April 2015, we screened 278 SystmOne general practices across 10 West
Yorkshire CCGs (Figure 1). A total of 243 (87.41%) were eligible and invited to participate; 56 (23.05%)
of these practices opted out, largely because of workload pressures, and nine were excluded for other
reasons (see Report Supplementary Material 1, Tables 1–5). Typically practices opted out within 2 weeks
of receiving the invitation letter (mean 12.51 days, SD 11.47 days); thus, 178 (73.25%) of eligible
practices were randomised. Practice characteristics were broadly similar between those not randomised
and those randomised (see Appendix 1, Table 19).
Forty practices were allocated to each of the diabetes control and risky prescribing arms in trial 1,
32 practices were allocated to each of the BP control and anticoagulation in AF arms in trial 2. A further
34 practices were allocated to a non-intervention control arm (see Report Supplementary Material 1, Tables 6
and 7). None of the randomised practices withdrew from any aspect of the trial. One practice in the
risky prescribing arm merged with a non- Action to Support Practices Implementing Research Evidence
(ASPIRE) practice following the third feedback report at 9 months; no outcome data were available after
9 months. One practice in the BP control arm closed during the study because of GP retirement. This
practice received two of the four planned feedback reports; outcome data were unavailable beyond
6 months’ follow-up. Two ASPIRE practices merged during the trial, one from diabetes control and one
from risky prescribing; all patients from both practices became registered at the diabetes control practice.
Both practices received all four feedback reports and final outcome data were available for both
practices. One further ASPIRE practice from risky prescribing merged with a non-ASPIRE practice.
This practice received three of the four planned feedback reports; outcome data were unavailable
beyond 9 months’ follow-up.
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Baseline practice characteristics were well balanced by trial and indicator (see Appendix 1, Tables 19
and 20, and Report Supplementary Material 1, Table 8): across all 178 practices, the mean list size was
7249.76 patients (SD 4306.72 patients); the mean IMD was 30.85 (SD 13.70, falling within the top
quarter of social deprivation); and mean pre-intervention adherence was 33.29% (SD 7.08%) for
diabetes control, 7.91% (SD 4.07%) for risky prescribing, 65.87% (SD 6.67%) for BP control and
66.20% (SD 11.82%) for anticoagulation in AF.
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6 n = 40 n = 40 n = 32 n = 32 n = 34
9 n = 40 n = 40 n = 31 n = 32 n = 34
11 n = 40 n = 39 n = 31 n = 32 n = 34
• Participated earlier in programme
• Practice recruited to process evaluation
• Not contactable
• Safe haven sitea
(n = 24, 68.57%)
(n = 7, 20.00%)
(n = 2, 5.71%)
(n = 2, 5.71%)
• Opted out
• Outside trial geographical area
• Closed/merged
• Practice recruited to process evaluation
• Return to sender
(n = 56, 86.15%)
(n = 4, 6.15%)
(n = 3, 4.62%)
(n = 1, 1.54%)
(n = 1, 1.54%)
Assessed for eligibility
(n = 278)
Eligible and invited to participate
(n = 243, 87.41%)
Randomised
(n = 178, 73.25%)
Allocated to trial 1
(n = 80)
Allocated to trial 2
(n = 64) Allocated to
non-intervention
(n = 34)
Diabetes
control
(n = 40) 
BP control
(n = 32)
Anticoagulation
in AF
(n = 32)
Risky
prescribing
(n = 40) 
Analysed
(n = 40)
Analysed
(n = 40)b
Analysed
(n = 32)c
Analysed
(n = 32)
Analysed
(n = 34)
Recruited to
process
evaluation
(n = 8) 
Ineligible
(n =35, 12.59%)
Not randomised
(n = 65, 26.75%)
FIGURE 1 The CONSORT flow diagram for cluster-randomised evaluation (WP4a). a, Safe haven practices are for those
patients who have demonstrated violent tendencies and have been removed from usual general practice or for ex-offenders;
b, one practice in the risky prescribing arm merged with a non-Action to Support Practices Implementing Research Evidence
(ASPIRE) practice in advance of the fourth feedback report; however, as they received the first three feedback reports some
outcome data are available and they are included in the final analyses; c, one practice in the BP control arm closed in advance
of the third feedback report; however, as it received the first two feedback reports some outcome data are available and
these are included in the final analyses. Adapted fromWillis et al.87 © 2020Willis et al. This is an open access article
distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,
and reproduction in any medium, provided the original author and source are credited.
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Baseline characteristics for patients within the populations relevant to the four indicators, as well as all
patients within the practices, were broadly similar between the trial arms (see Appendix 1, Table 21, and
Report Supplementary Material 1, Tables 9–12). The data obtained relating to polypharmacy (number of
repeat prescriptions per patient) were found to be incomplete and, hence, were not used in any analyses.
Primary outcomes
The primary outcome results are summarised in Table 10, with detailed summaries in Appendix 1,
Table 22. In trial 1, achievement of diabetes control at 11 months for practices assigned to this
implementation package was 24.19% compared with 23.74% for practices assigned to the control arm
(risky prescribing); an adjusted OR of 1.03 (97.5% CI 0.89 to 1.18), thus providing no evidence of an
intervention effect.
There was evidence of a significant intervention effect for the risky prescribing implementation
package. The proportion of patients with a record of risky prescribing at 11 months in practices
assigned to this implementation package was 4.94% compared with 5.99% for control practices
(diabetes control); an adjusted OR of 0.82 (97.5% CI 0.67 to 0.99). Thus, the odds of risky prescribing
for a patient in an intervention practice were 18.5% lower (i.e. better) than for a patient with the same
characteristics in a control practice.
In trial 2, there was no evidence of a significant effect on primary outcomes for either implementation
package. Achievement of BP control at 11 months for practices assigned to this implementation
package was 53.62% compared with 52.32% for practices assigned to the control arm (anticoagulation
in AF); an adjusted OR of 1.05 (97.5% CI 0.96 to 1.16). Achievement of anticoagulation in AF at 11 months
for practices assigned to this implementation package was 73.20% compared with 75.18% for control
practices (BP control); an adjusted OR of 0.90 (97.5% CI 0.75 to 1.09).
TABLE 10 Primary outcome achievement: baseline rates, adjusted outcome rates and adjusted odds (WP4a)
Primary outcomes
Baseline
achievementa (%)
Adjusted outcome
achievementb (%)
Adjusted OR
(97.5% CI) NNTc p-value
Trial 1: diabetes control
Intervention 33.72 24.19 1.03 (0.89 to 1.18) 223 0.697
Control (risky prescribing) 34.43 23.74 1 [reference]
Trial 1: risky prescribing
Intervention 7.20 4.94 0.82 (0.67 to 0.99) 95 0.017
Control (diabetes control) 7.43 5.99 1 [reference]
Trial 2: BP control
Intervention 66.66 53.62 1.05 (0.96 to 1.16) 77 0.215
Control (anticoagulation in AF) 65.50 52.32 1 [reference]
Trial 2: anticoagulation in AF
Intervention 66.42 73.20 0.90 (0.75 to 1.09) –51 0.2141
Control (BP control) 67.54 75.18 1 [reference]
NNT, number needed to treat.
a Calculation of achievement for diabetes control and BP control at baseline uses ‘any’ BP measurements taken in the
previous 12 months.
b Calculation of achievement for diabetes control and BP control at outcome uses ‘the most recent’ BP
measurements taken.
c The NNT has been rounded up (away from zero) to an integer value.
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Secondary binary outcomes
In trial 1, secondary analyses of individual indicators forming the composite primary outcomes and
recorded processes of care showed no statistically significant effects relating to the diabetes control
implementation package (see Report Supplementary Material 1, Tables 13–26).
The risky prescribing implementation package resulted in significantly lower (i.e. better) levels for
one individual indicator, ‘Patients aged 65 years or over prescribed aspirin and clopidogrel without
coprescription of gastroprotection’. Prescribing levels were 25.32% in implementation package
practices compared with 35.20% in control practices: an adjusted OR of 0.62 (97.5% CI 0.39 to 0.99).
Thus, the odds of risky prescribing for a patient in an intervention practice was 37.59% lower (i.e. better)
than for a patient with the same characteristics in a control practice (see Report Supplementary Material 1,
Table 30). We identified no other statistically significant effects relating to other risky prescribing
indicators (see Report Supplementary Material 1, Tables 27–37). In trial 2, we found no evidence of
significant intervention effects on any individual indicators or processes of care (see Report Supplementary
Material 1, Tables 38–51).
Secondary continuous outcomes
There were no significant intervention effects in the secondary analyses of the continuous intermediate
clinical outcomes: systolic and diastolic BP (in both the diabetes control and the BP control populations);
HbA1c and total serum cholesterol (diabetes control only; see Report Supplementary Material 1, Tables 52–57).
The conclusions for total serum cholesterol and HbA1c were robust to log-transformation of the outcomes
in a sensitivity analysis conducted following model diagnostic checks.
Secondary analysis of Quality and Outcomes Framework indicators
We explored intervention effects for QOF indicators to assess whether or not there were any benefits
in the achievements of QOF indicator groups relevant to any of the implementation packages and
whether or not there were any unintended harms of reduced achievement in QOF indicator groups not
relevant to any of the packages (summary statistics; see Report Supplementary Material 1, Tables 58–61).
Statistical modelling was not possible for all indicators because of violation of modelling assumptions,
particularly where large proportions of practices attained 100% achievement for an indicator. For those
indicators where modelling was appropriate, we found no statistically significant intervention effects
(see Report Supplementary Material 1, Tables 62–75).
Intervention fidelity
Full analyses of intervention fidelity are presented under the process evaluation (WP5). In brief,
all practices received A&F reports as intended (with the exception of those that closed or merged).
Outreach visits were delivered to 67 (46.53%) practices, with 8 (5.56%) receiving two visits. There was
similar uptake between trial arms (see Appendix 1, Tables 26 and 27). The offer of visits was declined by
77 practices, 52 (67.53%) of which did not give a reason (see Report Supplementary Material 1, Table 76).
One hundred and twenty-six (87.50%) practices activated access to searches and computerised prompts
(risky prescribing practices only; see Report Supplementary Material 1, Tables 102–103).
Discussion
An adaptable, multifaceted implementation package improved clinical care for one of four high-impact
indicators in general practices serving relatively socially deprived populations. The odds of risky
prescribing for a patient in an intervention practice was 18.50% lower than for a patient with the same
characteristics in a control practice, with a population impact likely to translate into reduced mortality,
morbidity and unplanned emergency admissions. There was no effect on diabetes control, BP control
or anticoagulation in AF. The varying effects are likely to be attributable, in part, to differences in
targeted behaviours, suggesting that in broad terms our adapted ‘one-size-fits-all’ approach was not
universally effective.
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It initially appeared as if one risky prescribing subindicator associated with a statistically significant
effect might have driven the composite indicator. For ‘patients aged 65 years or over prescribed aspirin
and clopidogrel without coprescription of gastroprotection’, the number of eligible patients was relatively
small (334 in the intervention arm and 405 in the control arm) compared with the much larger overall
eligible number of patients for the composite primary outcome (18,313 in the intervention arm and
18,131 in the control arm). However, the risky prescribing intervention had cumulative effects across
most of the nine subindicators.
Our work is best contextualised within the wider literature related to key features of our implementation
package, namely A&F, educational outreach visits, and prompts and reminders. Ivers et al.67 found that A&F
was more effective for targeting prescribing behaviours versus other outcomes related to diabetes and
cardiovascular disease management. Similarly, reviews of educational outreach visits and computerised
prompts suggested more reliable effects in changing simpler as opposed to more complex outcomes.68,70
However, these reviews include potentially confounded indirect comparisons between studies; our
programme of trials is novel in allowing direct comparisons of effects between different targeted clinical
behaviours, notwithstanding some tailoring of content according to each high-impact indicator. Our
findings, therefore, suggest that the nature of the clinical behaviours targeted can be as important as
the type of intervention in predicting the effects of implementation strategies.
Our findings are consistent with those of Dreischulte et al.,88 who first demonstrated that an intervention
including feedback reduced risky prescribing. However, where changes in patient as well as professional
behaviour are important in achieving treatment goals, such as for long-term conditions like type 2
diabetes, interventions targeting both patients and professionals are more likely to be effective than those
targeting professionals alone;89 our implementation package mainly focused on professionals.
Our robustly designed trials used balanced incomplete block designs to permit comparison of intervention
effects while minimising any potential Hawthorne effects.90 Furthermore, the trials were highly pragmatic
in three ways. First, opt-out recruitment is likely to have ensured that participating practices were
representative of the wider population.44,48 Second, we used minimally intrusive data collection. Third,
for intervention delivery all practices received, but were not obliged to read, feedback reports; outreach
visits were optional.74 Hence, the implementation packages were tested under ‘real-world’ conditions,
increasing confidence in wider applicability to routine general practice settings.
Our evaluation had five main limitations. First, the use of routinely collected data may have compromised
the precision of our outcomes and hence ability to demonstrate effects. Second, the multifaceted nature
of the implementation package precludes any attempts to quantify the effects of individual intervention
components. Third, educational outreach visits were delivered by facilitators who were not allocated to
specific arms of the trial, thereby risking contamination between arms. We had instructed facilitators
to focus only on delivering the implementation package to which each practice was assigned. Fourth,
our follow-up period of 11 months may have been too short to ensure detection of changes in clinical
outcomes, such as those related to diabetes or BP control, especially if a number of general practices
only received educational outreach visits later in this period. However, other trials have demonstrated
changed clinical outcomes within similar durations of follow-up89 and we also detected no improvements
in processes of care for diabetes and BP control. Fifth, our composite end point for diabetes control
requiring achievement of treatment goals for all of HbA1c, BP and cholesterol may have been too
demanding. Nevertheless, we observed no improvements in any of these three contributing indicators
separately and this end point was considered fair, if challenging, by our clinical and patient advisors.
Our work highlights three methodological controversies and challenges. First, the effect of our
implementation package on risky prescribing was modest but important at a population level. Forgoing
randomised designs, as some have suggested,91,92 would have reduced confidence in the validity of
our findings, and risked false positive conclusions.93 Second, although we see our pragmatic design as
a strength, we could have applied a more explanatory approach and made full engagement with our
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implementation package a condition of trial participation. However, such mandating is seldom possible
or even desirable in quality improvement programmes that depend on professional consensus, particularly
as it may encourage ‘gaming’ behaviours to achieve goals while circumventing real action. Similarly,
opt-out recruitment may have diluted the contribution of self-selected and more enthusiastic practices,
as well as reduced administrative burden for participants; however, those responsible for leading quality
improvement initiatives often wish to specifically include less enthusiastic or poorer performing practices.
Such an approach appears no longer feasible under current research governance arrangements, which
require explicit permission from general practices to participate in research (a de facto opt-in approach).94
Third, a critical challenge prior to pragmatic evaluations is to develop interventions that are sufficiently
feasible and durable to withstand the relatively harsh environments of busy clinical practice. Although
we largely followed the UK Medical Research Council framework for the development and evaluation of
complex interventions,95 practice engagement with our implementation package was highly variable. We
would now recommend more intensive, iterative cycles of testing and refining interventions prior to
scaling up within definitive evaluations.
Conclusion
We have demonstrated the effectiveness of a multifaceted implementation package in reducing risky
prescribing. Our findings are directly applicable to general practice given the highly pragmatic nature
of our evaluation. Interventions involving A&F have also been shown to reduce other undesired
prescribing behaviours, namely of antibiotics,96 and offer a means to address other urgent priorities,
such as rising opioid prescribing.97 However, there are still major challenges in addressing other
high-impact indicators that are likely to require better targeted interventions that can be sustainably
embedded within general practice.
Work package 4b: economic evaluation
Introduction
We conducted economic evaluations alongside the ASPIRE trial analyses. We used the trials data to
parameterise decision-analytic models as the trials did not collect patient-level data. We did not expect
any longer-term intervention benefits to be realised beyond the trials period and thus modelled any
such impacts.
Given resource and time constraints, we were unable to evaluate all four trial indicators and prioritised
the economic evaluations based on ASPIRE team and steering committee advice while accounting for
the availability of ‘off-the-shelf’ decision models. There was a consensus that the risky prescribing
indicator was the first choice for evaluation, followed by BP control; hence, we evaluated these two
indicators and built associated de novo decision models. As a model was freely available for type 2
diabetes (UK Prospective Diabetes Study version 2),98 we also evaluated this indicator.
Methods
General approach and model choice
We treated the implementation packages as separate interventions, and hence did not aggregate costs
and effects. We aggregated subindicators for relevant composite indicators. Since we were evaluating
the implementation of NICE recommendations, we aimed to mirror evaluative tools used in the
evidence syntheses underpinning NICE guidelines. This was not possible for risky prescribing since this
was a new indicator although we relied heavily on previous modelling for NSAIDs.
Where possible we followed the reference case set out by NICE.99 As such, we reported cost per
incremental quality-adjusted life-year (QALY) from a health and personal social service provider perspective.
We adopted a lifetime perspective and discounted costs and benefits post 1 year at the NICE preferred
rate of 3.5% per annum. Where we developed or adapted models, we conducted targeted searches to
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identify parameter values. We developed and parameterised the models iteratively with ASPIRE team
clinicians (RF, SA and DP). The decision models allowed the generation of cost per QALY estimates by
translating trial effectiveness results on implementation and clinical outcomes into event risks and
expected costs, survival and quality-of-life impact. We estimated costs where necessary using standard
sources including NHS Reference Costs100 and the Personal Social Services Research Unit report.101 We
converted relevant historical or non-UK costs to 2017 UK prices using a health-related inflation tool.102
We report incremental cost-effectiveness ratios (ICERs) per QALY gain in each evaluation. To aggregate
cost-effectiveness within indicators (for risky prescribing and BP control), we generated weighted
averages of costs and benefits based on the proportion of a general practice list eligible for each indicator.
ICERs below the NICE preferred threshold of £20,000–30,000 cost per QALY were taken to indicate
cost-effectiveness. We ran deterministic sensitivity analyses to test the impact of changes in parameter
values and assumptions.Where possible, we also ran probabilistic sensitivity analyses to test the overall
impact of parameter uncertainty on model results. We present these results as cost-effectiveness planes
and cost-effectiveness acceptability curves (CEACs).103
Intervention costing
The ASPIRE implementation package costs comprised fixed and variable components that were all
expressed at practice level since all reported outcomes, namely QALY gain and health-care savings,
were computed for the average practice list size of 7130 patients. The fixed cost consisted of preparing,
delivering and receiving the interventions. To illustrate, outreach education involved costs relating to
facilitator training, including their time and room hire (preparation costs); the time delivering the outreach
visit (delivery costs); and the time of practice staff participation in outreach sessions (receipt costs).
The fixed costs of the interventions are provided in Table 11 (further details available on request).
Our assumptions were generally conservative.
We assumed the fixed costs were equally distributed across all four ASPIRE implementation packages.
However, to retain a conservative stance in our base-case analysis, we doubled the value of this per
intervention cost when computing the fixed cost per practice (n = 144) of implementing each specific
intervention.We undertook sensitivity analysis on the magnitude of the risky prescribing implementation
package fixed cost. The base-case fixed cost was £2439 (£175,592.36/144 × 2) per practice.We tested an
optimistic scenario where the per-practice fixed cost was £1219 (£175,592.36/144).
Variable implementation package costs included additional GP consultations to review and change
patients’ prescriptions, additional tests and the cost of additional medication (e.g. coprescribing
gastroprotection). The variable cost element of ASPIRE was directly related to implementation package
effectiveness in changing care processes; thus, no additional variable costs were incurred if GPs did not
change practice on intervention receipt. Implementation package effects were measured using the trial
arm differential in the proportion of eligible patients for each relevant indicator achieving recommended
care or outcomes.
TABLE 11 Economic evaluation: fixed costs of ASPIRE implementation package (WP4b)
Fixed costs (£) Educational outreach A&F Computerised tools
Intervention preparation 29,773.88 43,122.53 1459.32
Intervention delivery 39,269.49 7980.16 0.00
Intervention receipt 29,589.87 24,397.12 0.00
Subtotal 98,633.23 75,499.81 1459.32
Overall total (n = 144 practices) 175,592.36
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Risky prescribing
Our evaluation included all of the risky prescribing subindicators except for indicator nine, which
covers the prescription of a diuretic in combination with an angiotensin-converting-enzyme inhibitor or
angiotensin receptor blocker in those taking an oral NSAID. We could not find an acceptable evidence
base on which to base parameters and it was relevant for only 3% of the current sample.
We based the risky prescribing model around a previous model of NSAID prescription used for the
NICE osteoporosis guideline (CG177104) (Figure 2). We recreated and adapted this model and populated
it using results reported for three of the most commonly prescribed NSAIDs (diclofenac, naproxen and
ibuprofen) and aspirin. Patients receiving NICE adherent prescriptions (e.g. a proton pump inhibitor
with NSAIDs where indicated) are less likely to experience negative health events such as a gastric
bleed. We assumed that patients experiencing an event would stay in the post-event health state for
the remainder of the model time horizon. We assumed that patients in the post-event state had their
NSAID stopped and were prescribed nothing or a simple analgesic such as paracetamol. The model has
3-month cycles and a lifetime duration.
The risk of adverse events per treatment were adjusted down to reflect lower-dose prescriptions in
the UK.We estimated baseline adverse event risks by applying the following weights to each NSAID
treatments based on data reported in the NICE guideline (see Report Supplementary Material 1, Table 87):
diclofenac, 0.459; ibuprofen, 0.248; and naproxen, 0.077. Report Supplementary Material 1, Table 88,
includes the additional risks associated with risky prescribing identified with targeted literature searches.
Report Supplementary Material 1, Table 89, includes the effectiveness values used and Report Supplementary
Material 1, Table 90, includes the model costs.We assumed variable intervention costs comprising two GP
Dyspepsia
(Post)
Symptomatic
ulcer
(Post)
Complicated GI
(Post)
MI
(Post)
Stroke
(Post)
HF
Dead
Alive
FIGURE 2 Economic evaluation: risky prescribing model structure (WP4b). GI, gastrointestinal; HF, heart failure.
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visits (an initial consultation and one follow-up, £72 in total) and a proton pump inhibitor prescription
where relevant (i.e. indicators 1–5 and 7). Given that changes in prescription may be made at other GP
visits or by another means (e.g. telephone), our assumption of two GP visits is conservative.
As in the NICE guideline, the impact of adverse gastrointestinal and cardiovascular events on individuals’
quality of life was modelled via utility multipliers (Report Supplementary Material 1, Table 91) applied to
age-specific baseline utility scores for the general UK population.105 The UK population baseline scores
used were 0.78 [standard error (SE) 0.26] at age 65 years and 0.73 (SE 0.27) at age 75 years. With the
exception of stroke, we assumed utility would return to pre-event levels after one cycle.
We created an additional model, based on that used to inform the NICE acute kidney injury (AKI) guideline
(CG169),106 to capture the risky prescribing indicator (9) covering the prescription of NSAIDs in patients
with CKD (Figure 3). Transition probabilities are included in Report Supplementary Material 1, Table 92,
with costs in Table 93. The variable intervention cost was assumed to be two additional GP consultations
to review and change NSAID prescriptions (£72 per patient). Report Supplementary Material 1, Table 94,
includes utility values, the same as used in CG169.106 Report Supplementary Material 1, Table 95,
includes the proportions used to weight the results.
Blood pressure control
The economic evaluation broadly followed the above methods for risky prescribing. We identified but
could not obtain the model107 informing the BP indicator (CG127);108 therefore, we recreated and
adapted it (Figure 4 summarises the model structure). We based the modelling approach on that used
for the NICE guidance for hypertension.108 The model had a lifetime horizon and 3-monthly cycles with
future costs and benefits discounted at 3.5% per annum. The cost and risks of a health event are often
higher immediately post event and often decrease as time passes. To reflect this, all health states in the
model have an ‘acute’ health state and a post-event health state. In all cases, if patients survive, they
move automatically to the post-event health state after a period of 3 months (one cycle). The post-
event health states are generally less costly and have reduced mortality risks.
CKD 5
CKD 3–4
RRT
Cycle 1
RRT
Cycle 2 +
Dead
AKI
Stage 2–3
AKI
Stage 1
FIGURE 3 Economic evaluation: risky prescribing submodel – CKD (WP4b). RRT, renal replacement therapy. RRT are
tunnel states only.
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Report Supplementary Material 1, Table 96, includes the modelled effectiveness estimates and Table 97 details
transition probabilities. The risks for coronary heart disease and stroke are taken from the NICE CG127
model.108 The original model based these risk parameters on outputs from the Framingham coronary heart
disease and stroke equations by gender and age groups.109 We employed these values and simulated
associated CIs using a risk calculator spreadsheet developed by the University of Edinburgh.110 Although
the Framingham equations have been generally superseded in the UK by QRISK,111 we mirrored the
original modelling approach. As the risk equations do not provide more granular detail about type of
coronary heart disease and stroke, we followed NICE CG127108 modelling and used percentage
distributions across coronary heart disease (MI, stable angina, unstable angina) and stroke [stroke or
transient ischaemic attack (TIA)] event types.112 Although some health-event risks described may be
correlated (e.g. stroke and MI), the NICE approach assumes the events are independent; we followed
this assumption. Patients meeting treatment targets for hypertension have a lower risk of coronary
heart disease and stroke. Intervention effectiveness was determined by mean, adjusted, systolic BP
outcomes at trial end. The relative risk reduction for male and females following treatment receipt were
taken from a meta-analysis.113 To cover all indicator populations, we identified additional risk parameter
values using targeted searches and risk calculators. However, we used the same background mortality
(UK life tables) and BP control risk reduction values for all indicators.
We based the average cost of hypertension treatment on antihypertensive drug therapy and an annual
check with the GP (see Report Supplementary Material 1, Table 98). As we had no data on changes in
process of care, we explored alternative costs associated with differing levels of implementation. We
took costs of cardiovascular events from the NICE guideline,108 national cost sources and published
studies. As in the original evaluation, we assumed that these costs were fixed and thus not random in
Alive
UA
SA
Post SA
Post UA
Post MIMI
Dead
Stroke
Post stroke
TIA
Post TIA
FIGURE 4 Economic evaluation: BP control model structure (WP4b). SA, stable angina; TIA, transient ischaemic attack;
UA, unstable angina.
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the probabilistic sensitivity analysis. We based the quality-of-life (utility) values (see Report Supplementary
Material 1, Table 99) for the cardiovascular event health states on the NICE statins assessment.
We assumed no utility decrement for receipt of hypertension treatment or experience of a TIA. Report
Supplementary Material 1, Table 100, includes the proportions used to weight the results.
Diabetes
We used the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model,98 which had informed
the NICE diabetes guideline (NG28)114 and is a comprehensive outcomes model based on a large, UK
longitudinal data set. The model produces estimates of life expectancy, quality-adjusted life expectancy and
cost of therapies and complications. Confidence intervals were created using the bootstrapping technique.
This individual-level model requires patient-level data on a range of demographics (e.g. age and ethnicity),
risk factors (e.g. body mass index and smoking status) and existing health conditions (e.g. amputations
and blindness). As the trials did not provide patient-level data, a cohort of individuals were simulated
using the mean and CIs from the trial analyses. For simplicity, and in the absence of other data
permitting an alternative approach, we assumed these to be normally distributed. We randomly
generated data on other model input parameters (e.g. gender, smoking status and presence of AF) such
that they satisfied prevalence estimates in this group (e.g. such that 3.9% of patients had existing AF;
see Report Supplementary Material 1, Table 101). As correlations between these input parameters were
unknown and uncontrolled for, the simulations are likely to lead to more rather than less uncertainty.
A sample of 1000 patients was simulated for each arm, the only difference in the sample being trial
effectiveness data (systolic BP, low-density lipoprotein cholesterol and HbA1c), simulated based on trial
results (and their CIs). We captured first order uncertainty by simulating outcomes for each patient
multiple times in loops and second order (sampling) uncertainty was captured by bootstrap resampling
of the 1000 patients. One hundred loops and 1000 bootstraps were conducted. As a sensitivity
analysis, we also ran the model for 1000 loops and no bootstraps, including only the mean outcome
values for the two trial arms. In the absence of other data to inform dynamic parameter values, we
carried forward baseline model input values into each model year. The fixed cost of the intervention at
a patient level was £0.28 [(£175,592.36/178 × 2)/7130]. As the outcomes from the trial entered in the
model were continuous health outcomes, it was not possible to attach to them costs associated with a
change in practice (process outcome); however, we explored this using sensitivity analyses in which
additional resource was expended in the trial arm.
Results
Risky prescribing
For an average UK practice of 7130 patients, the implementation package targeting all risky
prescribing indicators (except indicator 9) is more expensive but more effective than standard care
(Table 12). The risky prescribing implementation package ICER is below the threshold (£20,000) used
by NICE. Although the values are per practice, the ICER of £1359 is also that per patient and generally
represents comparative value.
TABLE 12 Economic evaluation: mean outcomes for the composite risky prescribing indicator (WP4b)
Mean incremental QALY 0.902
Mean incremental cost £1225
ICER £1359
Incremental net monetary benefit at £20,000 per QALY £16,810
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Figures 5 and 6 show the probability sensitivity analysis (PSA) results in a scatter plot and a CEAC,
respectively. The spread of the simulated ICERs on the plane suggest greater uncertainty in terms of
incremental QALYs than in incremental costs. A greater proportion of ICERs fall below than above
the cost-effectiveness threshold line. The probability that the implementation package ICER is below
£20,000 is relatively high, chiefly because of low intervention costs; hence, even at a low benefit, it is
likely to represent value for money. At a QALY willingness-to-pay (WTP) threshold of £20,000, the
risky prescribing intervention has a > 79% chance of being cost-effective.
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FIGURE 5 Economic evaluation: composite indicator of risky prescribing – scatterplot of simulated incremental cost and
QALY (WP4b).
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FIGURE 6 Economic evaluation: composite indicator of risky prescribing – CEAC.
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Results vary greatly by indicator. Figures 7–10 contrast cost-effectiveness results for indicator 4, where
the trial-arm difference in prescribing is statistically significantly better in the implementation package
arm; and for indicator 2, where the prescribing was better in the control arm. For indicator 4, a far
greater proportion of simulated ICERs are below the cost-effectiveness threshold. Figure 11 is a CEAC
run when the fixed intervention costs are adjusted to alternative optimistic (cheaper) and conservative
(more expensive) scenarios. Even using a conservative costing scenario, the risky prescribing
implementation package has a > 70% chance of being cost-effective.
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FIGURE 7 Economic evaluation: risky prescribing indicator 4 (prescribing of aspirin and clopidogrel in patients aged
≥ 65 years without coprescription of gastroprotection) – scatterplot of simulated incremental cost and QALY (WP4b).
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FIGURE 8 Economic evaluation: risky prescribing indicator 4 (prescribing of aspirin and clopidogrel in patients aged
≥ 65 years without coprescription of gastroprotection) – CEAC (WP4b).
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Blood pressure control
The BP implementation package at practice level was more expensive (incremental cost = £42,192) but
more effective (incremental QALYs = 13.00) than standard care (Table 13). The incremental values at
patient level were very small (£5.92 for costs and 0.0018 for QALYs). The estimated ICER per practice
and patient was £3246, which is indicative of cost-effectiveness; however, there is considerable
uncertainty in the results.
Figures 12 and 13 show the PSA scatter plot and CEAC, respectively. A slightly greater proportion of ICERs
fall below than above the cost-effectiveness (£20,000 per QALY) threshold line. This is reflected in the
finding that the probability of the intervention being cost-effective is only just above 50%, at 51.9%.
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FIGURE 9 Economic evaluation: risky prescribing indicator 2 (prescribing of traditional oral NSAID in patients aged
≥ 75 years without coprescription of gastroprotection) – scatterplot of simulated incremental cost and QALY (WP4b).
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FIGURE 10 Economic evaluation: risky prescribing indicator 2 (prescribing of traditional oral NSAID in patients aged
≥ 75 years without coprescription of gastroprotection) – CEAC (WP4b).
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FIGURE 11 Economic evaluation: composite indicator of risky prescribing – CEAC for three sets of fixed intervention
costs (WP4b).
TABLE 13 Economic evaluation: mean PSA outcomes at the practice level for the composite BP control indicator (WP4b)
Mean incremental QALY 13.00
Mean incremental cost £42,192
ICER £3246
Incremental net monetary benefit at £20,000 per QALY £217,730
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FIGURE 12 Economic evaluation: composite indicator of BP control – scatterplot of simulated incremental cost and
QALY (WP4b).
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Results by subindicator are largely similar with the intervention yielding positive net benefit, either
dominating standard care or yielding an ICER of < £6000 per QALY gained. Two exceptions were the
indicators relating to patients with a history of stroke or TIA and relating to patients with diabetes
for whom standard practice (no intervention) was more cost-effective than the BP implementation
package. This was as a result of greater mean reductions in BP in the control arm. In a third indicator
(peripheral arterial disease) the outcomes were practically the same across arms. In the best performing
indicator (9.5: BP control in patients with CKD), the PSA indicated a 63% chance of being cost-effective
(Figures 14 and 15).
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FIGURE 13 Economic evaluation: composite indicator of BP control – CEAC (WP4b).
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Diabetes control
Table 14 includes the mean of the individual-level summary results from the UKPDS model. The differential
between trial arms in costs and benefits was negligible. Over the model’s lifetime horizon, 12.26 and
12.24 life-years were generated by the implementation package and control arms, respectively. This
equated to 9.78 and 9.76 QALYs, respectively; thus, the package appeared more effective than standard
practice (incremental QALYs= 0.02). The implementation package was more expensive overall (incremental
cost £12.79); these incremental values yielded an ICER of £573.37. At WTP thresholds of £20,000 and
£30,000 per QALY, the implementation package has only a 34% and 35% chance, respectively, of being
cost-effective. The spread of ICERs from the bootstrapping is shown in Figure 16; however, the Monte
Carlo Error (MCE) for the initial model (100 loops and 1000 bootstraps) was of the same magnitude
as the incremental values indicating highly uncertain results. A second model run where the sample
outcomes were simulated over 1000 loops (0 bootstraps) indicated incremental QALYs of –0.0007 and
costs of £6.37 over a lifetime (control dominates). A further run including only mean values for the arms
over 10,000 loops (0 bootstraps) generated incremental QALYs of –0.0085 and costs of £28.04.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
P
ro
b
a
b
il
it
y
 o
f 
co
st
-e
ff
e
ct
iv
e
n
e
ss
WTP for a QALY (£000)
0 2010 30 40 50 60 70 80 90 100
FIGURE 15 Economic evaluation: BP control indicator 5 (achievement of BP < 140/90 mmHg in patients aged < 80 years
with peripheral arterial disease) – CEAC (WP4b).
TABLE 14 Economic evaluation: mean individual-level summary results from the UKPDS model (WP4b)98
Life expectancy (years) QALYs Complication costs (£) Total cost (£)
Mean 95% CIs Mean 95% CIs Mean 95% CIs Mean
With 1st order uncertainty
ASPIRE 12.26 12.10 to 12.64 9.78 9.65 to 10.07 24,420.87 24,043.73 to 25,124.88 24,421.15
Usual care 12.24 12.11 to 12.65 9.76 9.65 to 10.10 24,408.36 24,027.83 to 25,103.85 24,408.36
Incremental 0.02 0.02 12.51 12.79
ICER 573.37
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Given these outcomes, their sensitivity to model processes and the magnitude of differences observed,
we cannot be confident in the results and we cannot recommend the diabetes implementation package.
As the intervention costs were negligible, and there was no reasonable argument for adjusting the
effectiveness parameters input into the model, sensitivity analyses were not conducted.
Discussion
Although the need to consider the economic consequences of implementation is acknowledged,115–117
full economic evaluations of implementation interventions are relatively rare. We undertook economic
evaluations addressing three of the four ASPIRE implementation packages. Where possible, we followed
the reference case set out by NICE99 and applied the same modelling approaches used to inform the
development of the original NICE guidance. We conducted detailed costing of the preparation, delivery
and receipt of different components of the implementation packages. At a practice level, the cost for
all four packages was low (£1219.39) and at a patient level negligible (£0.17). Details on the costs may
facilitate wider commissioning and uptake of such interventions.
The risky prescribing implementation package was, on average, more expensive and more effective
than usual care. This yielded an ICER of £1359, well below the £20,000-per-QALY threshold. This was
supported by the PSA in which > 75% of simulations yielded ICERs below this threshold; however, the
intervention benefit was not evenly spread across subindicators and some (e.g. subindicator 4) drove
the results.
The BP implementation package was also more expensive and slightly more effective than usual care with
the evaluation yielding an ICER of £3246. Although this is indicative of cost-effectiveness, the uncertainty
around this result was considerable and only 50% of the ICERs fell below this threshold in the PSA.
There was mixed trial evidence for the effectiveness of the diabetes implementation package where it
was observed to be either minimally more, or less, effective than usual care, depending on the clinical
end point. This led to minimal differences in costs and benefits and the conclusion that the package
was unlikely to be cost-effective.
–200
–150
–100
–50
0
50
100
150
200
–0.08 –0.06 –0.04 –0.02 0.02 0.04 0.06
Incremental QALY
In
cr
e
m
e
n
ta
l c
o
st
 (
£
)
WTP threshold
FIGURE 16 Economic evaluation: cost-effectiveness plane for diabetes control implementation package (WP4b).
SYNOPSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
Given that there were so many elements to the models, it was not possible to systematically vary
parameters deterministically in the analysis; hence, apart from some sensitivity analyses based on
intervention costs, we relied on the probabilistic analyses to inform on the uncertainty in the results.
In general, the results of the evaluations were insensitive to changes in costs given that these were
negligible. The results indicate that although effects may be small and statistically non-significant in
some cases, the relatively low cost of the implementation packages (especially around risky prescribing
and possibly around BP control) suggests that they are worthy pursuits and may represent value for
money. Value for money may even be underestimated if any intervention effects can be sustained
beyond trial follow-up periods.
A limitation of the evaluations is their reliance on decision modelling rather than an individual-level
data analysis; however, it is unclear whether or not access to individual data would have changed
results and would have been worth the added complexity.
Conclusion
Economic evaluations alongside implementation studies are relatively uncommon but are important to
inform priority setting and resource allocation. We have demonstrated that there is a good probability
of the risky prescribing implementation package representing value for money but we would be more
cautious in recommending the BP control package.
Work package 5: a multimethod process evaluation of an adaptable
implementation strategy
Background
The randomised evaluation of the adaptable implementation package found a cost-effective reduction
in risky prescribing but no effects on diabetes control, BP control or anticoagulation for AF. Our
process evaluation aimed to help explain these findings. We created chronological accounts of how the
implementation package was delivered, received and acted on. We applied the TDF54 to conceptualise
planned intervention content and implementation (i.e. the theoretical domains targeted by the intervention
and likely to influence processes of care and outcomes). Normalisation process theory (NPT) offers a
sociological approach to understand the dynamics of implementing, embedding and integrating a new
technology or complex intervention.118,119 It is concerned with explaining what people do rather than
their attitudes or beliefs. It explains actions according to a set of four constructs; coherence, cognitive
participation, collective action and reflexive monitoring. We applied NPT to help identify implementation
processes in practice teams over time. We developed process models to explore how actual
implementation compared with planned implementation.
Methods
Participants
Eight general practices not participating in the trials took part in the in-depth, mainly qualitative
process evaluation. An independent statistician randomly assigned practices to one of four adapted
implementation packages, which were the same as those used in both trials. Allocation was balanced
to reflect CCG membership and practice list size. We gathered further fidelity data from all practices
assigned to the implementation package in the trial.
Field work (Table 15) with the process evaluation practices was conducted by Cheryl Hunter, a social
scientist researcher. Her role was to observe and collect data but not to interfere with implementation
package delivery, as far as possible.
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Interviews
Cheryl Hunter carried out theory-based semistructured interviews (informed by the TDF and NPT
constructs) with key members of practice staff at two time points. These included clinical leads,
practice managers and other staff involved in the organisation or delivery of care for the specific QI.
The first interviews followed delivery of the initial educational outreach session and explored the role
and responsibilities of the staff member, barriers to and facilitators of achieving the QI, responses to
the intervention components and subsequent actions by the practice (35 participants; 3–6 per
practice). The second interviews took place towards the end of the intervention year and revisited
questions from the first interview as well as exploring changes within the practice and perceived
intervention usefulness and fit (27 participants; 2–4 per practice). Interviews were audio-recorded,
transcribed and anonymised.
Cheryl Hunter conducted a final group interview at all eight practices 1–3 months after delivery of
the final feedback report. She asked practices to reflect on the entire year, provide feedback on
intervention components and explore any further plans to conduct work around their assigned QI.
Group interviews were written up in detailed anonymised field notes.
Cheryl Hunter conducted interviews with nine facilitators who delivered the educational outreach
visits and outreach support. These interviews explored how outreach sessions and support were
delivered in practice, whether or not the facilitators felt that these were delivered as intended and
what seemed to work (or not) when delivering these components in practice.
TABLE 15 Summary of fidelity data collection methods (WP5)
Intervention components Data collection methods Data collected from
A&F, including reports, computerised searches,
significant event audit forms
Post-trial survey (receipt and
use of reports and searches)
All practices
Record of educational outreach
visit
All practices
Record of joining organisational
group (to access searches)
All practices
Observations and interviews Process evaluation practices
Initial educational outreach visit, including
outreach support
Record of visits from facilitators All practices
Record of reasons for declining
visit
All practices
Observation of visits/support Process evaluation practices
Interviews with practice staff Process evaluation practices
Interviews with facilitators All practices
Prompts, including computerised protocols
(for risky prescribing arm only) and physical
reminders (laminates, pens and sticky notes)
Record of visits from facilitators All practices
Observations and interviews
with practice staff
Process evaluation practices
Record of joining organisational
group (to access protocols)
Risky prescribing practices
Reproduced from Glidewell et al.71 This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
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Observations
Approximately 10 hours of observation was conducted over the year at each practice. Observations
were informed by TDF and NPT constructs (e.g. attending to staff, individually and collectively,
conceptualise the intervention and what barriers or enablers might contribute to implementation).
Cheryl Hunter attended ASPIRE-related meetings, such as educational outreach sessions and on-site
outreach support. Cheryl Hunter also observed routine practice in reception or administrative areas
and attended a variety of practice meetings (including peer review, nursing team, clinical and business
meetings). No clinical interactions, such as consultations, were observed. Anonymised field notes
structured around the TDF and NPT constructs were created of all meetings and conversations at
practices.
Documentary data
We collected related documents including protocols for the assigned QI, letter templates for
patients, patient information leaflets and minutes from relevant clinical or practice meetings. E-mail
correspondence and notes from telephone conversations between Cheryl Hunter and practice staff
were anonymised. Practice managers were also given box files and invited to use these to store any
documents relevant to the QI.
Intervention administrative data
Feedback reports were sent quarterly by post and e-mail, and copies were taken by facilitators to
outreach visits. E-mail delivery receipts were recorded. For the eight practices that participated in the
in-depth process evaluation, delivery, receipt and use of feedback reports, searches and significant event
audit forms were tracked through observations, interviews and documentary records. Practices were
invited to join a SystmOne organisational group and were reminded about it in feedback reports, by
e-mail and at outreach visits.We collected data on whether or not practices joined the group (which gave
automatic access to the computerised searches), but it was not possible to digitally track use of the
searches. All practices were invited to participate in outreach visits by a programme administrator, who
recorded data on reasons for declining outreach visits. The facilitators delivering educational outreach
and support also recorded who attended outreach sessions, how many sessions were delivered, what
additional pharmacist support was taken up and delivered to practices, and whether or not feedback
reports were received and used. For risky prescribing only, practices were given access to computerised
prompts through an organisational group (in the same manner as the computerised searches). Further
insight into the delivery and receipt of the risky prescribing computerised protocols came from interviews
and observations with two process evaluation practices allocated to this intervention. Laminates, pens
and sticky notes summarising key clinical messages were delivered by post throughout the year (and
sometimes via facilitators at outreach visits). Interviews and observations at the eight practices gave
further insight into intervention receipt and use.
Post-trial survey
We aimed to estimate intervention fidelity post trial in both trial and process evaluation practices.
We developed a brief e-mail survey based on NPT to explore intervention receipt, enactment and
ongoing workability. The survey asked whether or not the practice received the reports, the reports
were relevant to the practices, the reports were shared with colleagues in the practice, the reports
were discussed within the practice, the reports were used to change how people in the practice
worked and they had used the SystmOne searches. Response options were limited to ‘yes’ or ‘no’, but
practices could also provide further free-text feedback if desired.
Analysis
Interview and observational data were entered into a QSR NVivo 10 project and coded using a
framework approach.54,120,121 The analytic framework included TDF constructs to compare planned
with actual implementation and NPT was adopted to understand individual- and team-implementation
processes, in particular how individuals and groups conceive of, engage with, and enact and reconfigure
work in response to the implementation package. Data were grouped by practice and chronologically
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ordered. Review of coded data, chronological accounts and process models was carried out in sequential
team meetings. The team comprised researchers with experience in psychology, sociology, implementation
science and primary care.
Cheryl Hunter developed a logic model (see Figure 18) and process models (see Figure 19) for each
intervention delivery mechanism to describe the planned process of implementation as conceived by the
intervention developers. Cheryl Hunter also drew up ‘disrupted’ process models, highlighting hypothesised
points where difficulties could arise to disrupt implementation as planned. Process and ‘disrupted’ process
models were used to sensitise the researcher and analysis team during data collection and analytic
discussions. Process models depicting implementation and chronological narrative accounts were developed
for each process evaluation practice documenting intervention delivery, receipt and use. The post-trial
fidelity survey coded fidelity as high, medium and low. Fidelity was considered high if practices received
feedback reports, took up outreach and accessed patient-identifiable searches; medium if they received
feedback and outreach or searches; and low if they received only feedback reports. Survey and
outreach facilitator data from the trials were analysed descriptively and compared with the more
in-depth practice case narratives, to help explain the trial findings and augment insights into
implementation fidelity.
Results
We initially outline the pre-intervention context before describing the delivery, receipt and enactment
of the main implementation package components as well as how they appeared to work or not. We
then summarise how or whether or not the general practices appeared to change as a result of the
package. Our descriptions relate to the in-depth process evaluation practices unless stated otherwise.
Table 26 in Appendix 1 summarises findings related to delivery and receipt of the implementation
package, perceptions of package components and actions in response to the package.
Pre-intervention context
Pre-intervention achievement was broadly comparable between trial and process evaluation practices
across trials and indicators, with any variations reflecting the smaller sample of process evaluation
practices (see Report Supplementary Material 1, Table 83).
The practices had varying systems and procedures in place for targeted indicators. The most advanced
were generally for diabetes, for which there was a nominated lead GP and care was mainly shared
between nurses and GPs. Patients were recalled for reviews at intervals according to their progress
in attaining treatment goals. Care was organised similarly, if less intensively, for BP management. BP
monitoring was variously carried out by patients using home monitors, machines in waiting rooms or
in consultations with health-care assistants, nurses or GPs, with the latter mainly having responsibility
for prescribing. Practices had delegated GP leads for cardiovascular disease or AF. Neither practice
assigned to the AF package involved their nursing staff in managing this condition. Both practices were
aware of anticoagulation as a priority in their CCGs and of recent changes to clinical guidelines, and
had started or had plans to start systematically reviewing patients who were potentially eligible for
treatment. For risky prescribing, both practices assigned to this package had nominated GP prescribing
leads. In one practice, a prescribing clerk regularly reviewed repeat prescriptions and did work around
reviewing costs of prescribing for medicines management. The lead GP also met with the practice
manager routinely to review any audits or work required for the CCG. Risky prescribing was the only
targeted indicator without specific QOF-related systems of care and goals.
Intervention delivery and receipt
All trial and process evaluation practices received feedback reports as intended (except where there
had been closures or mergers). Outreach visits were delivered to 67 (46.53%) practices, with eight
(5.56%) receiving two visits. Uptake was similar between trial arms. Visit timings are presented in
Figure 17. Detailed summaries are in Appendix 1 (Tables 26–29).
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Outreach visits averaged 36 minutes (see Report Supplementary Material 1, Table 77). Risky prescribing and
anticoagulation outreach meetings were all attended by someone with leadership responsibilities compared
with BP control (81.82%) or diabetes control (85.00%). On average fewer practice staff attended risky
prescribing meetings: three (range 1–10) compared with four (1–13) for anticoagulation, 4.5 (1–15) for
diabetes control and 5.5 (2–14) for BP control (see Report Supplementary Material 1, Table 78). Key clinical
topic leads were present at most visits (see Report Supplementary Material 1, Tables 79 and 80). Most
practices (94.03%) that received outreach visits produced action plans (see Report Supplementary Material 1,
Tables 81 and 82). During the outreach session, practices reported participating in a wide range of other
quality improvement initiatives, particularly for diabetes (see Report Supplementary Material 1, Tables 83
and 84). Outreach visits were declined by 77 practices; 52 (67.53%) provided no reason and 22 declined for
reasons related to workload (11 practices; 14.29%) or lack of interest (11 practices; 14.29%). One hundred
and twenty-six (87.50%) practices joined the organisational groups (see Report Supplementary Material 1,
Table 82; for baseline characteristics, see Tables 85–86), allowing them to access searches and, for risky
prescribing, computerised prompts. Overall, fidelity receipt was high for 47 (32.64%) practices, medium
for 82 (56.94%) and low for 15 (10.42%) (see Appendix 1, Table 28).
Audit and feedback
Process evaluation practices consistently viewed their QI as important and the data source as credible;
however, practices typically interpreted the reports as relevant only to staff directly involved in clinical
care for that indicator. This was demonstrated in the pattern of report dissemination and in how and
whether or not reports were discussed as a group. Staff largely continued existing ways of working.
The feedback reports seemed motivational and to raise awareness of key clinical messages, but did
not consistently encourage individual or organisational behavioural change. Required actions were
generally interpreted as relevant only to one or two people, or seen as already aligned with existing
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tasks and organisational structures. Actions were typically assigned to one or two GPs with little
existing ‘slack’ and progress depended on whether or not and how they prioritised and managed
required work; subsequently, progress was often slow and sometimes non-existent.
Some staff responded negatively to continuing feedback; this occurred in diabetes control and BP
control practices in which the numbers to review were high (up to 400 patients) and considerable
resources were already directed towards QOF work. Feedback in this case created dissonance, as
practice staff felt overwhelmed yet saw no progress. They then queried the data or the outcomes
measured as a way to resolve this dissonance and protect their professional sense of self.
One practice seemed to take a whole-practice approach to involvement, facilitated by their small size
(< 10 staff members). Engaging their administrative staff kept the work going even when the GPs felt
too busy, and the different staff members reminded and supported each other. This collective action,
with clear roles for each staff member, may explain their steady improvement throughout the study.
The searches generated lists of patients requiring action by staff. However, the searches were not
particularly visible to staff, suggesting a mismatch between the administrative and managerial staff
who received them and the clinicians responsible for reviewing the generated patient lists.
Educational outreach and support
Practices tended to perceive educational outreach as the start of the intervention; they received the
initial reports and then awaited the proffered help. Facilitators perceived these visits to be more useful
when some practice staff had reviewed and considered the reports first; our observations suggested
that only a small proportion of practices did this.
Who attended outreach visits was left to the practice’s discretion. As noted earlier, practices generally
had existing team arrangements for diabetes, involved everyone to some extent in BP control, and mostly
had GP prescribers, with a named GP lead for prescribing. Practices also tended to fit the outreach
visit into a routine meeting (as we had intended). This meant that staff awareness of the study and
engagement with the educational outreach visit varied. It might have resulted in more tailored action
plans if the diabetes and BP arms were given more guidance as to who to invite and include in the visits.
Only practices in these two intervention arms provided any negative feedback on the outreach visits.
Outreach support seemed to create an expectation that someone else (the facilitator) would do the work
for the practice. Some practices turned the outreach support down as they felt it better to do the work
themselves; others accepted the offer because they lacked capacity to do the work themselves. The size
of the workload was an influence, with diabetes and BP control workloads being viewed as overwhelming.
Practices might have been more motivated if they had to focus on smaller target populations, or if plans
had more clearly outlined individual roles and expectations. The clear link between action and outcome
in the anticoagulation and risky prescribing practices facilitated engagement with action-planning and
motivated staff to engage; the link between action and outcome was much less clear in the diabetes and
BP control practices.
Delays between organising and delivering the outreach visits (see Figure 17) and support are likely to
have differentially affected progress by QI. Practices assigned to diabetes and BP control packages
typically required a number of staff to be involved in seeing patients (for tests, prescriptions and
lifestyle advice), and would then require further review to establish any effect of management changes
on outcomes. Arranging educational outreach sessions within the first 6 months of the trial was not
feasible for many practices. If the ostensible ‘start’ of the intervention work was after the outreach
visit, patients might not have been identified for action until near the end of the trial intervention period.
SYNOPSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
Computerised prompts and laminated reminders
Observations in the process evaluation practices suggested that the laminated reminders had low visibility
and were unlikely to have contributed to any intervention impact. The only observed indication that the
prompts influenced behaviour came from one practice, which improved the awareness of the prescribing
clerk and enabled her involvement in the work. This practice was alone in enrolling an administrative
member of staff in the intervention work over the full study period although others were involved in
educational outreach or initial search generation.
Change as a result of the implementation package
Across the trials, achievement of the four primary outcome indicators appeared marginally better in
practices that had received educational outreach meetings than in practices that had not (Table 16).
Practices allocated to the diabetes control and anticoagulation for AF implementation packages that
received feedback without educational meetings appeared to perform marginally worse than the
control practices that had not received these packages.
There were signals from the process evaluation practices that staff had internalised the key clinical
messages in risky prescribing and, to some extent, in anticoagulation for AF and felt more likely
to act in accordance. However, there were also continuing barriers to acting on messages routinely.
These included the relative infrequency of clinicians seeing new cases of AF, the relative complexity
of managing AF, difficulties finding information in patient records and competing demands
within consultations.
The anticoagulation and risky prescribing practices did systematically review all patients not achieving
recommended care – although this was repeated more than once throughout the year in only one
practice. The other three practices either completed a review once or were still in the process of
completing it by the end of the intervention period. Some practices recognised the work as ongoing
and discussed putting a further audit cycle or check on progress into their systems.
TABLE 16 Primary outcome achievement rate by uptake of outreach visit, with non-intervention group for comparison
(WP5)a
Diabetes control
(N= 40)
Risky prescribing
(N= 40)
BP control
(N= 32)
Anticoagulation
in AF (N= 32)
Outreach visit received
n 20 25 11 11
Mean (SD) (%) 25.36 (5.69) 5.53 (3.89) 53.30 (7.02) 76.98 (4.72)
No outreach visit
n 20 15 21 21
Mean (SD) (%) 22.97 (6.73) 5.90 (2.06) 52.27 (7.13) 69.20 (9.95)
Non-intervention group achievement
n 40 40 32 32
Mean (SD) (%) 24.35 (6.89) 7.14 (5.05) 51.17 (4.93) 75.20 (9.99)
a The outcome data presented in this table use the most recent primary outcome data available for each of the
randomised practices.
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The diabetes and BP control practices tended not to engage in the systematic review of patients,
unless the outreach support did substantial preparatory work for them. They struggled with capacity
and felt as if they had already poured extensive resources into, and had developed particular working
structures for, addressing these topics; there was a collective failure to understand how the package
differed from usual ways of working. They were resistant to changing these structures or adding in
extra resources. As they continued to work within structures, and using reminders, oriented towards
achieving QOF – with some small adjustments that might improve QOF achievement – it seemed
unlikely that the intervention would have a lasting effect in these practices.
Discussion
We had set out to devise an implementation package that could be adapted to target a range of
high-impact indicators and be delivered within existing resources and ways of working in general
practice. Our process evaluation offers three main explanations of why the implementation package
was effective for one of four indicators. First, we observed losses in fidelity from delivery through to
enactment by practice teams. Second, the type and scale of targeted behaviour changes varied by
indicator, so that practice teams may have perceived and exerted greater control over risky prescribing.
Third, we had sought to ensure that targeted indicators were well aligned with existing clinical priorities;
this inadvertently resulted in the implementation package being insufficiently differentiated from
normal activity.
We observed significant losses in the receipt of intervention components. The overwhelming majority
of trial practices received quarterly feedback reports but we could not mandate actions beyond
receipt. Reports may have been circulated to only those already involved in delivering care, limiting the
opportunity to maximise capacity (e.g. by employing administrative support). Our observations of a
selected group of practices suggested that practice managers did not share the feedback reports as
widely or as frequently as we had intended. This was despite being engaged in the process evaluation
and, therefore, being aware of being observed. Just over half of trial practices accepted the offer of an
outreach visit, whereas only a minority took up further outreach visits and support. Waiting for an
outreach visit is likely to have been perceived as a reason not to start work in response to feedback
reports. Although the implementation package aimed to offer explicit advice and encourage action-
planning, practices remained uncertain about expectations and roles (e.g. who should attend outreach
visit meetings or act on patient searches). These were relatively observable fidelity losses; the absence
of any effects for process outcomes in the trials strongly suggests that any remaining implementation
package effects for three indicators (diabetes control, BP control and anticoagulation for AF) dissipated
before or at the point of clinical care.
With regard to targeted behaviours, all signals from the process evaluation suggest that practices welcomed
support to improve achievement for indicators; however, the complexity and amount of work required to
achieve treatment goals was a barrier. For the anticoagulation and risky prescribing practices, the actions
required were relatively straightforward, involving one member of staff and one change to care. Practice
teams addressing risky prescribing may have been further motivated to change following observable
improvements in feedback reports. For the diabetes and BP control practices, there was little clear guidance
on who to involve and what they could do differently (rather than doing more) to get from the current
position to the desired outcomes, and practices had historically invested considerable time and resources in
these areas. Because the link between treatment goals and specific practitioner actions was relatively weak,
practice staff sometimes became disillusioned or disengaged over time, as their achievement did not
seem to improve despite consistent effort. This was apparent in the way that some staff started to
criticise or withhold the reports in order to manage its negative effect on their professional identities,
or express demoralisation given perceived gaps between effort and achievement. Negative effects of
feedback may have been mitigated by outreach educational visits; practices receiving visits appeared to
fare better than those that did not.
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The implementation package was specifically designed to align with priorities and existing initiatives
such as the QOF, an underlying assumption being that this would enhance motivation and engagement.
However, this alignment seemed to have the opposite effect; although priorities were generally aligned,
the additional work needed to improve, for example, diabetes or BP control could probably not be
achieved within existing ways of working or resources. Furthermore, our suggestions that practices
review their team roles and processes of care are likely to have fallen on ‘stony ground.’ In terms of
NPT, an intervention needs to be considered to be aligned with the individual and collective priorities
of the team, and sufficiently differentiated from current practice to ensure the value of engaging with
it. Our intervention was aligned with priorities, but perhaps insufficiently differentiated from the
ongoing work of QOF achievement, and, therefore, practices were reluctant to alter existing work
patterns and resources. Furthermore, given that practices were already working to capacity, there was
little organisational ‘slack’ and, therefore, little will to change.
We highlight three study limitations. First, fidelity data collection was limited by technical and pragmatic
considerations; for instance, we were unable to track uses of the searches on practice computers. Second,
in-depth work was carried out in only eight practices, which were recruited actively into the study.
This might result in more motivated practices (especially as we had reimbursed them for participation),
or those who are more used to research. This did not seem to be the case. The practices were not outliers
in terms of achievement, and covered a range of CCG areas and patient list sizes. Whereas some practices
had prior involvement with research, most of them did not. Third, our in-depth work across several
practices was still conducted within constraints. The limited opportunities for observational work in
the practices had an impact on relationship-building, which probably affected the observational data as
the researcher remained a visitor. This was also indicative of overall engagement with the study and
lent important contextual insights into the practices. We relied on practitioner self-report of whether or
not and how they changed their work with patients, and they may have been more positive about the
impact of the intervention than was warranted. It would not have been feasible to observe any clinical
interactions with patients, where some of the work would have occurred.
Conclusion
Our process evaluation suggests three main explanations for the partial effect of the implementation
package and why it was effective for one of four QIs. First, we observed fidelity losses from delivery
through to enactment by practice teams. Second, the type and scale of targeted behaviour changes
varied by QI, especially those related to perceived control and clarity of actions required to achieve
outcomes. Third, the package often seemed indistinguishable from normal activity. We also identified
unintended negative as well as positive consequences, such as when continuing feedback showing
lack of progression towards goals demotivated teams. The future design of implementation strategies
should learn from our successes and failures and ensure that interventions are sufficiently robust to
survive fidelity losses, clarify required expectations and roles, and are targeted efficiently at key
patient, team and organisational determinants of behaviour.
Patient and public involvement
Roles and experience within ASPIRE
Our PPI panel has demonstrated commitment to and engagement with ASPIRE throughout the
programme’s lifetime. The panel chairperson (MR) was a co-investigator and member of the Programme
Management Team. The PPI panel met at quarterly intervals throughout the ASPIRE programme and
played an integral role in the development and conduct of our research. The panel’s contributions included:
l WP1. The consensus panel included patient representatives. All panel member ratings were
weighted equally, meaning that patients’ views helped to determine which indicators would be
taken forward.
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l WPs 2 and 4. We debated the relative merits of opt-in versus opt-out methods for recruiting
general practices to share anonymised patient data and take part in the trials. The panel took the
view that it would expect practices to share such data for research as a matter of routine and were
keen to ensure that ASPIRE involved ‘typical’ practices as far as possible. We were therefore able to
cite the panel’s support in our application for ethical review and in our subsequent communications
to CCGs and general practices. In addition, the panel provided helpful suggestions to support
recruitment (e.g. recommending the use of recorded delivery when sending ‘opt-out’ invitations).
l WP3. Panel input was explicitly designed into the implementation package development. The panel
provided feedback throughout the process, considered the acceptability of proposed interventions
to patients and the potential contribution of patient-mediated delivery mechanisms. In addition,
one panel member assisted with the procurement process through which we identified partners to
deliver our outreach sessions.
l WP5. The panel provided feedback on process evaluation methods and interpretation of emerging
data. Prior to the trial, panel members were interviewed by our process evaluation researcher to
gather their perspectives on how the implementation package might work. Their responses fed into
the production of ‘logic models’ (Figures 18 and 19) outlining hypothesised method(s) of action.
l More broadly, the panel assisted our ongoing networking and relationship-building efforts with
CCGs and practices in the region. Panel members suggested and organised meetings at local general
practices, including introductions from lead GPs outlining initiatives to improve patient interaction
and health outcomes.
l Panel members attended and contributed to the three stakeholder engagement events held during
the ASPIRE programme.
Subjectively, our panel members have indicated that they considered the PPI to be sufficiently planned
and resourced, that their opinions and perspectives were respected, and that they were treated as
equal partners in programme discussions.
Beyond ASPIRE, our PPI panel members have become involved in other research studies (e.g. as
steering group members) and have contributed to other bids and funded research led by our group.
We intend to build on this foundation to sustain and further develop our PPI partnership.
The role of patient and public involvement in implementation research
Patient and public involvement is generally an essential requirement for research funding. Distinctions
can be drawn between clinical research, which generally focuses on patients, and implementation
research, which generally focuses on health professionals’ behaviour. There is uncertainty about the
role of PPI in the latter field; therefore, we explored and defined the roles of PPI in implementation
research to inform good practice guidance.
We used a structured consensus process with a panel comprising our nine active PPI members and two
researcher members. We drew on available literature to identify 21 potential PPI roles in research.
The panel rated their agreement with roles independently online in relation to both implementation
and clinical research. Disagreements were discussed at a face-to-face meeting prior to a second online
rating of all roles. Median scores were calculated and a final meeting held to review findings and
consider recommendations.
Ten panellists completed the consensus process. For clinical research, there was strong support and
consensus for the role of PPI throughout most of the research process. For implementation research,
there were eight roles with consensus and strong support, seven roles with consensus but weaker support
and six roles with no consensus. Those with strong support included prioritising and shaping research
questions, and advising on supporting participant recruitment strategies. There were more disagreements
relating to the roles of PPI in implementation research than in clinical research. PPI was generally rated
as contributing less to the design and management of implementation research than clinical research.
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Inputs ImpactsProcessesActivities
Funding for research
project and associated
administrative costs
Significant event
audit forms delivered
with reports or at
outreach
Physical resources
(reports, computerised
searches, significant
event audit forms,
computerised
protocols, laminated
reminders) 
Audit and feedback
reports delivered
quarterly (five in total)
Encouraging action
through social comparison
and feedback on own
performance 
Enabling action planning
Outreach support
(maximum =  2 days)
delivered remotely
or on site 
Educational
outreach visits
(with action-planning)
(maximum = 2) 
Laminated reminders
delivered with reports
Computerised
searches – initial 
e-mail invite, plus
reminders on reports
Recruitment and
training of
administrator for
organising outreach
Manual for delivery of
educational outreach 
Recruitment and
training of facilitators
Raising awareness and
knowledge of a clinical topic
Computerised
protocols –
initial e-mail invite 
Practice staff feeling more able
to tackle the issue 
Coherent view of the issue and
need for action across practices 
Individual staff feel motivated to
tackle the issue 
Practice staff having increased
awareness and knowledge of
the issue 
Growing
competence and
confidence of
staff around reviewing
and changing practice
in line with guidelines
through repeated
action 
Individual named staff have the
intention to tackle the issue
(named on action plans) 
Practice team has agreed goals
of what to do, when to do it and
who to do it 
Improved
rates of
adherence to
quality
indicators 
Practice staff have acted on their
intentions in order to review
patients and change practice 
Suggesting small manageable
tasks (making engagement
seem easier) 
Setting realistic goals
Making it easier to start
process of reviewing
patients 
Addressing barriers to
change as a team 
Suggesting ways to address
issue with patients 
Reminding of study’s key
messages at regular intervals 
FIGURE 18 Process evaluation: intervention logic model (WP5).
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A&F form initially
sent to PM; request
to change to GP lead
as PM was part-time
and then leaving the
practice 
The A&F form is
recognised by PM as
useful and relevant
to GPs 
Form is circulated
within practice to the
two GPs 
GP lead reviews the
forms every time
individually; other
staff look only at
ASPIRE meetings,
leaving review of
forms to the lead 
Staff decide to have
outreach meeting but,
owing to availability
issues, it cannot go
ahead for several
months 
Attached action plan is
filed but not used – at
first meeting, looking at
the action plan, the GP
feels some of this work
is already underway
Outreach
facilitator
encourages
practice to write
down the goals;
GP partner writes
out action plan 
Staff set specific goals – small
numbers mean they decide
to do all the work 
At outreach meeting,
staff go through the
actions they have
decided on (and
started on) prior to
the meeting. They
ask about prescribing
costs and alternatives
to suggest to patients 
The practice is very
keen to improve as their
scores are low and see
the work as manageable
PM and prescribing
clerk identify people to
review from searches
and protocols 
PM receives and
accepts the searches
onto the system 
GP lead reviews patients
systematically after each
search list is handed to
him; the GPs also review
prescriptions flagged by
prescribing clerk  
GP lead talks to or recalls
patients identified through
systematic search; both GPs
review prescriptions flagged
by prescribing clerk 
Patient
receives
invite and
attends
Both GPs and prescribing
clerks feel like they are
remembering to address
NSAID use in
consultations/prescribing
actions  
The practice received the
computerised protocols  
The practice
implemented the
prompts, and the
prescribing clerk found
them useful and acted
on them 
Practice offered
outreach support at
outreach meeting 
Practice decided to do things
themselves at first then see if
they need help later on 
PM receives
message about
outreach 
Patient attends
for another
reason
GP lead
sent forms
to other GP
for review 
ASPIRE is kept
on the radar by
repeated audit
and feedback
forms 
GP lead is reviewing
progress each time and
asking PM to re-run
searches   
Searches are stored on
clinical system and GP
lead and PM know
where they are 
GP and PM run
searches before
outreach meeting
and start working
on it 
GP and PM (later, the
prescribing clerk) run
search after each
report 
Practice is keen to
receive the searches
so that they can start
working before
outreach visit 
This repeated searching
keeps the review work
going until PM leaves;
after that, the searching
stops until the prescribing
clerk is informed of the
searches’ existence 
As they get on with the work and see
an improvement, they do not bother
to ask for outreach support as the
intervention continues 
GP lead comments
that he is seeing the
computerised
protocols less
frequently when he
is prescribing 
Practice ask for repeat
forms to go directly to
GP lead as PM was
retiring soon 
At outreach, GP says
they have their own
system of reporting
(September 2015)
Practice does not
take up SEAs; blank
copies are stored
in ASPIRE box that,
once PM leaves
(November 2015),
no-one is aware of 
SEAs were brought 
up at the outreach 
meeting; copies were 
given to the practice 
(September 2015) 
Staff feel motivated and able
to complete any tasks assigned
to or agreed by them – this is
enabled by PM’s skills in
searching and routine
meetings between PM and
GP lead to discuss 
Staff have assigned review
work to the GP lead and PM
prior to the outreach meeting 
FIGURE 19 Process evaluation: example of implementation process model for Treetop Practice (WP5). PM, practice manager; SEA, significant event audit.
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Patient and public involvement roles need to be tailored according to the nature of the research to
ensure authentic and appropriate involvement. We provided a framework to guide the planning, conduct
and reporting of PPI in implementation research, which has been published in Gray-Burrows et al.122
Conclusions
We set out to design and apply an implementation package that could be delivered sustainably using
resources typically available to primary care. We involved health professionals, commissioners and
patients in structured deliberations to prioritise and develop a set of ‘high-impact’, evidence-based QIs
associated with scope for improvement and that could be measured using routinely collected data.
We demonstrated marked variations in indicator adherence among general practices and used a
behavioural framework in interviews with health professionals to explore the reasons for variations
in practice. We drew on these findings and existing evidence in work with stakeholders to develop
a set of implementation packages adapted to target four indicators: avoidance of risky prescribing;
treatment targets in type 2 diabetes; BP targets in treated hypertension; and anticoagulation in AF.
The implementation packages were largely built around A&F, educational outreach and clinical
prompts, within which we embedded BCTs and tailored content to each indicator.
Our pragmatic, cluster-randomised trials indicated the value of an implementation package targeting
risky prescribing. However, the similarly adapted implementation packages targeting diabetes control,
BP control and anticoagulation for AF were ineffective. Our mixed-method process evaluation
highlighted cumulative losses in fidelity, especially around delivery and enactment. In the current
pressurised context of primary care, practices found it difficult to achieve change for indicators related
to behaviours perceived as less immediately within their control compared with relatively discrete
prescribing decisions.
Particular programme strengths included a systematic approach to intervention development and
evaluation, the use of opt-out practice recruitment and routinely collected data within a pair of ‘real-world’
balanced incomplete block cluster-randomised trials, and the participation of clinicians and patients
throughout the programme. We also developed, with our PPI panel, a framework to guide the planning,
conduct and reporting of PPI in implementation research.
Three features of our programme worked less well than we had hoped. First, we invested considerably
in the ‘diagnostic’ phase of our programme. This limited the time and resources available to field test
the implementation package to ensure that it could be delivered with reasonable fidelity. We would
recommend dedicating less time to diagnostic work, especially as we already had a fair understanding
of implementation challenges within the primary care context, and more time on iterative cycles of
stress testing and enhancing the implementation packages before wider roll-out in the trials. Second,
we focused on addressing determinants of practice largely based on the TDF and around evidence-
based interventions that could feasibly be delivered within a cluster-randomised trial using general
practices as the unit of allocation (e.g. A&F). Our ability to address some of the higher-level, meta-
themes we identified in our interviews (WP2), such as internal and external sources of support, is more
questionable. Such determinants are potentially less amenable to change and efforts to change them
within our implementation packages were unsuccessful. We would encourage further work to develop and
evaluate interventions targeting organisational and system-level influences on practice. Third, our ‘opt-out’
approach to recruit general practices to the randomised trials means that trial practices may not have
engaged with the implementation package as much as if they had actively volunteered. However, an ‘opt
in’ approach may also have limited the applicability of our findings to ‘real-world’ quality improvement
initiatives targeting all practices within a given locality. We therefore suggest that others learn from our
first lesson and ensure that interventions are designed to be sufficiently robust to withstand the buffeting
they will inevitably receive in pragmatic trials in a challenging primary care context.
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Publications lists and includes links to published articles resulting from this programme.
Implications for practice
For national agencies with implementation roles:
l There is a growing, if imperfect, evidence base on implementation strategies to promote the uptake
of evidence-based practice,83 as well as a variety of approaches to improvement underpinned by
conviction more than evidence,123 to consider in planning implementation.
l A realistic appraisal of the likelihood of being able to bring about change for a given targeted
recommendation or behaviour can inform the selection of priorities for implementation
support activities.
For CCGs, practice networks and general practices:
l We have demonstrated an approach to set priorities and to develop high-impact indicators that
could be adapted for local quality improvement initiatives.
l Overambitious goals for change can undermine the motivation of general practice staff; focusing on
continuous and cumulative improvements in evidence-based care has the potential to deliver major
improvements in population health.
l The likelihood of successful improvement may depend on the degrees to which any goals for change
are within the control of the professionals and patients who need to change behaviour.
l Gaps between evidence and practice are generally multifactorial and related to barriers operating
at one or more of system, team, professional and patient levels.124 We suggest that plans to tackle
evidence–practice gaps take account of this and address barriers that are most amenable to change.
l Where there are existing routine data demonstrating variations in practice, A&F to support general
practices, providing repeated feedback accompanied by persuasive messages, feasible goals and action
plans has modest but scalable effects. Educational outreach visits may augment the delivery of
feedback and help with action-planning. We demonstrated an approach to reduce risky prescribing
that yielded an ICER of £2337 per incremental QALY, falling below the NICE preferred threshold of
£20,000–30,000 cost per QALY.
l Computerised prompts can help change specific behaviours and are more likely to work if users
need to provide a justification for over-riding recommendations;70 but practices will circumvent
them if they are too intrusive or disruptive.125 Administrative staff processing repeat prescriptions
can offer an alternative target to consultations.
For patient advocates and groups:
l Practice and commissioner patient groups face a wide-ranging quality agenda. This agenda could
include taking an interest in variations between general practices in adherence to evidence-based
practice. Supporting and making changes here could yield significant population benefits.
l It is important that participation in research to improve the quality of patient care is not dominated
by general practices that are already more interested in research and quality. Patient groups may
wish to encourage general practices to share data and take part in quality improvement studies.
l Our research suggests that a range of roles and expectations can be discussed with researchers
when planning research to address professional and/or patient behaviour.
Implications for future research
For researchers:
l There are challenges in designing implementation strategies that are sufficiently robust to bring
about change in the face of difficult clinical contexts and likely losses to fidelity. Maximise feasibility
and ‘stress-testing’ work prior to rolling out interventions in a definitive, pragmatic trial.
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l Our implementation package was unsuccessful for three QIs (type 2 diabetes control, BP control
and use of anticoagulation for AF). Yet these are not intractable problems.62 Although implementation
strategies may have small to modest effects, these can translate into worthwhile population health
gains; therefore, we recommend further implementation research addressing these problems that
builds on our lessons and the wider body of research literature. Concerted research strategies that
target system, organisational and patient levels as well as general practices may be required to bring
about more significant change.
l The ASPIRE programme effectively represented a nascent ‘implementation laboratory’ embedded
within 10 CCGs.126 It is possible to develop and test incremental ways of improving the delivery of
health care that cumulatively both improve patient care and develop the scientific basis of health-care
provision.127 As well as cumulative improvement, implementation laboratories also offer a means of
improving research efficiency and generalisability. Cluster-randomised trials typically require larger
numbers of patients than individually randomised trials to account for lack of independence within
clusters. Increasing the number of sites allows greater statistical efficiency than increasing the number
of patients. Although this augments logistical challenges, embedding trials in an existing network or
major improvement initiative facilitates recruitment and helps ensure ‘real-world’ generalisability.
We recommend that researchers build collaborations with those responsible for large-scale regional
or national improvement to establish implementation laboratories.
l Researchers will need to consider how best to recruit general practices to trials, given current research
governance arrangements. We were able to recruit general practices to a pair of cluster-randomised
trials using a relatively light-touch ‘opt-out’ approach. This both minimised any administrative burden
for participating practices and ensured that our trials remained highly pragmatic. However, such an
approach to this type of intervention study no longer appears feasible under research governance
arrangements that require permission from general practices to participate in research as explicit
research sites (a de facto opt-in approach).94
l Considering PPI, distinctions can be drawn between clinical research, which generally focuses on
patients, and implementation research, which generally focuses on health professionals’ behaviour.
A flexible approach to PPI may help optimise the use of finite research and PPI resources.
Researchers may find the framework we have developed to guide the planning, conduct and
reporting of PPI in implementation research useful.122
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to make
better use of information from people’s patient records, to understand more about disease, develop new
treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect
everyone’s privacy, and it’s important that there are safeguards to make sure that it is stored and used
responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You
can find out more about the background to this citation here: https://understandingpatientdata.org.uk/
data-citation.
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Appendix 1 Supplementary tables
and figures
TABLE 17 Description of developed implementation package following the template for intervention description and
replication (TIDieR) checklist65 (WP3b)
A&F
Educational outreach
(supplemented by A&F)
Computerised and manual
prompts and reminders
Rationale To develop an implementation package that can be applied within existing primary care systems and
resources and adapted to target specific determinants of change for four QIs
Control
interventions
Both control and intervention practices were exposed to standard ‘background’ practice quality
improvement initiatives (e.g. national guidelines, QOF)
Materials and
training
Practice-specific quarterly
audit reports. Each report
compared practice achievement
of targeted indicators with
those of other participating
practices within their CCG, with
all participating practices and
trends over time. Reports
encouraged reflection on
progress and prompted change.
Reports included information
on clinical recommendations,
suggested change strategies
and suggested consequences
of inaction. Practices were
encouraged to set goals based
on graded tasks (based on
the number of clinical
recommendations and the
number of patients requiring
attention) and use an action-
planning template specifying
who would do what, in what
circumstances, and how and
when the achievement would
be reviewed. Subsequent
reports included potential
actions identified during
outreach sessions
Computerised searches were
offered to systematically
identify all patients whose
care required review and to
facilitate repeat searching
Short and longer significant
event audit templates were
developed for risky prescribing
and anticoagulation for AF
indicators to facilitate root
cause analyses and action-
planning from harmful events
or near misses
We commissioned and recruited
experienced pharmacists as
facilitators. The pharmacists
received 2 days’ training aimed
to increase motivation, prompt
individual and group reflection,
increase confidence and
intention to act. For each
outreach visit, a practice-specific
outreach pack was developed
containing the most recent (and
all previous) audit report(s); a
session outline; an action plan
template that included space for
noting current performance,
setting a target, identifying who
will do what and review date;
and templates for assessing costs
and benefits
For risky prescribing nine
computerised prompts were
developed to be triggered
within the consultation and
during repeat prescribing on
the basis of a clinical code
algorithm for age/diagnosis and
drug. When triggered a brief
message notified that the
patient was at risk and
presented an evidence-based
statement (e.g. ‘This patient has
CKD. NSAID use accounts for
an estimated 15% of all cases
of acute renal failure and 36%
of drug-induced cases’). A one-
click justification was required
(e.g. continue with risk, add
medication or stop medication)
Two prompts were developed
for anticoagulation for AF but
could not be made available
within the study timelines
Patient-directed checklists
were developed to facilitate
shared decision-making for
managing BP and diabetes
outcomes but could not be
made available within the
study timelines
Reminders in the form of
laminated information sheets
were created to convey key
clinical information (BP and
anticoagulation for AF)
Pens and sticky notes were
sent to all practices with a
topic-specific reminder to
prompt behaviour
continued
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TABLE 17 Description of developed implementation package following the template for intervention description and
replication (TIDieR) checklist65 (WP3b) (continued )
A&F
Educational outreach
(supplemented by A&F)
Computerised and manual
prompts and reminders
Supportive
activities
None Two-day pharmacist training
included a one-day face-to-face
meeting with intervention
developers focusing on
goal-setting, action-planning,
clinical barriers and persuasive
communication. This was
followed by a half day of
independent study using
a folder of supporting
documentation relevant to each
indicator. The first outreach
meeting of each facilitator was
observed by an experienced
facilitator and feedback given
None
Intervention
provider
The research team Trained pharmacists The research team
Mode of
delivery
Reports were sent by post and
e-mail. Practices were sent
invitations to use computerised
searches via their clinical
information system
Researchers e-mailed the
practice manager and
colleagues introducing
significant event audit
templates
Face-to-face sessions were
offered to practices
Practices were invited to use
computerised prompts via their
clinical information system.
Researchers e-mailed the
practice manager and colleagues
recommending local activation
of the prompts
Schedule and
intensity
Quarterly feedback reports.
Practices were offered access
to searches and significant
event audit templates at the
beginning of the study and
reminded of their availability
via quarterly feedback reports
Practices were offered an initial
30-minute session. All relevant
practice staff were invited to
identify and review patients
requiring action. A key clinical
contact was identified to
support practice engagement.
Initial visits focused on practice
achievement data (from audit
reports), identifying models of
good practice, addressing barriers
to change and creating an action
plan to facilitate and review
change. Up to 2 days of
pharmacist time were offered to
support patient identification and
review. An additional follow-up
visit was offered to review
progress and support the practice
to create more challenging or
attainable action plans
Practices were offered access
to prompts at the beginning
of the study and reminded of
their availability via quarterly
feedback reports. Practices were
offered access to checklists at
the beginning of the study and
reminded of their availability via
quarterly feedback reports.
Sticky notes and pens were sent
to all practices
Tailoring Searches could be tailored by
practices, allowing them to
identify patients relevant to all
or individual recommendations,
or adjust target values to select
specific groups of patients
Session content could be
modified to practice
requirements
Prompts could be copied
and modified to practice
requirements
Modifications None
Fidelity of
delivery,
receipt and
enactment
Assessed in the subsequent process evaluation
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BOX 2 Illustrative denominator and numerator information for two ‘high-impact’ QIs (WP1)
Example 1: secondary prevention of MI
Recommendation
All patients who have had an acute MI should be offered treatment with a combination of the following drugs:
angiotensin-converting-enzyme inhibitor; aspirin; beta-blocker; statin.
Statements linked by logical operators to describe numerators and denominators
Denominator
Coding for MI (drawing on QOF Read code clusters used by QOF indicator CHD14 – although note
difference in our requirement of any prior MI coding).
Numerator
Coding for MI (drawing on QOF Read code clusters used by QOF indicator CHD14 – although note difference in
our requirement of any prior myocardial infarction coding) AND [currently treated with: ACE inhibitor OR ARB
(angiotensin II receptor blocker)] AND (currently treated with: aspirin OR alternative anti-platelet medication)
AND (currently treated with a beta-blocker) AND (currently treated with a statin).
Example 2: BP targets for hypertension
Composite recommendation
a. Aim for a target clinic BP < 140/90 mmHg in people aged under 80 years with treated hypertension.
b. Aim for a target clinic BP < 150/90 mmHg in people aged 80 years and over with treated hypertension.
Statements linked by logical operators to describe numerators and denominators
Denominators
a. On hypertension register AND age < 80 years (drawing on QOF Read code clusters used by QOF
indicator BP5 – although note additional age criteria).
b. On hypertension register AND age ≥ 80 years (drawing on QOF Read code clusters used by QOF
indicator BP5 – although note additional age criteria).
Numerators
a. On hypertension register AND age < 80 years AND last BP (measured in the preceding 9 months)
< 140/90 mmHg (drawing on QOF Read code clusters used by QOF indicator BP5 – although note
additional age criteria and lower BP target compared to QOF).
b. On hypertension register AND age ≥ 80 years AND last BP (measured in the preceding 9 months)
< 150/90mmHg (drawing on QOF Read code clusters used by QOF indicator BP5 – although note
additional age criteria).
Reproduced from Rushforth et al.1 This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated.
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TABLE 18 Behaviour change techniques excluded from intervention development or intended but not subsequently
operationalised (WP3b)
BCTs for changing determinants of behaviour52
BCTs excluded because of delivery
mechanism or contextual constraints
(BCT taxonomy code reference)66
BCTs intended but
not operationalised
(BCT taxonomy code
reference)66
Relevant determinants
Core determinants
‘environmental context’ and
‘social and professional role’
Social support Social support emotional (3.3)
Antecedents Avoidance/reducing exposure to cues
for the behaviour (12.3)
Distraction (12.4)
Body changes (12.6)
Comparison of
behaviour
Demonstration of the behaviour (6.1)
Feedback and
monitoring
Monitoring of behaviour by others
without feedback (2.1)
Monitoring of outcomes of behaviour
without feedback (2.5)
Biofeedback (2.6)
Identity Incompatible beliefs (13.3)
Valued self-identity (13.4)
Identity associated with changed
behaviour (13.5)
Identification of self
as role model (13.1)
Covert learning Imaginary punishment (16.1)
Imaginary reward (16.2)
Prominent determinants
‘knowledge’, ‘memory’, ‘social
influences’ and ‘beliefs about
consequences’
Comparison of
outcomes
Comparative imagining of future
outcomes (9.3)
Natural
consequences
Monitoring of emotional
consequences (5.4)
Information about emotional
consequences (5.6)
Anticipated regret
(5.5)
Shaping knowledge Behavioural experiments (4.4)
Goals and planning Discrepancy between
current behaviour
and goal (1.6)
Repetition and
substitution
Behavioural practice/rehearsal (8.1)
Behaviour substitution (8.2)
Habit reversal (8.4)
Overcorrection (8.5)
Generalisation of target behaviour (8.6)
Associations Cue signalling reward (7.2)
Reduce prompts/cues (7.3)
Remove access to the reward (7.4)
Remove aversive stimulus (7.5)
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TABLE 18 Behaviour change techniques excluded from intervention development or intended but not subsequently
operationalised (WP3b) (continued )
BCTs for changing determinants of behaviour52
BCTs excluded because of delivery
mechanism or contextual constraints
(BCT taxonomy code reference)66
BCTs intended but
not operationalised
(BCT taxonomy code
reference)66
Satiation (7.6)
Exposure (7.7)
Associative learning (7.8)
Regulation Pharmacological support (11.1)
Reduce negative emotions (11.2)
Paradoxical instructions (11.4)
Reward and threat Material incentive (behaviour) (10.1)
Material reward (behaviour) (10.2)
Non-specific reward (10.3)
Social incentive (10.5)
Non-specific incentive (10.6)
Self-incentive (10.7)
Incentive (outcome) (10.8)
Self-reward (10.9)
Reward (outcome) (10.10)
Future punishment (10.11)
Less evident determinants
‘self-belief’ and ‘scheduled
consequences’
Self-belief Mental rehearsal of successful
performance (15.2)
Self-talk (15.4)
Verbal persuasion
about capability (15.1)
Scheduled
consequences
Behavioural cost (14.1)
Punishment (14.2)
Remove reward (14.3)
Reward approximation (14.4)
Rewarding completion (14.5)
Situation-specific reward (14.6)
Reward incompatible behaviour (14.7)
Reward alternative behaviour (14.8)
Reduce reward frequency (14.9)
Remove punishment (14.10)
Reproduced from Glidewell et al.71 This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
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The 2014–15 QOF measured achievement against 81 indicators; practices scored points on the basis
of achievement against each indicator, up to a maximum of 559.
All patients registered at ASPIRE practices at baseline are included in Table 21.
TABLE 19 Cluster-randomised evaluation: characteristics of the non-randomised and randomised practices (WP4a)
Characteristic Non-randomised practices (n= 100) Randomised practices (n= 178)
Practice list size
Mean (SD) 7217.35 (3369.46) 7249.76 (4306.72)
Median (range) 6961.50 (1622.00–15,290.00) 6565.50 (1268.00–25,495.00)
Missing 6 0
Number of GP partners (headcount)a
Mean (SD) 5.13 (3.07) 4.06 (3.07)
Median (range) 5.00 (1.00–13.00) 4.00 (0.00–15.00)
Missing 21 29
Number of GP partners (FTE)a
Mean (SD) 4.17 (2.45) 3.27 (2.49)
Median (range) 3.67 (0.44–10.23) 2.56 (0.00–11.41)
Missing 21 29
Number of salaried GPs (headcount)b
Mean (SD) 0.58 (1.14) 0.93 (1.44)
Median (range) 0.00 (0.00–7.00) 0.00 (0.00–6.00)
Missing 21 29
Number of salaried GPs (FTE)b
Mean (SD) 0.36 (0.73) 0.65 (1.04)
Median (range) 0.00 (0.00–4.27) 0.00 (0.00–4.37)
Missing 21 29
Number of GPs (headcount)b
Mean (SD) 5.71 (3.18) 4.99 (3.37)
Median (range) 5.00 (1.00–13.00) 4.00 (1.00–15.00)
Missing 21 29
Number of GPs (FTE)b
Mean (SD) 4.52 (2.49) 3.92 (2.72)
Median (range) 4.27 (0.44–10.23) 3.22 (0.61–11.41)
Missing 21 29
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TABLE 19 Cluster-randomised evaluation: characteristics of the non-randomised and randomised practices (WP4a)
(continued )
Characteristic Non-randomised practices (n= 100) Randomised practices (n= 178)
Deprivation score (IMD 2015)c
Mean (SD) 31.32 (12.23) 30.85 (13.70)
Median (range) 31.49 (6.42–59.74) 30.22 (5.54–57.72)
Missing 9 3
% patients who would recommend practice
Mean (SD) 76.06 (14.46) 74.33 (14.11)
Median (range) 79.29 (16.98–96.70) 76.59 (34.35–98.46)
Missing 9 4
% patients who saw/spoke to nurse or GP same or next dayd
Mean (SD) 52.34 (12.23) 51.94 (15.61)
Median (range) 52.57 (24.28–77.27) 52.93 (13.13–89.72)
Missing 9 3
QOF scoree
Mean (SD) 532.63 (29.16) 531.11 (31.70)
Median (range) 541.42 (384.54–559.00) 539.61 (336.07–559.00)
Missing 7 1
Teaching practice?
f
Yes, n (%) 33 (33.0) 67 (37.6)
No, n (%) 67 (67.0) 111 (62.4)
FTE, full-time equivalent.
a The number of GP partners (headcount or FTE) has been derived as the difference between the total number of GPs
and the number of salaried GPs in each practice.
b GP staff data have been taken from the NHS Digital General and Personal Medical Services data set85 and reflect
the general practice workforce at 30 September 2015.
c The deprivation scores are a population-weighted average over the IMD 2015 scores of the Lower Layer Super
Output Areas in which the practice population lives. These scores take a positive value where a higher score
indicates a more deprived area. The deprivation data have been obtained from the Public Health England National
General Practice Profiles45 for the year 2015.
d Patient satisfaction scores have been obtained from the Public Health England National General Practice Profiles45
for the financial year 2014/15.
e The 2014/15 QOF score measured achievement against 81 indicators; practices scored points on the basis of
achievement against each indicator, up to a maximum of 559.
f All known teaching practices in West Yorkshire (as of 10 January 2017) are categorised as ‘Yes’, otherwise they
have been set to ‘No’.
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TABLE 20 Cluster-randomised evaluation: general practice characteristics at baseline by trial arm (WP4a)
Trial 1 Trial 2
Non-intervention (n= 34) Total (n= 178)Diabetes control (n= 40)
Risky prescribing
(n= 40) BP control (n= 32)
Anticoagulation in AF
(n= 32)
List size
Mean (SD) 7084.35 (3786.47) 7175.75 (3857.00) 7538.94 (4932.93) 7421.28 (4171.20) 7097.82 (5057.86) 7249.76 (4306.72)
Median
(range)
6703.00
(14,33.00–14,822.00)
6764.50
(14,93.00–14,760.00)
6367.50
(1268.00–17,429.00)
7067.00
(1889.00–18,891.00)
6074.50
(1723.00–25,495.00)
6565.50
(1268.00–25,495.00)
Overall QOF scorea
Mean (SD) 535.40 (29.93) 531.06 (35.79) 527.17 (27.03) 532.99 (21.75) 527.92 (40.34) 531.11 (31.70)
Median
(range)
542.21
(387.44–559.00)
542.17
(389.19–559.00)
534.66
(447.18–557.33)
538.89
(461.17–559.00)
536.58
(336.07–559.00)
539.61
(336.07–559.00)
Pre-intervention achievement
Diabetes control
Mean (SD) (%) 32.87 (6.94) 34.33 (7.72) 32.50 (7.10) 33.37 (5.48) 33.24 (7.96) 33.29 (7.08)
Risky prescribing
Mean (SD) (%) 7.92 (5.14) 7.92 (3.61) 7.27 (3.64) 7.92 (2.53) 8.47 (4.82) 7.91 (4.07)
BP control
Mean (SD) (%) 66.53 (6.42) 66.42 (7.02) 65.91 (7.53) 65.27 (6.25) 64.96 (6.32) 65.87 (6.67)
Anticoagulation in AF
Mean (SD) (%) 66.50 (14.42) 67.30 (8.43) 66.54 (10.80) 66.35 (8.29) 64.08 (15.48) 66.20 (11.82)
a There was one practice with a missing value for overall QOF score in trial 2.
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TABLE 21 Cluster-randomised evaluation: patient characteristics at baseline by trial arm (all patients) (WP4a)
Trial 1 Trial 2
Non-intervention (n= 243,856) Total (n= 1,311,258)
Diabetes control
(n= 288,130)
Risky prescribing
(n= 290,407) BP control (n= 249,571)
Anticoagulation in AF
(n= 239,294)
Age
Mean (SD) 38.03 (22.88) 37.60 (23.14) 39.36 (23.20) 38.99 (23.22) 36.93 (22.48) 38.16 (23.00)
Median (range) 36.00 (0.00–107.00) 36.00 (0.00–106.00) 39.00 (0.00–105.00) 39.00 (0.00–107.00) 35.00 (0.00–108.00) 37.00 (0.00–108.00)
Gender
Female 141,328 (49.05%) 144,426 (49.73%) 124,824 (50.02%) 120,289 (50.27%) 120,680 (49.49%) 651,547 (49.69%)
Male 146,799 (50.95%) 145,980 (50.27%) 124,746 (49.98%) 119,003 (49.73%) 123,169 (50.51%) 659,697 (50.31%)
Indeterminate 2 (0.00%) 1 (0.00%) 1 (0.00%) 1 (0.00%) 7 (0.00%) 12 (0.00%)
Unknown 1 (0.00%) 0 (0.00%) 0 (0.00%) 1 (0.00%) 0 (0.00%) 2 (0.00%)
Comorbidity
0–3 276,280 (95.89%) 277,184 (95.45%) 239,455 (95.95%) 229,329 (95.84%) 234,116 (96.01%) 1,256,364 (95.81%)
4 + 11,850 (4.11%) 13,223 (4.55%) 10,116 (4.05%) 9965 (4.16%) 9740 (3.99%) 54,894 (4.19%)
Adapted from Willis et al.87 © 2020 Willis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
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TABLE 22 Primary outcome analysis: diabetes control (WP4a)
Variable Comparison Estimate SE OR
Lower limit of
97.5% CI for OR
Upper limit of
97.5% CI for OR F-value
Degrees of
freedom p-value
Allocation Diabetes control implementation
package vs. control (risky prescribing
package)
0.0251 0.0635 1.0254 0.8894 1.1822 0.16 1 0.6926
Gender Female vs. male –0.1237 0.0270 0.8837 0.8317 0.9389 20.91 1 <0.0001
Age (years) 0.0219 0.0010 1.0221 1.0198 1.0245 454.34 1 <0.0001
Relative to 100 patient increase
in list size at baseline
0.0006 0.0010 1.0006 0.9984 1.0028 0.38 1 0.5400
CCG NHS Airedale, Wharfedale and Craven
CCG vs. NHS Wakefield CCG
–0.1485 0.1712 0.8620 0.5873 1.2652 1.65 9 0.0940
CCG NHS Bradford City CCG vs. NHS
Wakefield CCG
0.2278 0.1607 1.2559 0.8761 1.8003
CCG NHS Bradford Districts CCG vs. NHS
Wakefield CCG
0.1804 0.1130 1.1976 0.9297 1.5428
CCG NHS Calderdale CCG vs. NHS
Wakefield CCG
0.1343 0.1570 1.1437 0.8044 1.6261
CCG NHS Greater Huddersfield CCG
vs. NHS Wakefield CCG
0.1470 0.1581 1.1584 0.8128 1.6510
CCG NHS Leeds North CCG vs. NHS
Wakefield CCG
0.4710 0.1628 1.6016 1.1120 2.3067
CCG NHS Leeds South and East CCG
vs. NHS Wakefield CCG
0.1329 0.1362 1.1421 0.8417 1.5497
CCG NHS Leeds West CCG vs. NHS
Wakefield CCG
0.3552 0.1557 1.4265 1.0062 2.0224
CCG NHS North Kirklees CCG vs. NHS
Wakefield CCG
0.2226 0.1415 1.2494 0.9098 1.7157
Pre-intervention achievement
for risky prescribing
0.0054 0.0082 1.0054 0.9870 1.0241 0.43 1 0.5123
Pre-intervention achievement
for diabetes control
0.0305 0.0048 1.0309 1.0199 1.0420 40.50 1 <0.0001
Overall QOF score –0.0016 0.0013 0.9984 0.9954 1.0013 1.52 1 0.2174
Comorbidity –0.0378 0.0410 0.9629 0.8783 1.0557 0.85 1 0.3572
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TABLE 23 Primary outcome analysis: risky prescribing (WP4a)
Variable Comparison Estimate SE OR
Lower limit of
97.5% CI for OR
Upper limit of
97.5% CI for OR F-value
Degrees of
freedom p-value
Allocation Risky prescribing implementation
package vs. control (diabetes control
package)
–0.2046 0.0855 0.8150 0.6729 0.9871 5.73 1 0.0167
Gender Female vs. male –0.1031 0.0451 0.9021 0.8153 0.9981 5.22 1 0.0224
Age –0.0125 0.0017 0.9876 0.9838 0.9914 53.35 1 <0.0001
Relative to 100 patient
increase in list size at baseline
–0.0001 0.0013 0.9999 0.9969 1.0029 0.01 1 0.9258
CCG NHS Airedale, Wharfedale and
Craven CCG vs. NHS Wakefield CCG
0.1944 0.2141 1.2146 0.7517 1.9626 1.72 9 0.0792
CCG NHS Bradford City CCG vs. NHS
Wakefield CCG
0.1304 0.2245 1.1392 0.6888 1.8841
CCG NHS Bradford Districts CCG vs. NHS
Wakefield CCG
0.0901 0.1460 1.0943 0.7888 1.5179
CCG NHS Calderdale CCG vs. NHS
Wakefield CCG
0.0940 0.1987 1.0985 0.7036 1.7151
CCG NHS Greater Huddersfield CCG
vs. NHS Wakefield CCG
0.3294 0.2027 1.3901 0.8826 2.1894
CCG NHS Leeds North CCG vs. NHS
Wakefield CCG
–0.1277 0.2180 0.8801 0.5400 1.4346
CCG NHS Leeds South and East CCG
vs. NHS Wakefield CCG
–0.2525 0.1820 0.7769 0.5167 1.1681
CCG NHS Leeds West CCG vs. NHS
Wakefield CCG
–0.2685 0.2134 0.7645 0.4739 1.2335
continued
D
O
I:
1
0
.3
3
1
0
/p
g
fa
r0
8
0
4
0
P
ro
g
ra
m
m
e
G
ra
n
ts
fo
r
A
p
p
lie
d
R
e
se
a
rch
2
0
2
0
V
o
l.
8
N
o
.
4
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
2
0
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
F
o
y
et
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
a
n
d
S
o
cia
l
C
a
re
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riv
a
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
x
tra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
v
id
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
v
e
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
L
ib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
v
a
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
iv
e
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
8
5
TABLE 23 Primary outcome analysis: risky prescribing (WP4a) (continued )
Variable Comparison Estimate SE OR
Lower limit of
97.5% CI for OR
Upper limit of
97.5% CI for OR F-value
Degrees of
freedom p-value
CCG NHS North Kirklees CCG vs. NHS
Wakefield CCG
0.0699 0.1823 1.0724 0.7127 1.6137
Pre-intervention achievement
for risky prescribing
0.0778 0.0109 1.0809 1.0549 1.1076 51.13 1 <0.0001
Pre-intervention achievement
for diabetes control
–0.0058 0.0066 0.9942 0.9797 1.0090 0.77 1 0.3792
Overall QOF score 0.0002 0.0018 1.0002 0.9961 1.0043 0.01 1 0.9040
Comorbidity 0.0294 0.0575 1.0298 0.9052 1.1716 0.26 1 0.6094
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TABLE 24 Primary outcome analysis: BP control (WP4a)
Variable Comparison Estimate SE OR
Lower limit of
97.5% CI for OR
Upper limit of
97.5% CI for OR F-value
Degrees of
freedom p-value
Allocation BP control package vs. control
(anticoagulation in AF package)
0.0520 0.0419 1.0533 0.9589 1.1571 1.54 1 0.2151
Gender Female vs. male 0.1262 0.0136 1.1345 1.1005 1.1696 86.39 1 <0.0001
Age 0.0265 0.0006 1.0268 1.0256 1.0281 2304.94 1 <0.0001
Relative to 100 patient
increase in list size at baseline
–0.0014 0.0006 0.9986 0.9974 0.9999 6.19 1 0.0128
CCG NHS Airedale, Wharfedale and
Craven CCG vs. NHS Wakefield CCG
0.0754 0.0958 1.0783 0.8700 1.3367 2.43 8 0.0126
CCG NHS Bradford City CCG vs. NHS
Wakefield CCG
–0.1343 0.0848 0.8743 0.7229 1.0574
CCG NHS Calderdale CCG vs. NHS
Wakefield CCG
0.2631 0.0936 1.3010 1.0549 1.6045
CCG NHS Greater Huddersfield CCG
vs. NHS Wakefield CCG
0.0079 0.0874 1.0079 0.8286 1.2259
CCG NHS Leeds North CCG vs. NHS
Wakefield CCG
0.1930 0.1035 1.2129 0.9619 1.5295
CCG NHS Leeds South and East CCG
vs. NHS Wakefield CCG
0.0518 0.0811 1.0532 0.8782 1.2631
CCG NHS Leeds West CCG vs. NHS
Wakefield CCG
0.0423 0.0804 1.0432 0.8711 1.2493
CCG NHS North Kirklees CCG vs. NHS
Wakefield CCG
0.1343 0.0827 1.1437 0.9501 1.3768
Pre-intervention achievement
for anticoagulation in AF
–0.0039 0.0025 0.9961 0.9905 1.0018 2.33 1 0.1266
Pre-intervention achievement
for BP control
0.0262 0.0036 1.0265 1.0184 1.0348 54.11 1 <0.0001
Overall QOF score 0.0007 0.0010 1.0007 0.9986 1.0029 0.59 1 0.4425
Comorbidity –0.0008 0.0227 0.9992 0.9496 1.0513 0.00 1 0.9713
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TABLE 25 Primary outcome analysis: anticoagulation in AF (WP4a)
Variable Comparison Estimate SE OR
Lower limit of
97.5% CI for OR
Upper limit of
97.5% CI for OR F-value
Degrees of
freedom p-value
Allocation Anticoagulation in AF package vs.
control (BP control package)
–0.1035 0.0833 0.9017 0.7482 1.0868 1.54 1 0.2141
Gender Female vs. male –0.0618 0.0566 0.9401 0.8280 1.0673 1.19 1 0.2752
Age –0.0117 0.0029 0.9883 0.9819 0.9948 16.35 1 <0.0001
Relative to 100 patient
increase in list size at baseline
–0.0005 0.0012 0.9995 0.9969 1.0022 0.16 1 0.6907
CCG NHS Airedale, Wharfedale and
Craven CCG vs. NHS Wakefield CCG
–0.0559 0.1582 0.9456 0.6632 1.3483 0.72 8 0.6724
CCG NHS Bradford City CCG vs. NHS
Wakefield CCG
–0.4125 0.2221 0.6620 0.4024 1.0891
CCG NHS Calderdale CCG vs. NHS
Wakefield CCG
0.0478 0.1765 1.0489 0.7061 1.5581
CCG NHS Greater Huddersfield CCG
vs. NHS Wakefield CCG
–0.0815 0.1758 0.9217 0.6215 1.3670
CCG NHS Leeds North CCG vs. NHS
Wakefield CCG
0.1597 0.1762 1.1732 0.7904 1.7414
CCG NHS Leeds South and East CCG
vs. NHS Wakefield CCG
–0.0243 0.1549 0.9760 0.6896 1.3813
CCG NHS Leeds West CCG vs. NHS
Wakefield CCG
0.0334 0.1501 1.0340 0.7386 1.4476
CCG NHS North Kirklees CCG vs. NHS
Wakefield CCG
0.0427 0.1528 1.0436 0.7409 1.4699
Pre-intervention achievement
for anticoagulation in AF
0.0372 0.0056 1.0379 1.0248 1.0511 43.52 1 <0.0001
Pre-intervention achievement
for BP control
0.0013 0.0071 1.0013 0.9855 1.0173 0.03 1 0.8593
Overall QOF score 0.0026 0.0021 1.0026 0.9978 1.0074 1.46 1 0.2276
Comorbidity 0.0218 0.0544 1.0220 0.9047 1.1545 0.16 1 0.6887
A
P
P
E
N
D
IX
1
N
IH
R
Jo
u
rn
a
ls
L
ib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry
.n
ih
r.a
c.u
k
8
8
TABLE 26 Number of practices in each trial arm where at least one outreach visit took place (WP5)
At least one
outreach visit held
Diabetes control
(n= 40)
Risky
prescribing
(n= 40)
BP control
(n= 32)
Anticoagulation in
AF (n= 32) Total (n= 144)
Yes 20 (50.00%) 25 (62.50%) 11 (34.38%) 11 (34.38%) 67 (46.53%)
No 20 (50.00%) 15 (37.50%) 21 (65.63%) 21 (65.63%) 77 (53.47%)
TABLE 27 Number of outreach visits held at each practice (by trial arm) (WP5)
Number of outreach
visits held
Diabetes control
(n= 40)
Risky
prescribing
(n= 40)
BP control
(n= 32)
Anticoagulation in
AF (n= 32) Total (n= 144)
0 20 (50.00%) 15 (37.50%) 21 (65.63%) 21 (65.63%) 77 (53.47%)
1 18 (45.00%) 22 (55.00%) 10 (31.25%) 9 (28.13%) 59 (40.97%)
2 2 (5.00%) 3 (7.50%) 1 (3.13%) 2 (6.25%) 8 (5.56%)
TABLE 28 Intervention fidelity level of practices by trial arm (WP4a)
Intervention fidelity
levela
Diabetes control
(n= 40)
Risky
prescribing
(n= 40)
BP control
(n= 32)
Anticoagulation in
AF (n= 32) Total (n= 144)
High 18 (45.00%) 8 (20.00%) 11 (34.38%) 10 (31.25%) 47 (32.64%)
Medium 22 (55.00%) 32 (80.00%) 12 (37.50%) 16 (50.00%) 82 (56.94%)
Low 0 (0.00%) 0 (0.00%) 9 (28.13%) 6 (18.75%) 15 (10.42%)
a Intervention fidelity levels are based on the following criteria:
1. A&F reports received at each time point
2. outreach visit 1 undertaken
3. joined organisational group for searches
4. joined group for prompts (risky prescribing only).
Where the levels are defined as:
l High – all of 1–3 achieved (and 4 for risky prescribing practices).
l Medium – achieved 1 and at least one other from 2–4.
l Low – achieved 1 only.
TABLE 29 Summary of delivery and receipt of intervention (WP4a)
Intervention components Delivery Receipt
A&F Reports Reports were sent by e-mail and post
every 3 months, and taken along to
outreach visits
All trial practices received reports as
intended (with the exception of those that
closed/merged)
All of the process evaluation practices
received the reports
Searches Practices were sent an e-mail inviting
them to join an organisational group
through SystmOne
126 (87.5%) trial practices joined the
organisational group
75.0% of responses from trial practices
stated that they downloaded and used the
searches when asked in the post-trial survey
continued
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TABLE 29 Summary of delivery and receipt of intervention (WP4a) (continued )
Intervention components Delivery Receipt
For the process evaluation practices, 75.0%
of practices joined the organisational group
and all of those that responded to the
post-trial survey indicated that they had
downloaded the searches
Significant event
audit forms
Forms were sent by post and taken
along to educational outreach visits
Receipt was not tracked in the trial
practices
In the relevant process evaluation practices
(n= 4), there was evidence of receipt in
one practice but no evidence of receipt in
the others
Educational
outreach
Initial educational
outreach meeting
Practices were offered an educational
outreach visit on every report. Every
practice was also contacted by an
administrator by telephone and e-mail
to arrange a date
Sixty-seven (46.53%) trial practices took up
the offer of an outreach visit. Reasons for
declining the offer included not interested,
too busy, do not need it, permanent closure
of practice
Within the process evaluation, 87.5% of
practices took up the offer; the practice
that declined said that it felt confident
about what it needed to do and was
able to do it itself
I think we just felt that we were pretty
much on the ball with it (. . .) we didn’t
need a pharmacist to push us. I think we
decided that we already had enough
resources to get on with it . . .
Valley practice (AF), interview with GP
partner, lead for cardiovascular disease
Outreach support Practices were offered outreach
support as part of the initial outreach
meeting. Outreach support was
offered to all practices. The possibility
of support was also mentioned on
each report
Outreach support was either delivered
face to face or remotely via e-mail
Outreach support was taken up by 77
(53.47%) trial practices
Most support was provided remotely by a
pharmacist external to the practice and
took the form of (a) running searches for
agreed indicators, (b) reviewing patient
notes for a number of relevant indicators
and (c) creating a list of recommendations
for management
In the process evaluation practices, two
practices had face-to-face outreach
support, three practices received support
remotely, two declined support and the
final practice was not offered support as
a result of declining the educational
outreach visit
Second outreach
meeting
All practices that took up an outreach
visit were offered a second outreach
meeting by an administrator
Five out of eight process evaluation
practices were offered a second visit;
resources and time constraints meant
that not all practices were contacted
by the end of the trial
Eight (5.56%) trial practices had a second
outreach visit
Three process evaluation practices had a
second outreach meeting. Out of the
remaining two that were offered a visit,
one practice declined it as it felt it did not
need it and one practice said yes but then
was unable to set a date for the meeting
before the trial ended
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TABLE 29 Summary of delivery and receipt of intervention (WP4a) (continued )
Intervention components Delivery Receipt
Reminders Computerised
protocols
Practices were sent an e-mail inviting
them to join an organisational group
through SystmOne
Eight (32.00%) trial practices joined the
organisational group that gave access
to the risky prescribing computerised
protocol
For risky prescribing, the protocols were
downloaded by both of the process
evaluation practices
Physical
reminders
Pens and sticky notes were sent to all
practices by post (with the second
A&F form) in August 2015
Laminates for BP were sent to the
relevant practices by post (with the
second A&F form) in August 2015
Laminates for anticoagulation in AF
were sent to the relevant practices by
post in January 2016
Receipt was not tracked in the trial
practices
All eight process evaluation practices
received the pens and sticky notes.
None of the process evaluation practices
remembered receiving a laminate for BP
(n= 2) or anticoagulation in AF (n= 2) and
the laminates were not seen by CH while
visiting the practices
TABLE 30 Perceptions of implementation package components (practices anonymised and assigned pseudonyms) (WP5)
Intervention component Content
A&F Reports Persuasive/credible [GP partner] commented on the quote on
the side, mentioning that [the expert
quoted] was a known atrial fibrillation
expert – knows what he is talking about . . .
Observation of meeting, Valley
I think the fact that the emphasis has
come, the challenge has come externally
has been quite useful for me because it
gets quite boring seen as being the
negative person that always says that we
should do better (. . .) so it’s been good in
terms of getting people thinking, the
conversation going . . .
GP partner/diabetes lead interview, Lake
Reinforcement/reminder It’s just having the ASPIRE presence, it’s
just a reminder, it’s just made us think, it’s
just brought it to the forefront of my mind,
because what we know what to do, it’s not
changed that, what we should do, it’s just
doing it
Final practice meeting, Brook
Informational (anticoagulation
arm only)
There was a bit of exclamation around the
five times higher risk of stroke part. As
they read through the first page, [GP
clinical lead] said that it was good they
were reading through the whole thing ‘so
that we’re all up-skilled’. . .
Observation of meeting, Valley
continued
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TABLE 30 Perceptions of implementation package components (practices anonymised and assigned pseudonyms) (WP5)
(continued )
Intervention component Content
Motivational (stimulated
competitiveness)
A GP said we are not that bad on the
graph, but it’s not where the rest of our
therapies are, which annoys me, ‘people
are above us – I don’t like it!’ Another GP
agreed, we are competitive . . .
Educational outreach, Lake
Searches Enabling (resource-saving) It was a big help, it saves us having to put
all the searches together . . .
Interview with practice manager, Brook
P: I have run the searches. I: (. . .) have they
been useful? P: Yeah, yeah ‘cos I wouldn’t
have known what to put [in them] . . .
Interview with practice manager, Treetop
Educational
Outreach
Initial educational
outreach meeting
Enabling (gateway to further support) I asked whether they had had any time to
look at the audit and feedback form and
she said no, they didn’t have time, they had
been waiting for the support to come . . .
Conversation with practice
manager, Flower
They decided they would take the outreach
session up to help them get going . . .
Meeting, Dale
Motivational (focused attention
on topic)
It was ‘nice to have the opportunity to
review’ what they were doing and ‘good to
have a pharmacist on board’ because they
‘don’t get input from them often’. It was
‘good to have an extra check on how
we prescribe’
Telephone call with GP partner/clinical
lead, Brook
The outreach meeting was ‘really useful’ as
it is always more helpful to have someone
come in and be there to ask questions of
[them] and ‘make what needs to be done
clear’ (. . .) It ‘needs to be on an agenda to
bring it up’. This was part of the reason
that being involved with ASPIRE was good,
because it put AF on the agenda and
helped keep it on the agenda long enough
for the work to get done’
Field notes from interview, practice
manager, Flower
Promoting whole practice engagement I: What difference does [having a group
meeting] make? P: a consistent approach
(. . .) less chance of people falling through
the net you know in error by mistake, here
in a hurry cos somebody else is always
looking at the prescriptions . . .
Interview with GP partner/clinical
lead, Treetop
Clarifying actions The chair said ‘yes, I think it made it
much clearer what the risk is, that you
were actually saving people’s lives by
anticoagulating’ . . .
Final practice meeting, Flower
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TABLE 30 Perceptions of implementation package components (practices anonymised and assigned pseudonyms) (WP5)
(continued )
Intervention component Content
[Educational outreach] made things a lot
clearer (. . .) just going through the
categories and knowing what to look for . . .
GP partner/clinical lead, Treetop
Outreach support Enabling (adding capacity) The key thing for her was the additional
support – it was a huge help. It’s much
easier for them to look at the sheet and get
on with the work now that the support had
done the lists, than it is to wait for a GP to
have the time to run the searches . . .
Field notes, interview with practice
manager, Brook
Not needed (using own resources) GP lead said we should do what we can
first, and then take up the support as
needed. He said, the ones we can’t do, we
will ask him to look at . . .
Educational outreach, Treetop
Reminders Computerised
protocols (risky
prescribing only)
Enabling (makes remembering to act
easier)
I’m more aware (. . .) It stays there. The
medication stays in my head and it prompts
me when I see that medication (. . .) Needs
protection or need to see a doctor to talk
about this . . .
Interview with prescribing clerk, Treetop
Not needed (too many protocols) The PM [practice manager] said she thought
they’d decided to not use them because
there are so many of those types of things
on there, people get a bit fed up of seeing . . .
Final practice meeting, Brook
TABLE 31 Reported actions in response to implementation package components (WP5)
Intervention component Response
A&F Reports In response to initial feedback
Social comparison – desire to do
better
Review current practice processes
I think the initial body of feedback where
we were right down the bottom (. . .) my
practice really doesn’t like that. They are
quite competitive in a lot of ways (. . .) to be
right down at the bottom wasn’t acceptable
so we had to do something about it. That
was just the sort of general (. . .) feeling’
Interview with GP, Valley
We realised where we were deficient and
how we compare to other people, it’s good
to have other people to compare against
‘cos you’re actually working quite a lot in
isolation in a way as a practice . . .
Interview with GP, Treetop
They had decided to use this [peer review
meeting] as a means to re-think their
approach to hypertension as a result of
ASPIRE [reports] . . .
Peer review meeting, Hill
continued
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TABLE 31 Reported actions in response to implementation package components (WP5) (continued )
Intervention component Response
Positive responses to repeat feedback
Discussing progress at meetings
Becoming more confident prescribing
The GPs said they discussed the reports,
it possibly raised the consciousness, but
that’s it . . .
Final meeting, River
I think when this started, as the male GP
was saying, we would have referred
everybody whereas I think I now feel
more comfortable starting people
[on anticoagulants] . . .
Final practice meeting, Flower
Negative response to repeat feedback
Reinterpretation of data
Limiting exposure to feedback
Demotivation
He said that they had felt like they had
done quite a lot of work but this was not
reflected in the figures. He laughed as he
said it, it felt a bit dispiriting really. He felt
they were doing so much work just to stay
in the same place. Other people nodded
and agreed . . .
Final practice meeting, River
I mean to be honest with you normally we’d
share it with all the partners, but because
the results didn’t look that good to me, I
didn’t want to embarrass [GP – diabetes
lead] by giving it to all the partners . . .
Practice manager interview, Dale
Erm I think the reports were interesting
erm and I think it becomes a little bit
demoralising when you see that things are
just getting worse . . .
GP lead interview, Lake
Searches Adapted searches to practice needs He explained that the GPs could not look
at the searches as they were, as they were
too long (. . .) targeting too many patients,
they didn’t have the resources (. . .) [they]
refined the searches (. . .) [so that] about
30 people were on the list given to the
diabetes lead . . .
Final practice meeting, River
Repeated use (stimulated by
reminders)
We did, we searched once every month (. . .)
And then we reviewed, brought in all those
patients in that we hadn’t. . . treated that
were on the recall list that we hadn’t treated,
and we reviewed them. So, although it’s
more work (. . .) We were on top of it . . .
Second interview, GP lead, April 2016
Limited use (lack of capacity) The GP lead said she did look at them, she
used the renal one, but that was the only
one she used. The medical student used
them at the beginning a lot to have a look
at what was going on . . .
Final practice meeting, Hill
[GP partner said] we have got good systems,
patients do get reviewed (. . .) we need to
make sure [BP] doesn’t break our systems . . .
Educational outreach, Lake
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TABLE 31 Reported actions in response to implementation package components (WP5) (continued )
Intervention component Response
Limited use (lack of awareness) None of them had seen any searches from
ASPIRE either, although they had done their
own sift through the AF QOF list last time . . .
Meeting with GP lead, Valley
Limited use (queried value of work) . . . there was a discussion about we’ve
got these searches to do but is it worth
doing, I think there was a valid judgement
about what we were going to get out from
doing it . . .
Interview with practice manager, Lake
Educational
outreach
Initial educational
outreach meeting
Agreeing an action plan and assigning
tasks
It looks like about 45 people (. . .) that doesn’t
sound too onerous does it? [Staff] were
nodding at this . . . [clinical lead] could do the
list review (. . .) should not be too difficult . . .
Educational outreach, Flower
Waiting for external support to carry
out action plan (ASPIRE or other)
It worked really well while I had my student
over the summer . . . I think we made a
massive improvement at the beginning and
then it’s sort of tapered off as [we] just
couldn’t keep the momentum going I think . . .
Interview with GP partner/clinical
lead, Hill
. . . we’ve kind of waited for [outreach
support] to happen (. . .) I hadn’t appreciated
that we actually needed to be chasing that
up and organising it!
Interview with GP partner/clinical
lead, Dale
Protecting limited resources (resisting
action-planning)
At the outreach meeting, the practice had
discussed adding in some hypertension work
during the flu work and he said yes, he
remembered, but that was wildly unrealistic
Field notes from interview with GP
partner, Lake
Doctors generally – unless well-resourced
clinically – won’t take this on – someone
else down the line has to take it on (. . .)
a list, like our searches generated (. . .)
doesn’t tell you what to focus on, how do
you decide? Someone has to think about it
and interpret it
Feedback from practice manager, River
Outreach support Rationalising workload from support [It] was targeting too many patients, they
didn’t have the resources. The chair agreed,
when you see a list to review of about 100
patients, your heart sinks. The PM [practice
manager] said we refined the searches,
then the pharmacist looked at it, and then
about 30 people were on the list given to
the diabetes lead so he could look if it was
clinically worthwhile to doing anything
with them. He said that they just don’t
have the time or capacity . . .
Final meeting, River
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TABLE 31 Reported actions in response to implementation package components (WP5) (continued )
Intervention component Response
Acting on recommendations He said that the input from the
pharmacist was good, there was only one
error in about 100 records (. . .) He said
that most of the comments by the
pharmacist were relevant and he acted on
most of the suggestions for change . . .
Conversation with GP partner/clinical
lead, Brook
Dissatisfaction/disengagement The GP said (. . .) if the impression is given
by an outside agency of right, OK, that
there’s a project we’re keen for you to be
involved in, we put up our hands and say
we’ll be involved, and then they come and
say how do you need support, and we say
these are the things that could help, and
they say right we’ll deliver on those things,
I think the tendency then – and I don’t
know about other practices – is to await
that action and then we will move it along
and that bit is where it fell down . . .
Final practice meeting, Dale
. . . there was a discussion about something
being then highlighted onto people’s records
(. . .) and I don’t think that ever appeared
(. . .) something that would automatically
appear on people’s records . . .
Interview with GP partner/clinical
lead, Hill
Reminders Computerised
protocols (risky
prescribing only)
Used as additional check on
prescribing practice
He felt the top few indicators were
something he did routinely, the message
had definitely stuck there, but the bottom
few indicators were not routine. He felt
that for those, the [protocols] were still
something useful to have
Interview with GP, Treetop
Ignored or deleted I don’t like all the flashing lights, I don’t
like the prompts and the templates, I think
it’s so complicated that it makes your job,
it’s ridiculous, you wouldn’t have a pilot
looking at something like this would you,
they wouldn’t be able to concentrate . . .
Interview with GP, Treetop
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